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Abstract 
 The Shiga-like toxins have DNA sequence homology to the toxins accountable for the 
dysentery brought about by the Shigella species.   Escherichia coli which encode and produce 
shiga-like toxins are referred to as shiga toxin-producing E. coli (STEC).  Upon infection with 
STEC, humans may develop a variety of clinical symptoms ranging in severity from bloody 
diarrhea to life threatening hemolytic uremic syndrome (HUS).  Hemolytic uremic syndrome is 
the most fatal disease manifestation for humans and has been documented to occur in up to 20% 
of patients upon STEC infection [29].  The Shiga toxins (Shiga toxin 1 and 2) are regarded as the 
principal virulence factor of STEC and are responsible for the clinical manifestations during 
HUS in humans [49]. 
 Cattle are the primary non-human reservoir for STEC and therefore represent an 
attractive target for pre-slaughter intervention as a means to reduce human infections.  To date, 
vaccination with secreted proteins including Shiga toxin 2 (Stx2), has reduced the numbers of 
bacteria shed in feces [3].  Even though published data exists supporting vaccination in cattle as 
a means to reduce STEC, commercially available vaccines are not being used by farms and 
STEC remain a significant zoonotic pathogen of humans causing disease and death.  To further 
our knowledge about STEC pathogenesis in cattle, we examined the effect of Shiga toxin 2 on 
bovine immune responses.  Bovine lymphocyte function was determined in the presence of Shiga 
toxin 2 and the magnitude of bovine immunological responses was measure after immunization 
with Shiga toxin 2.  In general, results suggest that Shiga toxin 2 downregulates bovine immune 
responses suggesting vaccination with effector molecules that exclude Shiga toxin 2 may induce 
a better immunological response and improve vaccine efficacy. 
 To examine the possibility that Stx2 modulates bovine immune responses, we 
investigated lymphocyte function in the presence of Stx2.  Menge et al [70] have reported that 
bovine lymphocytes express the Stx receptor and that Shiga toxin 1 inhibits lymphocyte 
proliferation in vitro.  We isolated two populations of lymphocytes, peripheral blood 
mononuclear cells (PBMCs) and ileal Peyer’s patch lymphocytes (IPPL) and compared 
lymphocyte function in the presence and absence of Stx2.  We found that Stx2 did not affect  
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IPPL viability in vitro but did inhibit IPPL proliferation after 12 hours of incubation in vitro.  In  
contrast, no altered PBMC function could be observed in the presence of Stx2.  These results 
suggest that receptor-bound Stx2 may inhibit IPPL proliferation and that the two populations of 
lymphocytes isolated are unique and distinct from each other in their response to Stx2. 
 To determine the effect of Stx2 on bovine immune responses during STEC infection, a 
bovine ileal ligated loop model was employed.  Ligated loops were inoculated with either a Stx2
+
 
STEC strain or an isogenic Stx2
-
 STEC strain.  After 24 hours, IPPL populations were isolated 
from each ligated loop and immunophenotyped.  The results indicated a significantly reduced 
CD4+ T cell population in the presence of Stx2.  No differences in the levels of IFNα, TNFα, 
IL12 or IFNγ could be detected between groups.  These results suggest that Stx2 modulates 
bovine immune responses but not as a result of increased production of these cytokines.  To 
extend this finding, we determined the effect of Stx2 on bovine immune responses during active 
immunization by using ELISA to measure serological responses in the presence and absence of 
Stx2.  Serological responses to secreted proteins, as well as a co-administered antigen (hen egg 
lysozyme), were significantly reduced in the groups of cattle that were immunized with either 
purified Stx2 or secreted protein preparations isolated from STEC compared to groups 
vaccinated with antigens which did not contain the toxin.  Bovine proliferative responses were 
also measured and the results indicated significantly reduced proliferation in the groups 
vaccinated with the formulations containing Stx2.  Therefore, based on these results, we 
conclude that Stx2 downregulates bovine immune responses and thus may contribute to the 
colonization and persistence of cattle by STEC. 
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1.0 Literature Review 
 
Escherichia coli 
1.1.1. Nomenclature 
 E. coli normally colonizes the human gut within hours after birth and participates in 
maintenance and stability of gastrointestinal physiology.  Some E. coli strains have evolved the 
ability to cause human diseases through the acquisition of specific virulence factors.  Pathogenic 
E. coli are divided into four main groups i) diarrheagenic E. coli, ii) uropathogenic E. coli, iii) 
meningitis E. coli, and iv) avian pathogenic E. coli [1].  Diarrheagenic E. coli can be further 
divided into six pathotypes including one of the most important human pathogens, 
Enterohaemorrhagic E. coli (EHEC).  
 
1.1.2. STEC O157:H7 
 Enterohaemorrhagic E. coli are a subgroup of Shiga toxin-producing E. coli (STEC).  
Shiga toxin-producing E. coli includes all strains of E. coli that produce at least one shiga toxin.   
After much debate, scientists have agreed to formally define EHEC as “those STEC which have 
been demonstrated to cause diarrhea in humans” [2].  This includes the EHEC prototype serotype 
E. coli O157:H7.  Thus, by this definition, not all STEC strains are pathogenic to humans 
whereas all EHEC strains do cause disease [3]. The identification of EHEC as a defined group of 
pathogenic E. coli was a consequence of two unrelated findings.  First, Riley et al [4] showed 
that E. coli O157:H7 was the causative agent of haemorrhagic colitis (HC) during two outbreaks 
involving undercooked hamburger meat.  Second, in 1983 Karmali et al [5] discovered a 
cytotoxin in the stool of patients experiencing haemolytic uremic syndrome (HUS) and 
subsequently, it was shown that this was the same toxin that was being produced by the E. coli 
O157:H7 during the two 1982 outbreaks.  This cytotoxin was later identified as shiga toxin.  
Enterohaemorrhagic E. coli has been further divided based on the presence of virulence attributes 
into “typical EHEC” which includes strains that produce stxs, cause A/E lesions and possess the 
60-MDa plasmid.  These strains include E. coli O157:H7 and “atypical EHEC” which produce 
shiga toxins but do not produce A/E lesions and/or the 60-MDa plasmid [3].  The absence of 
these virulence factors does not indicate decreased virulence in humans; in fact Paton et al [6] 
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showed that an atypical EHEC strain lacking the ability to produce A/E lesions was frequently 
associated with HC and HUS. 
 The most common means of characterizing STEC strains is through serotyping.  The 
serotype of an E. coli isolate is based on its O and H antigens.  The O antigen is part of the cell 
wall lipopolysaccharide. 174 O antigens had been described although less that 10 O groups are 
responsible for the majority of human disease [7].  The H antigen is the flagella subunit, 53 H 
antigens had been described [6].  The most relevant serotype is E. coli O157:H7 as it 
predominates in many countries and human infection has been described on at least 6 continents 
[3].  E. coli O157:H7 is also most commonly associated with HUS [1].  The number of 
documented human infections of E. coli O157:H7 within the United States has increased 
between the years 1982 and 1998 [1].  In 2005, human infections with E. coli O157:H7 had 
increased to 2,621 cases within the United States [1].  Other countries experiencing large 
outbreaks of E. coli O157:H7 infections include Canada, Japan and the United Kingdom [1].  E. 
coli O157:H7 can be identified through a number of biochemical tests including a delayed D-
sorbitol fermentation rate, the inability to ferment rhamnose on agar plates and the inability to 
produce β-glucuronidase.  The completed genome of E. coli O157:H7 showed that it had 
acquired an additional 1.34-Mb region of genomic DNA not present in the genome sequence of 
non-pathogenic E. coli K-12 [8].   
 
1.1.3. Non-O157 Serotypes 
 Recent data has confirmed that many non-O157 serotypes are responsible for human 
infection.  Regions such as Australia, Latin America and Europe have experienced sporadic 
outbreaks due to O26, O103 and O145 serotypes [9].  A global assessment done by Hussein et al 
[10] in 2007 showed that up to 30% of ground beef was contaminated with non-O157 STEC and 
up to 50% contamination of other retail cuts.  To date, the majority of non-O157 serotypes 
associated with human disease are O26:H11, O103:H2, O111:NM (non-motile) and O113:H21 
[3].  In North America, epidemiological data suggests that approximately 20% of HUS cases are 
due to non-O157:H7 serotypes [3].  However, many non-O157 serotypes have been shown to 
cause less bloody diarrhea and less HUS overall and are often routinely isolated from stool 
samples.   
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1.1.4. Human Diseases 
 Most of the time, infection with E. coli O157:H7 is self-limiting, but severe renal and 
neurological complications develop in approximately 5% of cases [11].  
 
1.1.4.1. Diarrhea and Hemorrhagic colitis 
 The most common clinical manifestations in humans after ingestion of EHEC are 
diarrhea, HC and HUS [3].  The initial complaint is usually a nonbloody diarrhea with abdominal 
cramps and a short-lived fever.  The onset of nonbloody diarrhea ranges between 2 and 12 days 
but most often occurs between 3 and 4 days [9].  Vomitting occurs in approximately half of the 
cases usually around the same time as the nonbloody diarrhea.  Within a couple of days, 90% of 
patients experience bloody diarrhea with increased abdominal pain.   
 
1.1.4.2. Hemolytic uremic syndrome 
 Hemolytic uremic syndrome is the most often fatal disease manifestation for humans 
following STEC infection and has been documented to occur in up to 20% of STEC infected 
patients [12].  It has been suggested that the Stxs produced by STEC traverse the intestinal 
epithelial layer to the bloodstream.  Once in the bloodstream, Shiga toxins target tissues with 
high levels of the Stx receptor.  In humans, renal endothelial cells have a high Gb3 content and it 
has been shown that Stxs are cytotoxic to these cells in vitro.  Various cytokines such as TNFα 
and IL1β increase expression of Gb3, exasperating the cytotoxic effects of the Stxs [9].  Patients 
with HUS often exhibit elevated levels of these cytokines in serum and urine [32].   
 It is estimated that HUS occurs at a frequency of 2.1 cases per 100,000 persons (within 
the total population) [12].  Acute renal failure is seen in 55 to 70% of cases with patients 
experiencing HUS [9].  The Center for Disease Control estimated that there are approximately 
70,000 cases of STEC induced illness including 60 deaths per year within the United States [13].  
The occurrence of HUS is seasonal with a higher frequency in the summer months.  The 
progression to HUS is aided by a variety of factors including age (the very young and the 
elderly), patients experiencing bloody diarrhea and fever, and patients treated with antimotility 
agents [9].  Recurring cases of HUS are not common.  In one study  in Utah, HUS occurred twice 
in the same patient only 2.6% of the time over a 20 year span [9].  Approximately 10% of 
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children under the age of ten experiencing illness due to infection with STEC develop HUS. 
Without proper treatment, 3-5% will die due to complications associated with HUS [9].   
 
1.1.5. Animal Reservoirs 
 Bacterial zoonotic pathogens are a threat to public health around the world.  Ruminants 
are an important source of STEC and are considered to be the primary means of transmission to 
humans leading to infection and disease. 
 
1.1.5.1. Bovine 
 Shiga toxin-producing E. coli is the only group of pathogenic E. coli that have a zoonotic 
origin as either direct or indirect animal contact has been shown to be a principal transmission 
route [3].  Cattle are the most important source of STEC causing human disease as the majority 
of outbreaks have been associated with undercooked ground beef or water contaminated with 
bovine feces [3].  As well, cattle are asymptomatic excretors of STEC and shed STEC in their 
feces all year round [14].  Shiga toxin-producing E. coli can remain viable in faeces from several 
weeks to many months facilitating spread [15].  It has been documented that fecal shedding is 
higher during the warmer summer months of the year and is influenced by the age of the animal 
as younger calves excrete higher amounts of STEC than older cattle [15].  Therefore since cattle 
are asymptomatic reservoirs, this makes detection of STEC difficult because infected animals are 
not removed from the herd due to illness or death.  In 2003, Naylor et al [16] proposed that the 
terminal rectum was the predominant site of E. coli O157:H7 colonisation within the bovine host 
although conflicting data suggested the bovine fore-stomachs.  Later Nart et al [17] confirmed 
Naylor’s findings and in addition also identified minor sites of E. coli O157:H7 colonisation 
within the rumen, small intestine and the proximal colon. 
 
1.1.5.2. Non-bovine Species 
 Other reservoirs for E. coli O157:H7 include sheep, water buffalo, rabbits and horses [7].  
Both meat and milk from sheep are relevant sources of STEC and goat milk has been linked to 
an STEC outbreak [18].  Over 100 STEC serotypes have been isolated from sheep [7].  Buffalo 
dairy herds in southern Italy were shown to be colonized with STEC and thus another potential 
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source for infection.  E. coli O157:H7 has also been isolated from pigs in Europe, Japan and the 
United States.  Faecal carriage was reported to be low (2%) and due to possible contamination of 
foodstuff or poor husbandry practices [15].  Both E. coli O157:H7 and non-O157 serotypes have 
been isolated from gull droppings suggesting a potential vector for the organisms.  Also, STEC 
have been isolated from pigeons and turkeys [15].  Finally, STEC has been isolated from bird 
droppings which may implicate another potential vehicle in STEC spreading [15].  
 
1.1.6. Modes of transmission 
 Shiga toxin-producing E. coli has a number of vectors aiding its transmission to humans.  
The fact that STEC is able to survive in water, feces, animal feed and on inanimate barnyard 
surfaces aids in its transmission.   
 
1.1.6.1. Food and Water 
 Meat, milk and water have been the primary sources of STEC infection [15]. 
Undercooked beef was a source of STEC infection in North America between the months of 
December 1992 and January 1993.  The undercooked beef was sold at a fast food chain and 
resulted in the infection of 732 individuals within the states of Washington, Idaho, California and 
Nevada.  Out of the 732, 195 persons were hospitalized and 4 died in the outbreak.  In May 
2000, the Walkerton water supply was contaminated with numerous pathogenic organisms 
including Salmonella, Campylobacter and E. coli O157:H7.  Both adults and children were 
affected by this contamination which resulted in approximately 2300 cases of gastrointestinal 
illness with 28 cases of HUS verified.  As a result, one child died of HUS and eight required 
kidney dialysis for recovery [19].   
 There are an increasing number of STEC infections arising from fruits and vegetables 
indirectly associated with contamination with cattle feces [4].  Fruits and vegetables fertilized 
with ruminant manure or contaminated during harvesting have been implicated as potential 
sources of STEC [15].  For example, bean sprouts, lettuce and tomatoes have been associated 
with STEC outbreaks [15].  A multistate outbreak of E. coli O157:H7 infections occurred in the 
United States in the summer of 1997 and epidemiological studies revealed the causative agent to 
be alfalfa sprouts grown from seeds contaminated with E. coli O157:H7 originating from a farm 
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in Idaho [20].  An outbreak in 2006 in the United States revealed spinach had been contaminated 
with E. coli O157:H7 as a result of coming into contact with contaminated water [21].  Studies 
revealed that the water had been contamined with bovine feces [15].  Shiga toxin-producing E. 
coli has been shown to be quite resilient as it can remain viable on lettuce at 4
o
C for 15 days.  
Finally, unpasteurized milk and fruit juices, such as apple juice, have become a safety concern 
[22, 23].  A study done by Cody et al [22] showed that apples contaminated with E. coli O157 
were grown in orchards that were frequented by deer that tested positive for E. coli O157:H7. 
 
1.1.6.2. Environmental Exposure 
 Various environment-related events have been associated with STEC exposure.  
Examples include swimming in contaminated water or attending open air events such as 
agriculture fairs resulting in exposure to contaminated animals [15, 24]. 
 
1.2 STEC Virulence factors 
 Since E. coli O157:H7 is an extracellular pathogen, it is important for it to successfully 
colonize its host before being cleared by the immune system.  Much effort has been put into 
elucidating the mechanism by which E. coli O157:H7 successfully colonizes its hosts.  The two 
main virulence factors that STEC possesses are a pathogenicity island (PAI) encoding a type III 
secretion system as well as to expression one or more Stxs. 
 
1.2.1. Type III Secretion system 
 It is known that  E. coli O157:H7 intimately attaches to the lymphoid follicle-dense 
mucosa in the terminal rectum resulting in attaching-effacing (A/E) lesions [25].  The genes 
required for A/E lesions are encoded on a PAI termed LEE (locus of enterocyte effacement).  
The locus of enterocyte effacement encodes a type III secretion system (TTSS) consisting of 
approximately 40 open reading frames within five operons.  The first four operons are designated 
LEE1, LEE2, LEE3, and LEE4.  LEE1-3 contains the genes required for the structural 
components of the TTSS that spans the bacterial inner and outer membranes [26].  LEE4 encodes 
proteins necessary for filament and pore formation.  These include EscF, EspA, D, F and B.  The 
fifth operon encodes proteins having effector activity within the host cell including Tir, intimin 
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and the Tir chaperone, Ces T [27].  One of the control mechanisms regulating LEE expression is 
the LER protein.  The LER activates transcription of the LEE genes by binding to the upstream 
regulatory region of LEE2 [28].   
 Type III secretion systems are exclusive to gram negative bacteria and are required for 
directly transporting bacterial proteins (referred to as effector proteins) from the bacterial cytosol 
into host cells [27].   This requires the formation of a needle complex that is able to span the 
inner bacterial membrane, peptidoglycan layer, the outer bacterial membrane and as well across 
the host cellular membrane and into the host cell interior [29].  In E. coli O157:H7, the surface 
translocon structure is a key component of the needle complex.  The translocon is made by the 
polymerization of EscF and the long filament portion is composed of EspA [29].  EspA subunits 
are assembled in a helical structure which develop into a cylindrical structure with a central 
channel [30].  The extent of the translocon structure is determined genetically [31].  Physical 
contact between EspA and EspB has been confirmed.  EspB (along with EspD) forms pores of 
approximately 3-5nm in diameter in the host cell membrane [32].  EspB is also translocated into 
the host cytosol and is involved in signal transduction events that provoke effacement of 
microvilli and the formation of pedestal-like structures, a prerequisite for the intimate attachment 
of E. coli O157:H7 to host cells [31].  Physical contact between EspB and EspD has been 
demonstrated [31].   EspD acts as a capping protein, as well as an anchor to connect the filament 
to the epithelial cell [1].  CesD, has been shown to be a secretion chaperone for the EspD protein 
and is needed for the overall extracellular secretion of EspB [33]. 
 The “export” apparatus of the needle complex is mainly located in the inner membrane of 
the bacterial cell and is required for targeting and propelling secretion of the outer membrane 
proteins as well as the effector proteins.  The export apparatus is composed of EscD, EscR, 
EscU, EscV, EscS and EscT proteins and is also associated with the cytoplasmic ATPase EscN 
[26]. The ring-shaped outer membrane protein in E. coli O157:H7 is EscC and is in direct contact 
with the translocon needle that protrudes from the bacterial cell [26].  The inner and outer 
membrane protein structures are connected by EscJ [26]. 
 One of the most important T3SS effector proteins of E. coli O157:H7 is Tir (translocated 
intimin receptor).  Tir is a multi-functional protein serving as a receptor for the bacterial outer 
membrane protein intimin and is also involved in activating host signalling pathways leading to 
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actin rearrangement [25].  Once inserted into the host cellular membrane, Tir adopts a hairpin-
like topology revealing an extracellular domain that binds to intimin, leaving the amino- and 
carboxy-terminal regions intracellular [34].  In eukaryotic cells, actin polymerization is under the 
control of the Arp2/3 complex.  This complex is stimulated by the WASP (Wiskott-Aldrich 
syndrome protein) family of proteins, particularly the N-WASP protein [25].  Subsequently, N-
WASP is activitated by the Rho-family GTPases, such as Nck [25].  Therefore, E. coli O157:H7 
recruit N-WASP to sites of infection through Tir in order to cause actin rearrangement and 
pedestal formation within host cells.  Recently it has been shown that residues 454-463 within E. 
coli O157:H7 Tir are crucial for pedestal formation [25].  The discovery of another bacterial 
protein called Tccp encoded by EHEC, was also shown to induce pedestals by the activation of 
N-WASP [35].  Tir also redirects  the recruitment of host cytoskeletal proteins such as α-actinin, 
ezrin, coractin, talin, fimbin, vasodilator-stimulated phosphoprotein, and actin-related protein 
complex in order to provoke pedestal formation [36].   
 Finally, the binding of intimin to its receptor Tir, initiates the intimate attachment of 
bacteria to intestinal epithelial cells increasing bacterial numbers and prolonging fecal shedding 
[31].  To date, intimin is the only agreed upon E. coli O157:H7 adherence factor shown to 
participate in intestinal colonization in vivo in an animal model [3].  Various subtypes of intimin 
have been shown to exist.  Enterohaemorrhagic E. coli O157:H7 strains expressing intimin-α 
produce A/E lesions in both the small and large intestines whereas EHEC strains producing 
intimin-γ produce A/E lesions in the large intestine in gnotobiotic piglets [31].  The different 
subtypes of intimin therefore influence tissue tropism in different hosts. 
 
1.2.2. Fimbrial Adhesins 
 E. coli O157:H7 contains a highly conserved plasmid called pO157 that was proposed by 
Karch et al [37] to encode fimbrial adhesions that allowed bacteria to attach to Henle407 
epithelial cells.  Since this study, conflicting data has emerged and the role of pO157 in 
adherence is controversial.  Hall et al [3] reported that loss of the plasmid had no effect on 
adhesion in serotype O5:H- whereas other serotypes did show reduced adhesion.  Oral 
inoculation of adult rabbits with strains that did not possess the plasmid showed decreased 
adherence to intestinal cells but the presence or absence of the plasmid made no difference in the 
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amount of diarrhea observed.  A critical limitation in establishing the role of pO157 is the lack of 
suitable animal models that replicate all aspects of the human disease.  After culturing E. coli 
O157:H7, Maneval et al [37] described rigid fimbrial structures on the surface of the bacteria but 
after sequence analysis, pO157 revealed no fimbrial gene cluster.  Despite the conflicting data 
about pO157, epidemiological data has shown that it is extensively distributed among human 
EHEC isolates.  A study done by Levine et al [3] revealed that 99% of 107 E. coli O157:H7 
human isolates possessed the plasmid.   
 
1.2.3 Nonfimbrial Adhesins 
 Many E. coli O157:H7 nonfimbrial adhesins have been suggested to play a role in 
bacterial pathogenesis.  Paton et al [38, 39] showed that antibodies to LPS blocked bacterial 
adhesion to Henle407 cells whereas the pre-treatment of the same cells with LPS did not block 
E. coli O157:H7 adherence.  This suggested that the antibodies were sterically hindering the LPS 
structure and thus physically blocking adherence [1].  Another nonfimbrial adhesin, a 94-kDa 
outer membrane protein associated with adherence to Henle407 cells and which is 
immunologically distinct from intimin [37].  Tarr et al [9] reported that an outer membrane 
protein termed Iha, located on O-islands 43 and 48 possibly involved in E. coli O157:H7 
adherence.  Also, the identification of a large outer membrane protein called ToxB encoded on 
pO157 has been implicated in E. coli O157:H7 adherence.  ToxB has homology to toxins A and 
B from Clostridium difficile.  ToxB facilitates the secretion of TTSS hence playing a role in full 
bacterial adherence.  Enterohaemorrhagic E. coli cured of their pO157 plasmid  resulted in lower 
numbers of bacterial colonies on Caco-2 cells and reduced secretion of EspA, EspB and Tir [7].   
The Efa1 (EHEC factor for adherence) has homology to ToxB and was detected when an efa1 
mutant showed decreased adherence to hamster ovary cells [7].  Further studies showed that Efa1 
contributes to bovine intestinal colonization.  Another nonfimbrial adhesin important for bovine 
colonization is Saa which has been shown to be associated with STEC isolated from cattle rather 
than from humans [7].  Finally, the outer membrane protein A (OmpA) seems to be an E. coli 
O157:H7 nonfimbrial adherence factor besides being associated with many other functions such 
as porin activity and conjugation mediation [1]. 
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1.2.4. Secreted proteases 
 Shiga toxin-producing E. coli encode several proteases that are suggested to contribute to 
the progression of disease in humans.  These proteases are not involved in the production of A/E 
lesions and often their functions are unknown.  E. coli O157:H7 secretes a plasmid-encoded 
serine protease termed EspP.  EspP has sequence homology to EspC of EPEC and both are 
known as autotransporters mediating their own secretion through the bacterial outer membrane 
[37].  One of the substrates of EspP is human coagulation factor V which suggests that E. coli 
O157:H7 may interfere with the human blood clotting cascade.  Not all E. coli O157:H7 that 
encode EspP produce EspP as shown in one study where only three of five E. coli O157:H7 
isolates produced EspP as detected by Western blots [40].  EspI is a serine protease functionally 
related to EspP.  EspI degrades pepsin A and again human coagulation factor V [7].  Shiga toxin-
producing Escherichia coli strains also secrete EpeA which is another plasmid-encoded serine 
protease which has mucinase activity.   
 
1.2.5. Hemolysin 
 STEC produce a plamid-encoded hemolysin termed Ehly 1-associated protein.  Ehly 1-
associated protein was first characterized by Beutin et al [41] by the production of small turbid 
zones of haemolysis on blood agar plates.  This description suggested a defective mechanism of 
secretion resulting in only small incomplete zones of haemolysis although clones of serogroup 
O103 have been isolated that produce large clear zones of haemolysis suggesting an 
overproduction of Ehly 1-associated protein [37].  Ehly 1-associated protein is a member of the 
repeats in toxin (RTX) family of toxins and has been shown to be expressed by a range of other 
pathogens [41].  It is hypothesized that Elhy contributes to disease in humans through the lysis of 
red blood cells and the subsequent release of haemoglobin as a source of iron.  Chart et al [37] 
showed that production of Elhy 1-associated protein can be increased by growing cells under 
conditions of low oxygen tension and anaerobic conditions which are similar to the environment 
found in the gut of humans and animals.   
 Ehly has been recently used as an epidemiological marker to detect STEC strains since 
many common serogroups such as O157, O26 and O111 produce Ehly 1-associated protein [37].  
A plasmid-based probe CVD419 showed good correlation with Ehly 1-associated protein 
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production and was subsequently used to confirm the presence of the ehly gene.  In 1992 a study 
done by Barrett et al [42] showed that 28 of 28 E. coli O157:H7 isolates were CVD419 probe-
positive.  Also in 1992, 29 of 48 non-O157 STEC isolates were found to be CVD419 probe-
positive and 125 of 224 cattle isolates were CVD419 probe-positive [42].  Surprisingly, when the 
same 224 cattle were tested for the eae gene, only approximately 62 were positive [37].  Schmidt 
and Karch found the incidence of Ehly 1-associated protein was higher in STEC isolates causing 
HUS compared to STEC isolates causing only diarrhea suggesting its importance in the 
development of HUS [43].   
 
1.2.6. Other possible virulence factors 
 Other important virulence factors encoded by many STEC strains include a 3169 amino 
acid protein termed cytolethal distending toxin (CDT), that has similarities to the large clostridial 
toxins (LCT) A and B [37].  Large clostridial toxins possess an N-terminal glucosyl-transferase 
that disrupts cell architecture suggesting that CDT encoded by STEC strains also acts through a 
similar mechanism.  Recent studies have also shown that CDT is lethal for two lines of human 
vascular endothelial cells suggesting it may be involved in intestinal damage [7]. 
 A very high percentage of E. coli O157:H7 strains possess the enteroaggregative heat-
stable toxin (EAST1) that was first identified in the pathotype Enteroaggregative E. coli 
(EAggEC).  The role of the toxin in human infection remains unknown but it has been shown to 
induce fluid secretions in a rabbit ileal model suggesting it may induce watery diarrhea in 
humans [37]. 
 Sequence analysis of pO157 has revealed a potential catalase/peroxidise encoded by the 
gene katP.  The exact role of the enzyme has yet to be determined but other bacterial catalases 
have been shown to neutralize cytotoxic oxidants produced by host macrophages thus aiding in 
bacterial survival [37].  To date the katP gene has not been found in sorbitol-fermenting E. coli 
O157:H7 and its distribution among O157 isolates is inconsistent. 
 The flagella produced by STEC can play an important role in pathogenesis.  A study done 
by Erdem et al [44] showed that H7 and H6 flagellin have adhesive properties that bind mucins I 
and II, and contribute to the colonization of cattle.  These results were later verified using a H7 
fliC mutant which showed reduced ability to adhere to a bovine terminal rectal epithelial cell 
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line, but adherence was restored through complementation [45].  However, complementation 
analysis with the heterologous fliC from H6 was unable to restore H7 adherence properties. 
 Finally, recent studies by Klapproth et al [37] have shown that some O157 isolates may 
be capable of inhibiting lymphocyte activation.  No specific gene(s) have been identified to 
attribute to this phenotype, but research on EPEC has shown that the gene(s) are non-LEE 
encoded.  Further studies are required to determine their significance and possible role in EHEC 
virulence. 
 
1.3 Toxins 
 Toxins possess very specific biochemical activities enabling them to either stimulate or 
disturb various cellular processes [46].  The different properties, targets and mechanisms of 
toxins are all important considerations when studying toxin biology [46].  Many bacterial toxins 
interfere with fundamental host functions therefore causing cellular death [47].  While other 
pathogens that are able to persistently colonize their host often use toxins to avoid the immune 
response by modulating a variety of cellular functions.  Often, bacterial toxins are not toxic at 
biological concentrations required to achieve persistent colonization.   
 Currently, researchers have found ways to use toxins to advance science and the medical 
field.  For example, tetanus and cholera toxins have been used to decipher critical steps in 
cellular pathways such as in signal transduction and regulated secretion [47].  The botulism 
toxin, one of the most toxic poisons known to humans is now used cosmetically and medically to 
treat wrinkles and urologic disorders [48].  This is made possible due to the extreme potency and 
specificity of the toxin which allows for the dose of the toxin to be so small that it remains at a 
biological concentration that is not toxic to its host. 
 
1.3.1 Shiga toxin family 
 In 1898, a Japanese scientist by the name of Kiyoshi Shiga discovered “Shiga toxin” 
during an epidemic of dysentery in Japan due to Shigella dysenteriae [49].  We now define the 
Shiga toxin family as a group of genetically and functionally related molecules consisting of two 
groups (Shiga toxin from S. dysenteriae and Stx1 from E. coli form group 1 and the Shiga toxin 
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2 family forms group 2) with five members including Shiga toxin 1, Shiga toxin 2, Shiga toxin 
2c, Shiga toxin 2d and Shiga toxin 2e [49]. 
 Shiga toxin 1 is a homogenous family of toxins and is neutralized by anti-serum to Shiga 
toxin [14].  Shiga toxin 1 variants exist that differ by one amino acid but toxicity remains 
unaltered [14].  Shiga toxin 2 is very heterogeneous possessing variants of human and animal 
origin and is therefore divided into a number of subtypes [4].  Two variants, one isolated from a 
pig and the other from a patient with HUS, have been isolated that are immunologically related 
to Stx2 [4].  DNA sequencing of the two isolates revealed that the genome of the porcine strain 
does not possess a toxin-converting bacteriophage [50].  This Stx2 variant is termed Stx2e and is 
associated with edema disease in pigs, produced by strains E57, S1191 and 412 and is only 
weakly active on HeLa cells in vitro [51].  The other Stx2 variant isolated from the HUS patient 
was shown to be produced by strain H.I.8 and is more closely related to Stx2e [14].  In 2000, 20 
variants of Stx2 had been reported with varying degrees of homology to Stx2 and Shiga toxin 
from S. dysenteriae I [52].  Shiga toxin 2 and Stx2c have been repeatedly isolated from humans 
with HUS and Stx2d is not usually associated with cases of diarrhea [15].  Finally, Stx2f has 
been isolated from STEC with an avian origin [15]. 
  
1.3.1.1. History and Nomenclature 
 The Shiga toxins are regarded as the principal virulence factor of STEC.  The history of 
the Shiga toxins produced by Enterobacteriaceae was first described by Conradi in 1903 [7, 51].  
Then in 1977, Konowalchuk described an E. coli cytotoxin that was lethal for Vero (African 
green monkey kidney) cells and was distinct from other E. coli toxins such as E. coli heat-stable 
toxin or heat-labile toxin [51].  Later in 1983, O’Brien et al [51] showed that the cytotoxin was 
indistinguishable in physiochemical features and biological activity to the Shiga toxin produced 
by Shigella dysenteriae I and was therefore named Shiga-like toxin (SLT).  Shiga toxin (or SLT) 
produced by E. coli O157:H7 was demonstrated to be the causative virulence factor for HC and 
HUS in humans [51].  DNA sequencing of the E. coli O157:H7 genome in 2001 revealed that the 
E. coli O157:H7 genome had 1,387 genes that were not found in the non-pathogenic K12 
genome [8].  Many of these genes were located on pathogenicity islands of bacteriophage origin 
including Shiga toxin 1 (Stx1) and Shiga toxin 2 (Stx2).  Later, British researchers found that 
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stx1 and stx2 gene expression was coordinated with prophage gene induction and for this reason 
alone, antibiotics are not recommended upon infection with STEC as they increase the amounts 
of free Stx in the gut lumen [8].  To date, 18 prophage and prophage-like elements have been 
recognized in the EDL933 genome [8].  Two of these include CP933V (Shiga toxin 1 encoding 
prophage) and BP933W (Shiga toxin 2 encoding prophage) [8]. 
 
1.3.2. Shiga toxin 2 
 The clinical significance of Stx2 in humans compared to Stx1 is linked to a more serious 
course of disease and is more important in the development of HUS.  For example, an STEC 
outbreak occurred in Japan where 131 patients were infected with a Stx1-producing STEC 
serotype.  In this outbreak, no cases of HUS were documented and the gastrointestinal symptoms 
were comparatively mild [53].  To further this point, a study on sporadic HUS cases in humans 
was completed.  The results of this particular study revealed that 94% of HUS cases involved 
STEC capable of producing Stx2 alone or a combination of Stx2 and Stx1 [54].  Finally, animal 
studies have demonstrated that Stx2 is more fatal than Stx1 in mice [55] and gastrointestinal 
pathology is worse in rabbits infected with Stx2
+
 strains of STEC than Stx1
+
 strains [56].   
  
1.3.2.1. Biological Activity 
 The Shiga toxins are comprised of 1 A subunit and 5 B subunits.  The A subunits of Stx1 
and Stx2 share approximately 57% nucleotide sequence homology and the B subunits share 
approximately 60% homology [51].  The A subunit has a molecular weight of approximately 32 
kDa and the B subunit approximately 7 kDa [57].  The B subunits of Stx2 are identical but the A 
subunits differ which leads to variations in lethality.  The B subunit is responsible for 
recognizing and binding to the blood-group-active glycolipid receptor globotriaosyl ceramide 
(Gb3) which has the structure Galα[1-4]Galβ[1-4]Glc-ceramide [39].  On the other hand, the 
Stx2e variant uses globotetraosyl ceramide, Gb4 [58].  Only two toxins are known to use 
glycolipid receptors; the cholera toxin and the shiga toxins.  All Stxs linked to human disease 
recognize the Gb3 receptor.  Upon receptor recognition and binding, the A subunit of the toxin is 
internalized via receptor-mediated endocytosis followed by retro-grade transport to the Golgi 
apparatus, the endoplasmic reticulum (ER) and finally translocation into the cytoplasm.  The A 
15 
 
subunit is proteolytically cut between Ala253 and Ser254 resulting in a 28-kDa N-terminal 
peptide with enzymatic activity (A1 peptide) that is linked by a disulfide bond to a 4-kDa peptide 
(A2 peptide) [14].  The N-glycosidase activity of the A subunit targets the 28S rRNA where it 
cleaves a specific N-glycosidic bond thereby removing a single adenine residue subsequently 
preventing elongation-factor-1-dependent binding of aminoacyl-tRNAs to ribosomes which 
inhibits protein elongation thus killing the cell [57].   
 
1.3.2.2. Structure 
 Structural analysis of Stx2 by Jackson et al [59] showed that a hydrophilic region at the 
N-terminus of the B subunit was responsible for the binding activity of Stx2 and another region 
at the C-terminus was required for extracellular localization.  Crystal and NMR structure 
analyses of the B subunit have revealed it is comprised of two three-stranded anti-parallel β-
sheets and an α-helix [52].   
 Crystal structures of Stx1 and Stx2 have revealed four major differences in their 
structures [60].  First, the active site of the A subunit was found to be much more accessible in 
Stx2 when compared to Stx1.  Second, the presence of an α helix in the carboxy terminus of the 
A1 peptide of Stx2 allows for binding at a receptor-binding site whereas this site remains 
unoccupied in the Stx1 structure.  Third, one of the carbohydrate binding sites in the B subunit 
has a different conformation when compared to Stx1 and this conformational variability may 
lead to different binding affinities for the Gb3 receptor.  Finally, the carboxy terminus of the A1 
peptide of Stx2 binds Gb3 in contrast to the A1 peptide of Stx1 [38].   
  
13.3 Genetics of Shiga toxins 
 As early as the 1920s, scientists began to discover the role of bacteriophages in bacterial 
pathogenicity.  Frobisher and Brown were the first to record that nontoxigenic streptococci 
acquired the ability to produce scarlatinal toxin after exposure to filtered supernatants of 
toxigenic streptococci [61].  Many examples exist of bacteriophage encoded toxin genes within 
bacteria including the pertussis toxin in B. avium, the botulinum toxin in C. botulinum, the 
diphtheria toxin in C. diphtheria and the Shiga toxins (Stx1 and Stx2) in E. coli [62].   
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1.3.3.1. Bacteriophage Origin 
 Shiga toxin 1 is encoded by a gene on a λ-like prophage called CP-933V and the gene for 
Shiga toxin 2 is encoded on a λ-like prophage called BP-933W [8].  Both Stx1 and Stx2 
production is controlled by the bacteriophage lifecycle.  When a lambdoid phage lysogenizes a 
cell, the specific phage repressor inhibits transcription of most phage genes and the prophage is 
in a quiescent state.  Removal of the repressor results in the induction of the lytic cycle and the 
transcription of phage-encoded genes such as stx1 and stx2.  The stx genes are located in λ-like 
prophages within the late gene operon suggesting that they are co-ordinately expressed following 
prophage induction from the late phage promoter (pR’) [63].  Wagner et al [63] showed in 2001 
that stx2 gene expression relies primarily on the pR’ promoter and therefore on prophage 
induction from the lysogenic state to the lytic state.  They constructed a mutant prophage that 
was deleted for the pR’ promoter region and results showed a significant reduction in Stx2 
protein production. 
 
1.3.4. Shiga toxin Receptor 
 Glycolipids are ubiquitous membrane components that display cell type-specific patterns 
and are present in bacteria, plant and animal species.  Both bacteria and plants express 
glycoglycerolipids but animals express glycosphingolipids (GSLs) [64].  There are four classes 
of glycosphingolipids based on their carbohydrate core structure and these include the 
gangliosphingolipids, the globosphingolipids, the lactosphingolipids and the 
mucoglycosylceramides [65].  All Shiga toxins specifically recognize and bind to the globo 
series GSLs such as Gb3 [58].  Apart from being the Shiga toxin receptor, Gb3 is also the Pk 
antigen of the P blood group system and Gb3 is also known as CD77which is the Burkitt’s 
lymphoma antigen [66].   
 In 1998, Menge et al [67] demonstrated that bovine lymphocytes including peripheral 
blood mononuclear cells (PBMCs) and intraepithelial lymphocytes (IEL) express surface 
glycolipids, specifically the Gb3 receptor.  Subsequently they showed the immunomodulatory 
effects of purified Stx1 on bovine PBMCs was through the inhibition of mitogen induced 
proliferation [68].  Later the same group of researchers concluded that Stx1 directly affects 
bovine lymphocytes suggesting that the immune system is a major target for Stxs in cattle [69].  
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Cattle are the primary nonhuman reservoir for STEC and the pathogenicity of STEC for cattle is 
low.  Some experimentally infected calves developed bloody diarrhea but no disease state in 
adult cattle has been associated with STEC infection [70].  Some researchers have hypothesized 
that the lack of disease in cattle has contributed to its spread to humans and therefore much effort 
has been put into understanding how STEC is able to persistent asymptomatically in the bovine 
host. 
 
1.3.4.1. Structure 
 Glycolipids are composed of one or multiple monosaccharides glycosidically bonded to a 
lipid moiety [64].  In general, an amide bond links the fatty acid moiety to the amino group of 
the sphingosine which forms the ceramide portion of the molecule.  As just mentioned, the 
ceramide portion is also glycosidically bonded to a carbohydrate head. Often the lipid moiety is 
hidden in the cellular membrane bilayer extruding the carbohydrate moiety on the cell surface.  
The structure of Gb3 is shown in Figure 1. 
 
1.3.4.2. Interaction of Gb3 with Shiga toxins 
 Initial Stx-cell interaction experiments were done using cultured cell lines which revealed 
that only sensitive cells were able to remove Stx bioactivity from the overlying culture media 
[71].  Further experiments demonstrated that the addition of tunicamycin, an inhibitor of N-
linked glycosylation, inhibited Stx activity indicating that Stx binds to a carbohydrate-containing 
receptor [71].  Upon the advent of purified iodinated Stx, direct binding studies were possible 
and in 1983 Brown et al [72] using thin-layer chromatography, proposed that glycosphingolipids 
were the Stx receptor.  They showed that Stx bound to glycosphingolipids possessing terminal 
galα1-4gal disaccharides such as Gb3 [71].  Also, Jacewicz et al [73] showed that Stxs bind to 
globotriosylceramide isolated from rabbit jejunum and a few years later, Lindberg et al [71] 
confirmed the requirement for the terminal galα1-4gal disaccharide for Stx binding.  As well, 
Mobassaleh et al [74] demonstrated that rabbit jejunal membranes showed age-dependent 
susceptiblity to fluid secretions caused by Stxs which correlated with age-dependent Gb3 levels.  
Finally, loss of eukaryotic cell susceptibility to Stxs was shown through a variety of experiments 
including the inhibition of Stx-binding using monoclonal antibodies which bound to Gb3, 
18 
 
destruction of Gb3 by digestion of membrane glycolipids, and through the inhibition of Gb3 
biosynthetic pathways [75].   
 Cellular susceptibility to Stxs is not determined exclusively by Gb3 content. It was 
demonstrated that the ceramide (lipid) portion of Gb3 had a direct role on Shiga toxin 
recognition and binding as Shiga toxin did not bind to a lipid-free oligosaccharide nor to an 
oligosaccharide bound to bovine serum albumin [76].  Subsequently Lingwood et al [58] showed 
that the ceramide portion of Gb3 determined the orientation and portion of the carbohydrate 
moiety displayed on the cellular surface thus affecting the interaction of the oligosaccharide head 
group with Stx.  They found that unsaturated fatty acids with chain lengths between 20 and 22 
showed the highest binding affinity for Shiga toxin 1 and chain lengths of 18 for Shiga toxin 2.   
 It is understood that carbohydrates have a very poor affinity for monovalent binding 
therefore multivalent interactions of ligands and receptors are necessary for efficient binding 
[64].  In 1998, Hooper et al [77] showed that membrane GSLs are bunched together in the outer 
leaflet of the membrane bilayer which can contribute to both the structural rigidity of the outer 
leaflet and efficient multivalent ligand interactions.  This finding agreed with the X-ray 
crystallography structures generated of Shiga toxins bound to the Gb3 receptor analogue Pk-
MCO which revealed three trisaccharide molecules bound to each B subunit monomer of Stx.    
Therefore this finding implies that each B subunit has three distinct sites postulated to interact 
with Gb3 and that there are 15 bound trisaccharides per Stx pentamer [64].    
 
1.3.4.3. Receptor Distribution 
 The distribution of the glycolipid receptor amongst various eukaryotic cell types greatly 
influences the pathogenesis of disease.  In humans, high levels of Gb3 are found in the cortical 
region of the kidney which is also the primary site of renal lesions in HUS patients [38].  Studies 
using human, baboon and mouse kidneys showed similar amounts of Gb3 in their cortex and 
medulla regions and Stxs were primarily associated with the tubular epithelial cells [38].  Takeda 
et al [78] also showed increased levels of tubular injury markers during the early stages of HUS 
which coincided with the number of HUS patients displaying tubular necrosis.   
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Figure 1.  Structure of Gb3 as presented by Lingwood et al [58]. 
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The finding that red blood cells possess the glycolipid receptor on their surface may also 
influence the pathophysiology of HUS.  As previously mentioned, the human P blood group 
antigens are glycolipids.  More specifically, the Pk antigen is Gb3, the P antigen is Gb4 and the 
P1 antigen is a neolactoceramide containing  a Galα1-4Gal moiety [38].  In 1990, Taylor et al 
[38, 79] hypothesized that red blood cells may remove Stxs from the circulation and in turn 
protect Gb3-possessing tissues.  Subsequently, in vitro studies showed that purified Stxs are able 
to bind to red blood cells but direct red blood cell-Stx binding during human STEC infection has 
yet to be investigated [38].   
 The Shiga toxins are able to bind to human endothelial cells and majority of 
histopathological lesions related to HUS are due to this interaction [38].  Early in vitro analyses 
revealed the susceptibility of cultured endothelial cells to the Stxs through loss of viability.  The 
addition of certain cytokines such as TNFα and interleukin-1β enhanced Stx cytotoxicity and this 
was shown to be a result of the upregulation of Gb3 on the cell surface [38].  However, 
experiments using cultured endothelial cells have been difficult to interpret because cells isolated 
from different human tissues exhibit varying properties.  For example, human renal  and 
intestinal microvascular endothelial cells do not display increased sensitivity after pre-incubation 
with either TNFα or lipopolysaccharide (LPS) whereas human cerebral endothelial cells do [38]. 
 
1.3.5. Entry of Shiga toxin 2 
 After binding to the  receptor Gb3, Stxs are exclusively internalized through clatharin-
coated pits [80].  Shiga toxin internalization can be inhibited by the removal of clatharin pits 
using hypotonic shock followed by potassium depletion as well as when the formation of the pit 
vesicle is inhibited by acidification of the cytosol [80].   After endocytosis, internalized Stx can 
follow several pathways.  One route used by Stx-resistant cells involves the rapid transport of 
Stxs to lysosomes where they are degraded.  A second possible route is through retro-grade 
transport of endosomal Stxs to the cytosol via the Endoplasmic Reticulum (ER) and the Golgi 
apparatus is required for intoxication.  It has been suggested that Stxs first enter the Golgi 
apparatus from endosomes using a pathway dependent on a GTP-binding protein called Rab9.  A 
third possible route might include the transport of endosomal Stxs directly to the trans-Golgi 
network (TGN) via the endosomal perinuclear recycling compartment [80].  From the TGN, it 
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has been reported that Stxs are transported to the ER by a Rab6-dependent process and that Stxs 
finally reach the cytosol by the Sec61 translocator complex [81].  Johannes et al [82, 83] showed 
that the B subunit of Stx rather than holotoxin is sufficient to guide retro-grade transport to the 
ER but that the B subunit does not possess a trafficking sequence in the carboxy-terminus end 
that many proteins that traffic to the ER via the Golgi do.  Subsequently, it was demonstrated 
that the lipid portion of Gb3 rather than Stx itself contains the trafficking sequence necessary to 
drive the retro-grade transport of Stxs to the cytosol [75].  Thus, treatment of cells with butyric 
acid has been shown to sensitize cells by changing their lipid composition (increasing fatty acid 
chain length) and therefore increasing Stx transport to the Golgi apparatus [81].   
 
1.3.6. Mode of Action of Shiga toxin  
 The A subunit of Shiga toxin contains a loop formed by an internal disulfide bond.  This 
loop is very sensitive to trypsin and cleavage results in the formation of A1 and A2 subunits.  The 
A1 subunit is enzymatically active and is necessary for inhibiting protein synthesis in cells [81].  
Studies using site-directed mutagenesis altering the trypsin-sensitive site revealed that Stx 
retained cytotoxicity for cultured epithelial cells but that the effect was grossly delayed [81].  
This pointed to the possibility of an alternative processing pathway most likely dependent on 
cellular enzymes.  Two enzymes were subsequently demonstrated to cleave the A subunit of Stx 
strategically located in different areas of the cell.  Garred et al [75] first showed that furin, a 
calcium-sensitive serine protease, was responsible for cleaving the A subunit within endosomes 
and the TGN.  Furin recognizes the consensus motif Arg-X-X-Arg, which is found in the loop 
region of the A subunit while cleavage occurs optimally at low pH [75].  Also the cytosolic 
protease calpain was shown to cleave Stx as inhibition of calpain prevented cellular toxicity. 
 It is well accepted that the enzymatically active A1 subunit must enter the cytosol in order 
to contact ribosomes and inhibit protein synthesis [81].  The A1 subunit has been shown to be 
responsible for cleaving an adenine base from the 28S rRNA at position 4324 thereby inhibiting 
peptide chain elongation by preventing aminoacyl-tRNA binding to the acceptor site on the 
ribosome. [75].  Therefore the holotoxin undergoes transport to the Golgi apparatus and along 
the way the A1 subunit may be generated by furin in the endosome and/or TGN and released 
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from the A2 subunit in the ER [75].  If for some reason holotoxin or whole A subunit reaches the 
cytosol, calpain provides a less effective means for proteolytic cleavage [75]. 
 
1.3.7. Role of Shiga toxins in Pathogenesis 
 Since STEC are exclusively non-invasive pathogens, limiting their colonization to the 
intestinal mucosa, the translocation of Stxs from the gut lumen to underlying tissues and the 
bloodstream is assumed since infection with STEC causes systemic sequelae in both humans and 
animals.  However, Stxs have not been detected in the blood of patients with HUS [52].  Clinical 
manifestations of patients experiencing HUS show that the gastrointestinal tract and kidneys are 
the organs most commonly affected and the vascular endothelial cells of these organs are the 
primary targets.  Thrombotic lesions have also been reported in HUS patients in the 
microvasculature of the pancreas and brain [38].  Based on both in vivo and in vitro studies, the 
Shiga toxins have been shown to have multiple potent effects which include i) cytotoxicity ii) 
enterotoxicity and iii) paralytic activity.  These effects have been shown to be dependent upon 
the targeted organ and specific cell type [84]. 
 
1.3.7.1. Gastrointestinal Tract 
 It has been hypothesized that Shiga toxins breach the intestinal epithelium either through 
lesions in the mucosal barrier and/or the destruction of tight junctions providing the portal of 
egress for Stxs into the circulation.  In 2002, Hoey et al [85] showed that the bovine intestinal 
epithelium including the ileum and jejunum express the Gb3 receptor.  The direct translocation of 
toxins through epithelial cells has also been shown using polarized cell lines.  Damage of the 
intestinal epithelium was shown using a ligated rabbit ileal loop model where purified Stx was 
inoculated directly into the loops [86].  Direct enterotoxic properties including mucosal 
inflammation and fluid accumulation, resulted in altered glucose and amino acid absorption.  
O’Loughlin et al [75] have hypothesized that this increased mucosal inflammation enhances 
luminal Stx absorption increasing the amount of intact Stx into systemic circulation.  How the 
Stxs cross the epithelial barrier, studies have shown that the vascular endothelial cells are the 
primary target of Stxs within the GI tract.  The diarrhea induced by infection with STEC in 
humans is due at least in part to exposure of enterocytes to Stx in the gut.  Purified Stx was 
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shown to induce haemorrhagic lesions on the large intestine and thrombosis in the blood vessels 
of the mesentery in rabbits [75].  Tashiro et al [87] showed that the Stxs produce hemorrhagic 
lesions in the small intestine in rats.  As well Sjogren et al [75] used a rabbit model to show the 
presence of microvascular thrombosis in the submucosal vessels of the cecum and colon when 
infected with Stx-producing STEC compared to those infected with Stx-negative strains.  In 
contrast, studies using piglets showed that the presence of Stx did not affect the outcome of 
disease [88]. 
 
1.3.7.2. Kidneys 
 Studies using cultured cell lines revealed that Stxs are cytotoxic for renal endothelial, 
epithelial and mesangial cells [75].  The human kidney expresses high levels of the Stx receptor, 
Gb3 in both the cortex and medulla which is consistent with the histopathological differences 
observed in patients diagnosed with HUS [75].  The principal histopathological changes 
associated with HUS include swollen and detached glomerular endothelial cells and deposition 
of fibrin in the renal microvasculature [38].  This led to the belief that vascular endothelial cells 
in certain organs, including the kidneys, are specifically targeted by Stxs.  Lingwood et al [58] 
showed that fluroescein-conjugated Stx binds to renal distal convoluted tubules, collecting ducts, 
glomeruli and proximal tubules and another study done by Uchida et al [75] showed that Stx 
binds to both renal endothelial and epithelial cells in distal tubules.  Also, β2 microglobulin levels 
are elevated in HUS patients indicating considerable tubular dysfunction [75].  No small animal 
model of HUS is currently available although studies using rabbits and mice have resulted in 
noteworthy conclusions.  Studies using mice fed E. coli K12 containing either the stx1 or stx2 
gene cloned into a high-copy plasmid revealed acute renal bilateral cortical tubular necrosis and 
after 5 days, all of the mice that were exposed to Stx2 died.  Also, rabbits exposed 
intraperitoneally to STEC developed acute focal tubular necrosis in the kidneys as well as 
diarrhea and cecal lesions [75].  Similar results were observed when the rabbits were exposed 
only to purified Stx2 [89].  These studies led to the hypothesis that Stx2 is more commonly 
associated with HUS than Stx1.  Epidemiological studies have since revealed that Stx2-
producing STEC are more often associated with outbreaks of HUS than Stx1-producing STEC 
[52].  In mice, Stx2 has been found to be 400-fold more potent than Stx1 and when Stx2 and LPS 
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were administered together, there was enhanced lethality [55].  Also, passive immunization of 
mice with anti-Stx2 has been shown to be protective as these mice do not develop renal failure 
contrary to the mice that received anti-Stx1 antibodies after STEC infection [75].  One possible 
explanation to account for these findings is that the in vivo level of transcription of stx2 is higher 
since stx1 is iron repressible.  An alternative explanation is that the stx2 gene is a clonal marker 
for STEC strains possessing additional virulence factors [38]. 
 
1.4 The Immune System 
 The cells of the immune system can be divided into two groups based on function.  The 
first group are antigen non-specific and include monocytes/macrophages, natural killer (NK) 
cells, platelets and polymorphonuclear granulocytes.  The polymorphonuclear granulocytes are 
further divided into neutrophils, eosinophils and basophils [90].  These cells are part of the innate 
immune response that is mounted early in an infection due to their constitutive expression and 
relative non-specificity [91].  Thus, innate immunity provides the time required for the antigen-
specific cells or the adaptive immune response to develop.  The second group of cells are the 
antigen-specific cells or the lymphocytes.  These are part of the adaptive immune response which 
is inducible, highly specific and expresses positive memory [92].  
 
1.4.1 Innate Immunity 
 The innate immune system is a front-line barrier eliciting an immune response between 
0-4 hours after exposure to a pathogen. Within the gastrointestinal tract, the epithelial cells 
physically join together (a phenomenom known as tight junctions) to serve as a physical barrier 
and a first line of defense against pathogens.  The apical surface of the epithelials cells is coated 
in a continous layer of mucus and glycocalyx which is produced by goblet cells [93].  The innate 
immune system has three effector mechanisms including i) the phagocytic cells (including 
neutrophils, macrophages, natural killer cells and dendritic cells) ii) the complement system and 
iii) antimicrobial peptides including defensins and cathelicidins.  
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1.4.1.1. Phagocytic Cells 
 Phagocytosis is the uptake of foreign material by neutrophils, macrophages and dendritic 
cells.  STEC uses its functional type III apparatus to limit its uptake by preventing the F-actin 
polymerization required for uptake [94].  The ability of STEC to control this uptake by 
phagocytes is due to effectors EspF and EspJ, which are responsible for the inhibition of FcγR- 
and CR3 mediated phagocytosis [95].  Phagocytic cells are activated by the presence of invading 
pathogens through innate immune signalling receptors such as Toll-like receptors (TLRs) which 
are present on the surface of antigen presenting cells such as macrophages and dendritic cells. 
Toll-like receptors are of germline origin and they have evolved to recognize molecules not 
typically found in mammalian cells and are hence called pathogen-associated molecular patterns 
(PAMPs) [96].  Toll-like receptors contain three major domains.  First, the amino-terminal 
domain consists of a series of leucine rich repeats (LRRs) followed by a transmembrane domain 
and a C-terminal Toll/IL-1 receptor (TIR) domain.  Following ligand recognition and binding by 
the LRR domain, a signal is transduced across the membrane to the TIR domain, which activates 
associated adaptor proteins and subsequent signal transduction cascades.  The detection of 
invading microorganisms by Toll-like receptors results in the induction of reactive oxygen and 
nitrogen intermediates as well as acquired immune responses [97].  Currently, there are 10 
human and 9 murine TLR’s known to exist within the mammalian TLR family which recognize 
different components of microbes [98].  The LRR domains of TLR2 and TLR5 have been shown 
to bind peptidoglycan (PG) and flagellin [99].  A single bacterium is able to activate multiple 
TLRs such as TLR4 by LPS, TLR5 by flagellin, or TLR2 which recognizes PG [100]. 
 
1.4.1.2. Complement 
 The complement system is a defence mechanism that generates effector molecules 
involved in both innate and acquired immunity.  Complement activation is mediated through 
three different pathways including the classical, the alternative and the lectin pathway. Their 
effector functions include lysis of bacteria, opsonization and the attraction of phagocytes to the 
site of complement activation [101].  Complement is activated through three different pathways 
and all merge together in the activation of C3 convertase which is a surface associated enzyme 
complex that cleaves C3. Cleavage of C3 activates deposition of C3b on the surface of 
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microorganisms and release of C3a which is a potent chemoattractant.  C3b and its by product 
C3bi, are deposited on the surface of microorganisms which results in their engulfment by 
phagocytic cells. 
 Evidence has been presented that suggests a significant proportion of HUS patients have 
mutations in genes encoding proteins belonging to the alternative complement pathway [102].  
The alternative pathway provides an antibody-independent means of clearing bacterial infections 
by coating them with C3b thereby activating the terminal complement pathway.  Many different 
proteins including Factor H, Membrane cofactor protein and Factor I are involved in this process 
and mutations in these proteins often impair the alternative pathway suggesting a possible role 
contributing to the pathogenesis of HUS.   
 
1.4.1.3. Antimicrobial Peptides 
 Antimicrobial peptides are small polypeptides that have an antimicrobial activity and are 
used by all eukaryotic organisms including plants, insects and animals [103].  They are 
synthesized and secreted by polymorphonuclear leukocytes, macrophages and mucosal epithelial 
cells. Major antimicrobial peptides known to exist in cattle include: defensins, cathelicidins and 
anionic peptides [104]. There are several cationic antimicrobial peptides and a few groups of 
anionic antimicrobial peptides in domestic animals [301]. The defensins (α, β and θ) are 
approximately 2-6 kDa in size and are cysteine containing cationic peptides possessing three 
disulfide bonds [105].  The cathelicidins all possess an N-terminal signal peptide called the 
cathelin prosequence [103].  Cathelicidins are α-helical peptides and have microbicidal activity 
against Gram-negative and Gram-positive bacteria [103].  The peptides have been demonstrated 
to bind to LPS and provide protection in animal models against bacterial infection [106]. Other 
mammalian antimicrobial peptides include histatins and dermicidin [107]. Antimicrobial 
peptides have different mechanisms of killing pathogens as well as different ways to stimulate 
the immune system.  Immunostimulatory functions include induction of chemotaxis of immature 
dendritic cells and T cells, activation
 
of antigen-presenting cells (APC), increased glucocorticoid
 
production, macrophage phagocytosis, mast cell degranulation,
 
complement activation, and IL-8 
production [108, 109]. 
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1.4.2. Adaptive Immunity 
 In 1938, Tiselius and Kabat [107,[110] used electrophoresis to show that cell-free serum 
from an animal immune to a certain toxin contained more material in the γ-globulin peak than 
the serum from a non-immune animal [110, 111].  This was the first identification of antibodies 
and the cell-free specific resistance referred to as humoral immunity. 
 It was shown in 1960 that animals depleted of their lymphocytes became 
immunodeficient.  Immunocompetence was re-established upon reconstituting the animals with 
lymphocytes from a syngeneic donor (genetically identical member of the same species).  This 
established the concept of cell mediated immunity (CMI) and confirmed that lymphocytes are 
indeed the cells responsible for mounting an immune response [58].  Another key revelation 
around this time was that lymphocytes express positive memory.  The same animal mentioned 
above was also reconstituted with cells from a syngeneic donor already exposed to a particular 
antigen.  The animal mounted an immune response that was characteristic of a secondary 
immune response [58].  Secondary immune responses are generated faster than a primary 
immune response and have increased magnitude [91].   
 
1.4.2.1. Antigen Presentation 
 There are two major classes of lymphocytes based on their origin and surface molecules.  
When an immature stem cell migrates from the bone marrow to the thymus, a primary lymphoid 
organ, a thymus-dependent lymphocyte (T cell) is generated.  T cells in mice, bear the Thy1 
antigen [112].  On the other hand, if an unspecialized stem cell differentiates in the bone marrow 
(another primary lymphoid organ), a B cell arises.  B cells bear surface immunoglobulins (sIg).  
B and T lymphocytes bear receptors on their cell surface which are antigen specific [58].  T cells 
possess a T cell receptor (TcR) which is MHC restricted.   Briefly, different MHC molecules are 
found on different cell types.  Overall, MHC class I molecules are found on all nucleated cells 
and MHC class II molecules are found on B cells, macrophages and dendritic cells [113]. 
Therefore, the TcR is specific to the antigen in the context of an MHC molecule [112].  Surface 
immunoglobulins on B cells serve as the receptor and are able to bind antigen directly (not MHC 
restricted).   When a B cell binds an antigen, this triggers the B cell to develop into antibody-
forming plasma cells.  Since B cells produce antigen-specific receptors with a single specificity, 
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the resulting antibodies secreted by the plasma cell have identical binding specificity to the 
original receptor.  A large pool of plasma cells is generated by the B cell in order to increase the 
amount of antibody that is necessary to combat infection successfully [58].  This process takes 
time and therefore it is usually quite a few days before antibodies are detected following primary 
contact with an antigen.   
 B and T lymphocytes leave primary lymphoid organs and enter the blood, circulating 
throughout the body searching for foreign antigens.  Some leave the blood and enter the 
secondary lymphoid organs such as the spleen, lymph nodes and Peyer’s patches.  Lymphocytes 
possess “homing receptors” that determine which secondary lymphoid organ the lymphocyte will 
emigrate to.  Secondary lymphoid organs also bear ligands called addressins that recognize the 
specific homing receptors [58].  Histological staining of lymph nodes showed that B cells 
primarily inhabit the cortex whereas T cells are located mostly in the paracortex [58].  Peyer’s 
patches are specialized lymph nodes located in the mucosa of the gastrointestinal tract containing 
both B and T cells [114].  Some researchers have speculated that the role of the Peyer’s patches 
in young calves differs along the length of the gastrointestinal tract.  For example, the Peyer’s 
patches in the ileum serve as a source of naïve B cells and the role of the Peyer’s patches in the 
jejnum act as a site of immune induction [115].  In the spleen, the white pulp region is the site of 
immune responses where both B and T cells reside [92].   
 
1.4.2.2. Activation of T cells  
 T lymphocytes can be further divided based on their surface antigens and restriction 
specificity.  Many surface markers have been identified using monoclonal antibodies hence the T 
lymphoctyes can be divided into the αβ CD4+ helper T lymphocytes, αβ CD8+ cytotoxic T 
lymphocytes, γδ T lymphocytes and CD4+, FOXP3+, CD25+ regulatory T lymphocytes [116].  
CD4+ T cells respond to antigen by proliferating and are MHC class II restricted.  This means 
that MHC class II bearing cells (commonly referred to as accessory cells) are required for CD4+ 
T cell activation and proliferation [58].  Studies have shown that accessory cells “process” 
antigens before presenting it on MHC class II molecules.  Later this “processing” was shown to 
be simply the breaking down of antigen into fragments [58].  Experiments using small synthetic 
peptides revealed that fragments derived from processing have two distinct sites.  The epitope 
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site is in contact with the TcR and the agretope site binds to the MHC class II molecule [16].  
Therefore, foreign substances must first be engulfed by the accessory cell, degraded inside the 
cell and their peptides displayed on the surface MHC class II molecules.  CD8+ T lymphocytes 
are cytotoxic (CTL), lysing infected cells and are MHC class I restricted.  The same process is 
required for the activation of CD8+ T cells except in MHC class I bearing cells.  Therefore the 
primary function of MHC class I and II bearing cells is to present peptides to CD4+ T cells and 
CD8+ T cells respectively [58]. 
 Peptides bound to MHC class II molecules are insufficient to cause activation of a 
peptide-specific resting CD4+ T cell [8].  Binding of the antigen-specific TcR to the peptide on 
an MHC-bearing accessory cell induces chemical changes within the T cell and this represents 
what is referred to as signal 1.  In order for CD4+ T cell activation to be completed, the CD4+ T 
cell must receive signal 2.  Signal 2 is generated from interactions between costimulatory 
molecules on the accessory cell and the CD4+ T cell [16].  The most well known costimulatory 
molecules are B7.1 and B7.2 which interact with CD28 on the CD4+ T cell [117].  Upon 
receiving signal 2, CD4+ T cells are fully activated.  After receiving signal 2 CD4+ T cells 
increase expression of IL2 receptors on their surface.  Interleukin 2 was originally called the T 
cell growth factor because it induces T cell proliferation [117]. 
 This model of CD4+ T cell activation is somewhat incomplete.  Many researchers believe 
that the activation of every lymphocyte requires the antigen-mediated interaction of the 
lymphocyte to be activated with a different antigen-specific “collaborator lymphocyte” [7].  This 
is supported by the fact that CD4+ T cell activation seems to require the presence of CD4+ T 
cells. This requirement also takes into consideration the need for self tolerance [118].  Accessory 
cells such as macrophages and dendritic cells take up antigen indiscriminately including self 
antigens [118].  Therefore a modified two signal model has been proposed that incorporates this 
theme.  The current model is complicated as the interaction between the CD4+ T cell and the 
“collaborator lymphocyte” is indirect and involves a few steps [16].  For example, an immature 
dendritic cell located just below the gut epithelium encounters a foreign pathogen.  The dendritic 
cell phagocytoses the pathogen and processes it for antigen presentation via MHC class II 
molecules.  This induces chemical changes within the dendritic cell resulting in expression of a 
greater number of costimulatory molecules (B7.1 and B7.2) on its surface [7].  The dendritic cell 
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then migrates to a Peyer’s patch (a secondary lymphoid organ) to present the pathogen’s peptides 
to the “resting” cells of the adaptive immune response.  First, a resting CD4+ T cell receives 
signal 1 and signal 2 from the mature dendritic cell.  Signal 1 is received upon the TcR 
recognizing and binding to antigen in an MHC class II-restricted manner and signal 2 is received 
through the binding of costimulatory molecules [117].  The CD4+ T cell is still not fully 
activated and still requires the participation of an antigen specific “collaborator lymphocyte”[16].  
Therefore, presentation of the antigen by a B cell also through MHC class II molecules to the 
CD4+ T cell has been proposed.  This requires that the B cell already expresses a receptor 
specific for this pathogen and that the B cell have already been activated by effector CD4+ T 
cells [16].  A final stage in CD4+ T cell activation could be the proliferation in response to IL2 
[7]. 
 The current model for CD8+ T cell activation is quite similar but slightly less 
complicated as the antigen-mediated interaction of the CD8+ T cell with the “collaborator 
lymphocyte” is more direct.  An accessory cell phagocytoses and displays antigen specific 
peptides in an MHC class II restricted manner to a CD4+ T helper cell.  The accessory cell is 
activated to increase expression of costimulatory molecules on its surface that are required for 
the activation of resting CD8+ T cells [16].  Resting CD8+ T cells bind to the peptide displayed 
in an MHC class I restricted manner and are fully activated through the binding of the recently 
induced costimulatory molecules [118].  If the accessory cell is not activated to express 
cosimulatory molecules, it will present antigens to resting CD8+ T cells but will not activate 
them [8]. 
 Accessory cells such as dendritic cells need to become activated themselves in order to 
thoroughly activate lymphocytes.  This is achieved through two main pathways.  The first 
pathway involves the binding of costimulatory molecules on CD4+ T cells such as CD40 with 
dendritic cells (via CD40 ligand or CD40L), CD80 and CD86 [113].  The second pathway 
involves activation through PRRs such as the TLRs.  Binding of PAMPs to PRRs activates 
dendritic cells to a more mature state which includes the expression of costimulatory molecules 
[113], MHC class II molecule presentation on the surface of the dendritic cells increases and 
dendritic cells cease to take up any other materials [113]. 
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 Therefore, it is hypothesized that accessory cells decide the type of cytokine profile to 
secrete based on the pathogen it encounters [113].  Based on the type of cytokines produced, the 
CD4+ T helper cell can stimulate either a cell-mediated (Th1 type) or humoral (Th2 type) 
immune response [119].  Interleukin 2 and IFNγ are considered as the dominant cytokines during 
the Th-1 response whereas IL4, IL5 and IL10 are characteristic of a Th2 response.   However, it 
is known that in cattle and humans, IL-10 can be produced by Th1 and Th2 cells and regulate all 
their activities [120].  In an attempt to characterize bovine Th cell subsets, Brown et al [121] 
found parasite antigen-specific Th cell clones that co-expressed IFNγ and IL4. 
 
1.4.2.3. B cell Activation 
 The activation of B cells also requires two signals.  Signal 1 is produced upon antigen 
binding to the B cell receptor or surface immunoglobulin (sIg).  The second signal is produced 
upon the binding of T helper cells (via the TcR) to antigenic peptides displayed by the B cell in 
an MHC class II restricted manner.  Further studies revealed that resting B cells also have a 
ligand on their surface for CD40 called CD40L.  The interaction of CD40L with CD40 from T 
helper cells is central to B cell activation.  Signal 1 alone in the absence of the second signal has 
been shown to be paralytic. 
 
1.4.2.4. T Regulatory Cells 
 CD4+, FOXP3+, CD25+ regulatory T cells are either thymus derived lymphocytes or 
peripherally activated lymphocytes that control peripheral immune responses to self and non-self 
antigens.  The ability of the immune system to differentiate between self-antigens and non-self 
antigens is based on multiple events in the thymus and periphery and is important for the 
preservation of immune homeostasis.  The immune system has evolved a variety of multistep 
mechanisms to attain self tolerance.  These include two mechanisms of tolerance resulting in 
either deletion of self-reactive T cells or the induction of non-responsiveness.  First is central 
tolerance which involves the clonal deletion of self-reactive T and B cells exposed to self 
antigens at the early stages of development [122].  Second is peripheral tolerance which is a 
mechanism by which self reactive T lymphocytes are prevented from causing autoimmune 
diseases [123]. 
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1.4.2.5 Adaptive Immune Responses to STEC 
 To date, the majority of studies done on adaptive immune responses to STEC have been 
limited to studies done with A/E pathogens using the Citrobacter rodentium model.  Studies 
have shown that mice lacking acquired immunity, such as RAG-1- knockout mice deficient in 
mature T and B lymphocytes, were unable to clear infection with C. rodentium.  In contrast, 
infection of wildtype mice leads to an inflammatory response with full recovery within 3 weeks 
[124].  Initially the RAG1 knockout mice showed a similar response to the wildtype, but within 
two weeks, the outcomes were dramatically different.  This suggests that the innate system is 
initially important in controlling the infection and the adaptive response may be necessary to 
resolve the infection.  Interestingly, IFNγ production was raised substantially in the wildtype 
mice which was in contrast to the IFNγ production in the RAG-1- knockout mice which dropped 
below uninfected level [125].  
 Other studies have shown that mice depleted of CD4+ T cells do not clear infection with 
C. rodentium.  It was suggested that the reduced number of CD4+ T cells were unable to assist B 
cells causing a reduced antibody response.  The use of μMT mice, which have no IgG+ or IgM+ 
B cells were shown to be extremely vulnerable to C. rodentium infection [126].  This 
susceptibility to systemic immunity was reversed by adoptive transfer of immune sera, 
suggesting that antibodies play a crucial role during infection [127].   
 
1.4.3. Bovine Mucosal Immunity 
 The intestinal immune system plays an important role in preventing disease as it 
represents a massive interface between the body and the external environment.  A variety of cell  
types belonging to the innate and adaptive immune systems are devoted to recognizing, 
presenting and/or removing foreign microorganisms within the GI tract.  The mucosa-associated 
lymphoid tissue (MALT) is distributed around the body for effective antigen sampling as it is the 
initial inductive site for mucosal immunity (Table 1) [128].  Structural features of the MALT 
include lymphoid tissue that is physically adjacent to the mucosal surface [128].  MALT also 
possesses organized structured lymphoid tissue.  This includes lymphoid follicles and 
interfollicular areas [128].  The epithelium overlying the MALT contains lymphocytes and cells 
specialized in the uptake of antigen (called M cells) [128].  Antigen sampling in the MALT 
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occurs only through M cells [128].  And finally, the high endothelial venules (HEV) are used by 
recirculating lymphocytes to enter the MALT [128].  The MALT is subdivided based on location 
within the body to include: 
 
 
CALT Conjunctiva-associated lymphoid 
tissue 
SALT  Salivary gland-associated tissue 
LADLT Lacrimal drainage-associated 
lymphoid tissue 
NALT Nose-associated lymphoid tissue 
LTALT Larnynx-associated lymphoid tissue 
BALT Bronchus-associated lymphoid 
tissue 
Gastric MALT  Gastric mucosa-associated 
lymphoid tissue 
GALT Gut-associated lymphoid  tissue 
 
Table 1.  Mucosa-associated lymphoid tissue distribution within the body.  Locations in the 
body where the MALT is situated in order to effectively sample antigens and thus induce 
appropriate immunoligcal responses (both adaptive and innate) to foreign material and invading 
pathogens. 
 
1.4.3.1. Innate Immunity 
 The innate immune system in the GI tract is particularly important because it is first to 
come into contact with invading microorganisms and hence is aimed primarily at preventing 
these microorganisms from getting access to the intestinal epithelium.  The intestinal epithelium 
consists of a single cell layer joined firmly together by tight junctions, highly regulated 
macromolecular protein formations [129].  Tight junctions are composed of numerous proteins 
including occluding and claudins and form a physical barrier against the penetration of invading 
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microorganisms [129].  The intestinal epithelial cells also physically impede pathogen 
attachment through their brush-border microvilli.  This physical hindrance is reinforced by 
mucus and glycocalyx that is continuously produced by goblet cells which are present in the 
crypt and villus epithelium of the GI tract.  This polysaccharide network traps invading 
microorganisms which are subsequently eliminated through gut peristalsis and hydrous flow 
from the digestive tract [93].  Trefoil peptides (pS2, SP and ITF), also produced by goblet cells, 
are secreted in response to intestinal injury [129].  Trefoil peptides have been shown to protect 
the epithelium from bacterial products such as toxins.  Antimicrobial peptides such as defensins 
and cathelicidins are also produced by the intestinal epithelium to combat invading 
microorganisms.   
 The innate immune system also directly senses invading microorganisms through PRRs.  
Stimulation of PRRs with bacterial products, such as LPS or pro-inflammatory cytokines, such 
as IL-1 and TNF-, activates signalling cascades that lead to inducible nitric oxide synthase 
(iNOS) transcription.  This pathway results in the activation of p38 mitogen-activated protein 
kinase (MAPK), NF-B and Janus-activated kinase–signal transducer and activator of 
transcription–interferon regulatory factor 1 (JAK–STAT–IRF1) pathways [130, 131].  In the GI 
tract, two PRRs are particularly important including the TLRs (mentioned previously in section 
1.4.1.1) and the Nod-like receptors (NLRs).  The NLRs are divided into sub-families based on 
the composition of their N-terminal domain [93].  Nod1 and Nod2 recognize bacterial 
peptidoglycan and in turn stimulate NF-κβ resulting in the induction of pro-inflammatory 
cytokines [93].  There are at least 10 known mammalian TLRs each recognizing their own 
unique agonists for example, TLR4 recognizes bacterial LPS and TLR5 recognizes bacterial 
flagellin [93].  Toll-like receptor signalling results in the induction of anti-microbial peptides and 
pro-inflammatory cytokines as well as the activation of dendritic cells.  Far less information is 
available for bovine TLRs than for rodent and human TLRs.  To date, the bovine homologues for 
TLR2 and TLR4 have been cloned and partial sequences exist for TLR3 and TLR9 [98].   Toll-
like receptor 2 is functionally associated with TLR1 and/or TLR6. The TLR2/TLR1 heterodimer 
recognizes triacylated lipopeptides, whereas the TLR2/TLR6 recognizes lipoproteins and 
lipoteichoic acid (LTA), found in the peptidoglycan layer of Gram-positive bacteria [132].  
Binding of LPS to TLR4 results in the recruitment of MyD88 (myeloid differentiation primary 
35 
 
response gene 88) through the interaction of TIR-homology domains in TLR4 and MyD88 [133]. 
Flagellin, a bacterial virulence factor, is recognized by TLR5 present on the basolateral side of 
the epithelial cell [134] whereas TLR9 is present in the endosome and recognizes unmethylated 
bacterial cytosine–phosphate–guanosine (CpG) motifs [135]. 
 
1.4.2.2. Cellular Immunity 
 The gastrointestinal-associated lymphoid tissues (GALT) represent the largest immune 
compartment within the body.  The GALT prevent pathogens from invading the mucosal tissues 
and recognizes commensal organisms that are required for effective food digestion and 
processing.  The GALT has been extensively studied in sheep and cattle and is present as patches 
in the colon, jejunum, ileum, cecum and the rectum [128].  These patches were first identified in 
1677 by Johann Conrad Peyer in sheep as “intestinal glands” and hence are referred to as Peyer’s 
patches [115].  The GALT is functionally divided into the inductive sites and the effector sites.  
The inductive sites include mesenteric lymph nodes, Peyer’s patches (in the small intestine) and 
isolated lymphoid follicles whereas the effector sites include the epithelium and the lamina 
propria.  The lamina propria contains most aspects of the immune system including a large 
number of lymphocytes such as B cells, macrophages, dendritic cells and T cells [136].  The 
epithelium expresses TLRs such as TLR 2, 3, 4, 5, 7/8 and 9 [100] and also contains a large 
number of T cells of which the majority are CD8+ [136] .  The bovine GALT develops at the 
fetal stage and jejunum Peyer’s patches (JPP) can be observed in five month old foetuses 
increasing in number during foetal life and remaining throughout the entire lifespan of the 
animal.  Ileal Peyer’s patches (IPP) however develop later in seven month old foetuses growing 
remarkably large and accounting for 80-90% of the total mass of Peyer’s patch tissue [128, 137].  
By the age of two years, both bovine and sheep IPP  undergo an age-dependent involution and 
isolated lymphoid structures have taken their place [128].   
 Peyer’s patches are areas of organized lymphoid tissue that contain follicle centers and 
well-defined cellular zones covered by the follicle-associated epithelium (FAE) [138].  The FAE 
is distinct in that is does not contain any goblet cells or secretory component but does possess 
shorter villi and specialized membranous (M) cells [114].  M cells function as antigen-sampling 
cells primarily transporting antigens to the sub-epithelial dome of Peyer’s patches which 
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subsequently primes underlying lymphocytes for an immunological response.  M cells are 
characterized by having irregular surface microvilli and a basolateral cytoplasmic invagination. 
This invagination creates a pocket permitting lymphocytes and macrophages from the sub-
epithelial dome to enter assisting the initiation of an immune response [114].  It has been 
hypothesized that M cells develop from undifferentiated dome-associated crypt cells in the 
presence of lymphocytes [114].  The sub-epithelial dome area contains plasma cells, dendritic 
cells, macrophages and B cells. 
 Ruminant IPP and JPP have distinct differences in their architecture, lymphocyte 
organization and life span [139].  B cell development in cattle occurs predominately in IPPs and 
therefore it is considered to be a primary lymphoid organ [115].  Ruminant IPPs develop into a 
single continuous aggregation of lymphoid follicles often reaching two meters in length [137].   
Approximately one month after birth, cattle IPPs have numerous long, densely packed oval 
lymphoid follicles that contain almost all B cells with very few CD4+ and CD8+ T lymphocytes 
as well as small sub-epithelial domes and interfollicular regions [137].  Rather, B cell 
lymphopoiesis occurs in the IPP at a very high rate generating approximately 3.6x10
9
 cells/hour 
supplying B cells to the periphery most of which possess surface IgM [115, 137].   Studies have 
shown though that only 5% of newly produced B cells actually migrate to the periphery as many 
die in situ by apoptosis.  This on-going selection within IPPs still produces 5x10
7
cells/hour 
which is 10 times greater than from JPPs [115].  Jejunum Peyer’s patches, on the other hand, are 
thought to be secondary lymphoid organs possessing large interfollicular regions and small pear 
shaped lymphoid follicles [140].  Jejunum Peyer’s patches occur as numerous distinct 
accumulations of lymphoid follicles often ranging in number depending on the species [137].  
Jejunum Peyer’s patches contain approximately 25%  mature CD4+ T lymphocytes whereas IPPs 
contain only 1% CD4+ T cells [115].  One study showed that injection of antigen into intestinal 
loops containing JPPs resulted in the formation of specific antibody forming cells and antibody 
titres indicating the JPPs are an efficient site for the induction of a mucosal immune response 
[115].  Both IPPs and JPPs are encapsulated and surrounded by lymphatic sinuses that are in turn 
connected to lymph vessels.  These lymph vessels drain the intestinal villi and surrounding 
sinuses thus continuously bathing PP follicles in lymph [115]. 
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1.5. Treatment, Control and Prevention of STEC 
 Treatment options for STEC infection can be categorized into three main areas including 
i) infection prevention ii) therapies directly targeting Stxs and iii) therapies targeting downstream 
molecular events [141].  Supportive therapy as well is necessary but often does not prevent 
microvascular injury or CNS and other organ complications. 
 
1.5.1. Treatment of STEC 
 More than 76 million people within the United States become ill from the consumption of 
contaminated meat products [142].  Therefore strategies aimed at reducing pathogenic 
microorganisms within meat products in order to reduce human exposure and thus decrease 
human foodborne illnesses have gained much attention.   
 
1.5.2. Control and prevention in humans 
 Shiga toxin-producing E. coli is responsible for 70-90% of HUS within children 
worldwide [141].  Therefore supportive treatment focuses on abolishing complications related to 
four main systems within the body including gastrointestinal, haematological, vascular and renal.  
Antimotility agents (drugs used to reduce gastro-intestinal motility) are not recommended as they 
have been associated with an increase in HUS.  As well, narcotics and nonsteroidal agents are 
also not recommended but morphine and acetaminophen are used to manage abdominal 
cramping and pain.  Volume expansion by IV rehydration with isotonic solutions has been 
shown to provide renal protection and stop STEC-induced HUS if administered within the first 
four days of diarrhea [141].  Approximately 80% of HUS patients require packed red blood cells 
to combat symptomatic anemia.  Also, dialysis has been found to improve morbidity by 
correcting severe electrolyte imbalances and fluid overload.  Hemo- and peritoneal dialysis has 
been shown to be equally effective and needs to be continued until recovery.   
 The use of antibiotics to treat STEC infections is a very important clinical matter.  It has 
been suggested that specific outcomes may be affected by the STEC strain, phage-encoded toxin 
genes, type of antibiotic administered as well as timing and concentration of antibiotic [141].  A 
Japanese study in 1999 revealed that administering fosfomycin during the first 2 days of illness 
reduced the incidence of HUS.  The specific strain, termed the Sakai strain, was shown to 
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express both Stx1 and Stx2.  Treatment during days 3-5 though showed no protective effect 
[143].  Two retrospective studies in Minnesota and Washington State showed no association 
between the use of antimicrobials and the development of HUS [144, 145].  In contrast, Wong et 
al [146] in 2000 showed an increase in the development of HUS with antibiotic treatment.  The 
design of the experiment ensured that only individuals likely to develop HUS were administered 
antibiotics.  Because of this study, many researchers recommend only supportive care during 
STEC infection.  Many in vitro studies have also revealed an increase in Stx production in the 
presence of certain antibiotics.  Thus, antibiotics interacting with bacterial DNA including 
fluroquinolones and β-lactams which induce bacteriophage replication, lead to an increase in Stx 
production. 
 The oral administration of Stx-binding agents has been extensively studied as a treatment 
option for STEC infection.  One study performed in mice showed that administration of a 
polymer of Gb3 protected all the mice from a fatal dose of STEC as well as reduced serum levels 
of Stxs [147].  Another study done in 2004 using a synthetic toxin binder called Synsosrb Pk 
showed no reduction in HUS or serious extra-renal complications in patients when administered 
immediately after the diagnosis of HUS compared to the placebo group.   Various hypotheses 
exist to explain the failure of the multicenter clinical trial including the timing of the agent and 
the low affinity of the agent for the polyvalent toxin [148].  More recent multibranched Stx 
receptor analogues have been developed and their therapeutic potential is being considered.  One 
example of this is an oligovalent, water-soluble carbohydrate ligand called STARFISH 
developed by a Canadian research team.  Crystallography of STARFISH binding to Stx showed 
all five B subunits simultaneously bound [149].  The intravenous administration of monoclonal 
antibodies to Stxs has also been considered.  Studies in mice and gnotobiotic piglets have shown 
that monoclonal antibodies to Stxs are protective against further oral STEC challenge [150, 151].  
Akiyoshi et al [152] have produced a human monoclonal antibody to the A subunit of Stx2 
which awaits further investigations.   
 The last treatment option that targets downstream molecular events has been the least 
developed.  Fu et al [153] demonstrated that FR167653 (a p38 inhibitor) reduced plasma levels 
of proinflammatory cytokines such as TNFα and IL-1 which decreased renal failure in rats.  
TNFα and IL1 are most likely involved in the apoptosis of glomerular endothelial cells and 
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inhibition of these proinflammatory cytokines may prevent HUS [153].  Other studies aimed at 
reducing proapoptotic signals or blocking the thrombotic cascade are ongoing [141].  Raife et al 
[154] have shown using greyhounds that pretreatment with lepirudin prevented the development 
of kidney lesions in two thirds of the test animals suggesting that inhibiting thrombin formation 
will also prevent the development of HUS.   
 
1.5.3. Control and prevention in animals 
 Cattle are the primary non-human reservoir for STEC and it had been shown that 19% of 
retail uncooked beef is contaminated with STEC in the United States [155].  A global assessment 
of the STEC problem in cattle was done by Hussein et al [156] in 2007.  They showed that over 
50% of ground beef and over 40% of whole beef carcasses were contaminated with E. coli 
O157:H7 in the United States [10].  Of the 162 STEC serotypes identified, 43 have been isolated 
from HUS patients.  Therefore much effort has been put into reducing the survival and 
transmission of STEC by focusing on i) farm management and disinfectant practices and ii) 
antibiotics, probiotics and bacteriophage use within cattle to increase cattle resistance to STEC 
infection.   
 Preventing cattle from coming into contact with STEC is tremendously difficult [157].  
Therefore on-farm interventions have been exploited including chlorination of water, general 
disinfection of living quarters, switching grain-fed cattle to an all hay diet prior to slaughter and 
quarantining animals until they test negative [157].  General disinfection and chlorination of 
water produced less than desirable results and quarantining animals proved impractical due to the 
transient nature of faecal shedding [155].  Russell et al [158] in 2000 found that switching cattle 
to a hay diet resulted in an increased number of less acid-resistant E. coli.  These less acid-
resistant E. coli are hypothesized to be less likely to survive the acid environment of the human 
digestive barrier. 
 The use of antibiotics has been considered but concerns over bacterial resistance have 
prevented the issuing of a license allowing their use in cattle to control STEC.  A promising 
study using a strain of Lactobacillus in cattle as a probiotic showed significant reduction in gut 
colonization and faecal shedding leading to further studies using Enterococcus and non-
pathogenic E. coli [155].  Several studies have been done using bacteriophages to reduce E. coli 
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in cattle.  Initial experiments were done using EPEC and studies showed that bacteriophage 
treatment of cattle reduced diarrhea and splenic EPEC colonization in calves [159].  Then Kudva 
et al were able to isolate E. coli O157-specific bacteriophages and demonstrated complete lysis 
of E. coli O157:H7 cultures in vitro [160].  Also treatment with E. coli O157:H7-specific 
bacteriophage reduced numbers of E. coli O157:H7 within the gastrointestinal tract of sheep 
experimentally infected with E. coli O157:H7 [161]. 
 
1.5.4. Vaccines 
 Since cattle are linked with human STEC infections, they are a logical vaccine target as a 
means to reduce the risk of human infections.  In 2004 Potter et al [162] successfully reduced 
colonization of cattle by STEC by vaccinating with several type III secreted proteins such as Tir 
and EspA.  These proteins play a role in colonization of the intestine.  Vaccination consisted of 
three 2ml (50ug/ml) doses of supernatant secreted proteins.  Results showed significant reduction 
in the numbers of bacteria shed in feces, the numbers of animals that shed, and the duration of 
shedding in an experimental challenge model [162].   
 A second vaccine trial was conducted where secreted proteins prepared from the wild 
type strain was compared to secreted proteins from a Tir mutant.  Three groups of yearling cattle 
were immunized on days 0, 21, and 35, followed by oral challenge with E. coli O157:H7 on day 
49 [162].  Vaccination with proteins from the Tir mutant was not as effective as those from the 
wild type strain.  However, vaccination with proteins from the mutant provided more protection 
than the placebo.  From day 2 post-infection onwards, 78.3% of the placebo group shed E. coli 
O157:H7 for at least 1 day as compared to 30% for cattle vaccinated with the Tir mutant vaccine. 
 In 2005, Peterson et al [163] performed a single commercial feedlot trial also to evaluate 
the effects of vaccinating cattle with type III secreted proteins.  Four vaccination treatments were 
done including no vaccination, vaccination on day 42, vaccination on days 0 and 42 and 
vaccination on days 0, 21 and 42.  The vaccine was administered sub-cutaneously in the neck of 
480 steers, with 120 animals per group.  Results of the trial showed that vaccination reduced the 
proportion of cattle shedding E. coli O157:H7 in their feces.   
 Recently a study doney by McNeilly et al [164] demonstrated how systemic vaccination 
of cattle with H7 flagellin reduced the colonization of STEC. This vaccination resulted in high 
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levels of serum IgG, high levels of IgA in nasal secretion and measurable levels of both IgA and 
IgG in rectal secretions.  In a another study, Dean-Nystrom et al showed that vaccination of dams 
using intimin was capable of protecting against challenge with STEC O157 [165]. Other 
potential vaccines have been tested using intimin as an antigen. Agin et al [166] vaccinated 
rabbits with a STEC strain containing a non-functional intimin protein that resulted in protection 
against further STEC challenge.  A study done in mice using a plant-based vaccine which 
included the carboxy-terminal cell binding domain of intimin, was proficient in reducing fecal 
shedding upon further challenge with STEC O157 [167]. Although vaccine trials using intimin as 
an antigen has shown promising results, a cross-protective vaccine based on this protein would 
be challenging because many different variations have been identified within STEC serotypes 
[168]. 
 One of the most recent vaccine trial published in 2009 by Smith et al [169] used 3683 
cattle and type III secreted proteins in which cattle were vaccinated on days 0 and 42.  To detect 
shedding E. coli O157:H7, the terminal rectal mucosa was swabbed 3-5cm proximal to the 
rectoanal juncture.  Results showed only 11 of 382 vaccinated animals were positive for E. coli 
O157:H7 revealing that vaccinated cattle were colonized significantly less with E. coli O157:H7 
than nonvaccinated cattle [169].   
 Another very recent vaccine trial published in 2009 by Thorton et al [170] used the outer 
membrane siderophore receptor of E. coli O157:H7 to reduce fecal shedding in cattle.  Two 
groups of fifteen cattle were used in the trial and were vaccinated on days 0 and 21 with either a 
placebo or the siderophore vaccine.  Antibody titres to the siderophore protein were analyzed 
weekly from both groups.  Two weeks after the second vaccination, cattle were challenged with 
E. coli O157:H7 and fecal samples and rectoanal swabs were taken to monitor bacterial 
shedding.  Results of the trial showed that the vaccinated group had a significantly higher 
antibody titre to the siderophore protein and decreased E. coli O157:H7 fecal shedding as well as 
reduced the number of cattle shedding [170].   
 Several vaccine trials have been done in mice including a trial done by Gu et al [171].  
They constructed a trivalent recombinant protein consisting of EspA, the C-terminal end of 
intimin and and the B subunit of Stx2.  Six-week old BALB/c mice were divided into seven 
groups each vaccinated with a different combination of recombinant proteins on days 0, 7 and 14 
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and then challenged with E. coli O157:H7.  Gu et al [171] concluded from the trial that the 
recombinant proteins induced strong humoral responses to the recombinant proteins and 
vaccinating with combinations ofrecombinant proteins was more effective than vaccinating with 
individual proteins alone.  Another recent vaccine trial in mice used two nonfused polypeptides 
consisting of the B subunit of Stx2 and the last 32 amino acids of the A subunit of Stx2.  
Antibody responses to Stx2 were produced as well the anti-Stx2 antibodies neutralized toxin in 
vitro and subsequently conferred partial protection against Stx2 in vivo [172]. 
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2.0 Hypothesis, Objectives and Specific Aims of this Study 
 
2.1. Hypothesis 
 
We hypothesized that Shiga toxin 2 acts as an immunomodulator in cattle by 
downregulating immune responses which contributes to persistent colonization. 
 
2.2. Objective 
 To date, little is known about STEC pathogenesis in cattle, in particular the virulence 
factors associated with persistence.  Bacterial pathogens use a variety of mechanisms including 
toxins, in order to avert immune responses and successfully colonize their hosts [46].  This has 
been reported for STEC but the mechanism has yet to be defined.  Therefore the primary 
objective of this project is to determine the effect of Shiga toxin 2 on bovine immune responses 
during STEC infection. 
 
2.3 Specific Aims 
Aim 1:  To analyze lymphocyte function in the presence of purified Stx2. 
 
Aim 2:  To compare cytokine gene expression profiles in vitro using a bovine intestinal 
epithelial cell line in the presence and absence of purified Stx2.   
 
Aim 3:  To analyze bovine lymphocyte populations and cytokine profiles in the presence (wild 
type Stx2-producing STEC strain) and absence (∆stx STEC mutant strain) of Stx2 in vivo.   
 
Aim 4:  To measure bovine immune responses during active immunization in the presence 
(secreted protein preparation isolated from a wild type Stx2-producing STEC strain) and absence 
of Stx2 (secreted protein preparation isolated from a ∆stx STEC mutant strain). 
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3.0 General Materials and Methods 
 
3.1 Bacterial strains and growth conditions 
 Bacterial strains used in this study include E. coli wild type Stx2
+
 strain 1961 and an 
isogenic mutant Stx2
- 
strain 92192 which were kindly provided by Dr. Carlton Gyles (University 
of Guelph, Guelph, Ontario, Canada).  The strains were stored at -70
o
C in 30% glycerol and 
grown in Luria-Bertani (LB) agar and LB broth (DIFCO, Becton-dickinson, Sparks, MD, USA) 
at 37
o
C with shaking.  Strain #92192 is gentamicin resistant and was therefore grown in LB agar 
and LB broth plus 15μg/ml gentamicin (Gibco). 
 
3.2 Isolation of specific cells of the immune system 
3.2.1 Isolation of bovine peripheral blood mononuclear cells (PBMC) 
 Blood was collected from the jugular vein of Holstein cows in 0.3% EDTA (Sigma 
#431788) and centrifuged at 1400x for 20 minutes at room temperature. The buffy coat cell layer 
was removed and transferred to a new tube.  The volume was adjusted with PBS (0.1M 
phosphate-buffered saline) + 0.1% EDTA and layered onto Ficoll-Hypaque (GE Health Care 
Biosciences AB, Uppsala, Sweden).  The samples were centrifuged for 20 minutes at 2000xg.  
Cells at the Percoll interface were collected and transferred to a new tube and the volume 
adjusted with ice cold PBSA (137mM NaCl, 2.7 mM KCl, 4.3mM Na2HPO4.7H2O, 1.4mM 
KH2PO4) + 0.1% EDTA.  The samples were centrifuged for 8 minutes at 325xg at 4
o
C.  The 
supernatant was decanted and the pellet resuspended in PBSA.  The samples were washed with 
PBSA two more times at 4
o
C.  Cell number was determined with a haemocytometer 
microscopically and viability measured using Trypan Blue [173] (Gibco #15250-061).  
 
3.2.2 Isolation of bovine intestinal lymphocytes (IL) 
 Gut specimens were obtained from healthy 6-week old Holstein calves and transported to 
the lab in ice cold CMF-HBSS (Calcium- and Magnesium- free Hank’s balanced salt solution, 
5.4mM KCl, 0.3mM NaHPO4
.
7H2O, 0.4mM KH2PO4, 137mM NaCl, 5.6mM glucose, pH 7.4) 
/5% FBS (Seracare)/antibiotic/antimycotic (Gibco) solution.  The gut tissue was cut into 10cm 
lengths and opened lengthwise.  The tissue was then cut into 5cm
2
 pieces and washed in an 
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environmental shaker for 15 minutes in CMF-HBSS/5% FBS/antibiotic/antimycotic/10mM DTT 
(Dithiothreitol) (Sigma #9760) at 37
o
C.  The tissue pieces were then removed and placed into a 
new flask containing CMF-HBSS /5% FBS (Seracare) /antibiotic/antimycotic (Gibco)/ 10mM 
EDTA for 60 minutes at 37
o
C.  After 60 minutes, the tissues were washed for 3 hours in CMF-
HBSS /5% FBS/ 200U/ml collagenase 4 (Cedar Lane #LS004189, 200U/ml)/ 30ug/ml DNase I 
(Sigma #4965, 185000KU/ml) changing the solution after 60 and 120 minutes and reserving all 
supernatants.  Each 50mls of supernatant was centrifuged at 300xg for 8minutes and the cell 
pellet resuspended in 10ml PBSA.  This was layered onto Ficoll-Hypaque and centrifuged for 20 
minutes at 2000xg.  The buffy coat was collected and washed three times in PBSA + 5% FBS.  
Cell numbers and viability was confirmed using Trypan Blue (Gibco #15250-61). 
 
3.3 Isolation of secreted proteins 
 Type III secreted proteins from both STEC strains were prepared as described [174].  A 
single colony of wild type Stx2
+
 E. coli O157:H7 and mutant Stx2
-
 E. coli O157:H7 strains 
(described in Section 3.1) were picked from LB plates, inoculated into 20mls of LB broth (or LB 
broth + 15μg/ml gentamycin) and allowed to grow at 37oC to stationary phase overnight.  Both 
the Stx2
+
 wild type E. coli O157:H7 and the Stx2
-
 mutant E. coli O157:H7 overnight cultures 
were subcultured the next morning by diluting 100 fold in M9 minimal medium (Sigma-Aldrich, 
St. Louis, MO, USA) [175] supplemented with 0.5M MgSO4 + 5% casamino acids + 0.5% 
glucose + 1% NaHCO2.  The cultures were then incubated using constant aeration at 37
o
C in a 
5% CO2 environment to an absorbance at OD600 of approximately 0.7 [174].  The cultures were 
centrifuged at 5000 rpm for 20 minutes at 4
o
C and the pellets discarded, this was repeated two 
times [174].  The supernatants (containing the secreted proteins) were concentrated using a 10K 
Amicon filter (Fischer #13721) at 4
o
C with nitrogen gas.  The filter was pre-soaked in sterile 
water overnight in a glass beaker.  The preparations made using the 10K Amicon filter were used 
to confirm the wild type Stx2
+
 strain and the mutant Stx2
-
 E. coli O157:H7 strains (Chapter 6.0) 
and for the secreted protein trial (Chapter 7) [174].  This procedure was repeated three times so a 
total of 1.5 litres of culture supernatant was concentrated.  The concentrations of the resulting 
secreted protein preparations were determined using the Bio-Rad DC Protein Assay. 
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3.4 Western blotting 
 Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) of secreted 
protein extracts was carried out as follows.  First, total protein was mixed with the same volume 
of 2X protein loading dye (100mM tris HCl, 200mM dithiothreitol (DTT), 4% SDS, 0.2% 
bromophenol blue, 20% glycerol) and the mixture was loaded into individual lanes of a 12% 
SDS-PAGE.  The proteins were separated at 120 volts in a gel apparatus (Model 250/2.5 Bio-
Rad) for an hour and visualized following staining with Coomassie Brilliant Blue (20% MeOH 
and 10% Glacial Acetic acid and 0.5 g/L of Coomassie Brilliant Blue ) for a period of 30 minutes 
and destained (20% MeOH and 10% Glacial Acetic acid) for 2 hours with regular buffer 
exchange [176]. For immunobloting, the proteins were transferred from the gel to a 
nitrocellulose membrane (Bio-Rad) using a power supply (PowerPac200, Bio-Rad).  
Transferring the gel to a nitrocellulose membrane by electroblotting as recommended by the 
manufacturer (BioRad Laboratories) and included soaking the gel and nitrocellulose membrane 
in transfer buffer (3g/L tris, 1.41g/L glycine, 200ml methanol, distilled water to a final volume of 
1000ml, pH 9) for 5 minutes.  The nitrocellulose filter was placed on top of the gel and two 
pieces of Whatman filter papers were placed on both the gel and the nitrocellulose sides.  This 
was placed between two thick membrane supports and the whole assembly placed in a power 
supply chamber (PowerPac200, BioRad) and into a tank containing pre-chilled transfer buffer.  
The proteins were transferred at a current of 0.3mA for one hour.  After the proteins were 
transferred to the nitrocellulose, the membrane was removed from the apparatus and the 
nitrocellulose membrane was placed in blocking solution (8.8g/L of NaCl, 0.2g/L of KCl, 3g/L 
of Tris base and 500μL of Tween-20, pH adjusted to 7.4) (TBS-T) with 3 % skim milk for 1 hour 
at room temperature.  After incubation, the membrane was washed three times with TBS-T and 
incubated with a primary antibody for 1 hour at room temperature.  After the incubation, the 
membrane was again washed three times with TBS-T and then incubated with an alkaline 
phosphatase-conjugated secondary antibody (1/2000) for one hour at room temperature.  After 
the final antibody incubation, the membrane was washed once with TBS-T and once with 
alkaline (AP) buffer (12.11g/L of Tris base, 5.84g/L of NaCl, 1.04g/L of MgCl2 6H2O, pH 
adjusted to 9.5).  The membranes were then incubated for 15 minutes with AP buffer and 
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developed using nitroblue tetrazolium (NBT) salt (Sigma) and 5-bromo-4-chro-3-indolyl 
phosphate (BCIP) (Sigma) [177]. 
 
3.5 Cattle immunization protocols 
 Vaccines containing type III secreted proteins were prepared by formulating 500 µg of 
total protein with the adjuvant VSA3 as described [162].  Adult Holstein cows were immunized 
with 500μg hen egg lysozyme with or without Shiga toxin 2.  Hen egg lysozyme was formulated 
with 30% VSA3 as the adjuvant and a total of 2mls administered subcutaneously in the neck of 
each animal.  In each trial, vaccinations occurred on days 0 and 21.  The serum samples were 
collected on days 0, 6, 10, 14, 21, 28 (35 if relevant) and serological responses were measured 
using an enzyme-linked immunosorbent assay (ELISA) as described [162].  Differences were 
considered significant at a P-value < 0.05 (Dunn’s Multiple Comparison Test). 
 
3.6 Cytokine Capture ELISA    
 The appropriate anti-cytokine specific monoclonal antibody was diluted (1/8000 for 
IFNγ, 8μg/ml for IL12, 1/2000 for IFNα, 1/1000 for TNFα, and 0.5μg/ml for IL10) and added to 
96 round bottom plates (Thermo Labsystems #3655) and incubated at 4
o
C overnight.  The plates 
were washed four times with TBST (TBS, 0.85% NaCl (w/v), pH7) containing 0.5% (v/v) of 
Tween 20).  Two-fold dilutions of the samples were applied to the plate at 100μl per well in 
TBST-g (TBST + 0.1% gelatin).  Each standard (see Table 2) was diluted in Fetal Bovine Serum 
(FBS) and serial two-fold dilutions were done for ten wells.  The plates were incubated overnight 
at 4
o
C then washed four times with TBST.  Each detection antibody was diluted in TBST-g 
(1/5000 for IFNγ, 1/1000 IFNα, 1/1500 for TNFα, and to 0.125μg/ml for IL10) and 100μl 
applied to each well for a minimum of one hour at room temperature.  The plates were washed 
four times with TBST.  The appropriate biotinylated antibody (Table 2) was diluted 1/10,000, 
added to each well and allowed to incubate for one hour at room temperature.  The plates were 
washed four times with TBST.  Streptavidin alkaline phosphatase (Jackson # 016-050-084; 50% 
glyercol) was diluted 1/5000 and 100μl was added to each well for a minimum of one hour at 
room temperature.  The plates were washed four times with TBST.  PNPP substrate (Sigma 
#N3254) was diluted in fresh PNPP buffer (1% diethanolamine, 0.5mM MgCl2) to 1mg/ml and  
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Cytokine 
ELISA 
 
Coating Antibody Detection 
Antibody 
Conjugate Antibody Standard 
 
IFNγ 
Mouse anti rBoIFNγ 
monoclonal antibody 
2-2-1A 
Rabbit anti BoIFNγ 
92-131 
(1ng/ml) 
Goat anti Rabbit IFN 
(H+L) biotin (Zymed 
#62-6140) 
rBoIFNγ 
(2ng/ml) 
 
IFNα 
Mouse anti rBoIFNα 
Monoclonal antibody 
A2 (E2-1C6) 
Rabbit anti BoIFNα 
92-133 
Goat anti Rabbit IgG 
(H+L) bitin (Zymed 
#62-6140) 
rBoIFNα 
(1ng/ml) 
TNFα 
 
Mouse anti rBoTNFα 
monoclonal antibody 
1D11-13 
Rabbit anti 
BoTNFα Pool 88 
Goat anti Rabbit IgG 
(H+L) biotin (Zymed 
#62-6140) 
rBoTNFα  
(20ng/ml) 
IL12 
 
Mouse anti rBoIL12 
CC301 (Serotec MCA 
1782EL) 
None Mouse anti bovine 
IL12 CC326 biotin 
(Serotec MCA2173B) 
(5μg/ml) 
rHuIL12 (Serotec 
PHP100) 
(200ng/ml) 
IL10 Mouse anti rBoIL10 
CC318 (Serotec 
MCA2110) 
None Mouse anti BoIL10 
CC320 biotin (Serotec 
MCA2111B) 
(0.125μg/ml) 
rBoIL10 
(75U/ml) 
IL4 Mouse anti bovine IL4 
(Serotec MCA2371) 
None Mouse anti BoIL4 
(MCA2372B) biotin 
(0.25mg/ml) 
rBoIL4 (Serotec 
PBP006 20μg/ml) 
 
Table 2.  Cytokine-specific ELISA details.  A description of the different antibodies used in 
each cytokine-specific ELISA.  The last column is a description of the standard used (including 
starting concentration) during the ELISA procedure to generate a standard graph (Figure 11).  
The standard graph was used to extrapolate cytokine concentrations from supernatant isolated 
from each ligated loop.  Note: the IL12, IL10 and IL4 specific ELISAs do not use a detection 
antibody. 
r: recombinant 
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100μl added to each well.  The reaction was stopped when the Optical Density (OD405) of the 
first dilution of the standard curve reached an OD405 of approximately 2.0. 
 
3.7 Flow cytometry Analysis  
 After cell isolation, appropriate cell types were thoroughly resuspended in FACola 
(0.03% sodium azide and 0.02% gelatin in PBSA)  and 100μl transferred to round bottom 
microtiter plates (1x10
6
 cells/well) (Nunc #449824).  Fifty microliters of the appropriate 
monoclonal antibody (see Table 3) was added to each well and incubated on ice for 15 minutes.  
One hundred microliters of FACola was added to each well and the plates were centrifuged for 2 
minutes at 350xg at a temperature of 4
o
C.  The media/FACola was flicked off between washes 
and this was repeated two more times for a total of three washes (second and third washes used 
200μl FACola).  One hundred microliters of the appropriate fluorochrome conjugated secondary 
antibody (see Table 3) was diluted in FACola and added to each well and incubated on ice for 15 
minutes.  A total of three washes were repeated (second and third washes used 200μl FACola) 
and the plates were centrifuged for 2 minutes at 350xg.  At the end, 200μl of 2% formaldehyde 
(in PBS) was added to each well to fix the samples.  The plates were wrapped in tinfoil and 
stored in the refrigerator at 4
o
C until ready to be analyzed (no longer than 2 weeks).  Ten 
thousand events were acquired for each sample using a FAC Scan (Becton-Dickinson, Mountain 
View, CA) flow cytometry and Cell Quest program.  Negative controls included cells with media 
only.  The amount of specific antibody binding was calculated by subtracting the population of 
cells that bound the isotype-matched irrelevant monoclonal antibody. 
 
3.8 Statistics  
 Statistical analysis of the humoral and cell-mediated immune responses (non-parametric 
Mann Whitney U test) were performed using GraphPad Prism 5 (Graphpad Software, San Diego, 
CA).  Differences were considered significant when P<0.05. 
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Cell Type Primary Antibody Secondary 
Antibody 
Isotype Control 
Antibody 
CD4+ T cell CACT183A FITC anti-mouse 
IgG1 
IgG1 
CD8+ T cell CACT80C FITC anti-mouse 
IgG1 
IgG1 
B cell AbD Serotec 
CC21/MCA1424G 
FITC anti-mouse 
IgG1 
IgG1 
Dendritic cell CD11c: VMRD 
BAQ153A 
 
FITC anti-mouse 
IgM 
IgM 
MHC class II: 
VMRD H34A 
PI anti-mouse 
IgG2 
IgG2b 
Gb3+/CD77+ 
cell 
CD77: Immunotech FITC anti-rat 
IgM 
IgM 
Leukocyte 
positive 
populations 
CD45: VMRD 
CACTB51A 
FITC anti-mouse 
IgG2a 
IgG2a 
 
 
Table 3.  Primary and secondary antibodies used during flow cytometry. 
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4.0 Functional Analysis of Shiga toxin 2 with Bovine Peripheral Blood Mononuclear Cells 
and Intestinal Peyer’s Patches Lymphocytes In Vitro 
 
4.1. Introduction 
 The shiga toxins represent a group of A-B cytotoxins in which there is one A subunit to 
every five B subunits.  The B subunits are responsible for recognizing and binding to the 
receptor.  In this case the receptor is a glycosphingolipid called Gb3 [76].  After receptor binding, 
the A subunit is internalized into the cell and is responsible for completely truncating protein 
synthesis which induces cell death [58, 68].  Shiga toxins only cause disease in a limited number 
of hosts, including humans.  In humans, symptoms can range from a mild diarrhea which is 
usually self limiting to the life threatening HUS.  Kidney failure results from the cytotoxic 
effects of shiga toxins with a mortality rate of 3-5% [49].  
 The Stx2 family consists of Stx2, Stx2c, Stx2c2, Stx2d, Stx2e, and Stx2f [50].  Stx2 has 
been associated with a more severe outcome of disease than Stx1, and is about 1,000 times more 
toxic for human renal microvascular endothelial cells than Stx1 [49].   In a study of 255 strains, 
all 20 cases of HUS included either subtype Stx2, subtype Stx2c or the two combined [49].  As 
well experimental evidence using a primate animal model showed that administration of Stx1 
failed to induce symptoms of HUS whereas the opposite was found with Stx2 [49]. 
 The primary non-human reservoir for STEC is cattle.  Contrary to what is observed in 
humans, cattle over the age of 3 weeks do not exhibit any apparent clinical symptoms of disease 
or histological lesions upon infection with STEC strains [70].  The reason(s) for the different 
outcomes upon infection with STEC in humans and cattle are unknown although there is an 
increasing amount of data suggesting that it may be in part due to the Shiga toxins  [46].  In 
2002, Stamm et al showed that bovine lymphocytes express a functional Gb3 receptor [178].  A 
few years later, Menge et al showed that Stx1 binds to Gb3
+
 lymphocytes and reduces their 
numbers in vitro after 4 days of incubation [68].  Lowered bovine lymphocyte proliferative 
responses are also seen in vitro in the presence of Stx1 [68, 179].  Therefore, aside from its 
known potent cytotoxic effects within humans, it has been hypothesized that the shiga toxins 
may possess additional immune modulating activities within the bovine host thus aiding in STEC 
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pathogenesis.  In the present study, we determined in vitro the effects of Stx2 on bovine PBMCs 
and Intestinal Peyer’s patches lymphocytes (IPPL) populations.  
 
4.2. Materials and Methods 
4.2.1 Cytotoxicity Assay  
 The purpose of the VERO cell cytotoxicity assay was to determine the concentration of 
purified Stx2 that kills half of the cell population in order to use an appropriate dose of Stx2 for 
future experiments.  It is accepted that VERO cells are highly sensitive to Stxs and for this 
reason they were chosen for the assay [68].  The cytotoxic activity of the Stx2 preparation 
(Sigma Aldrich, V2513-10UG, 0.1mg protein/ml) [180, 181] was determined as described by 
Gentry et al [182].  Briefly, 50μl of a 10-fold dilution series of the Stx2 preparation was added to 
a 96 well plate already containing 50μl of cell culture media (RPMI 1640 (Invitrogen 
#11875101) containing 10% FBS (Seracare), 2mM glutamine (Sigma #25030081), 100U 
penicillin (Invitrogen), and 100mg/ml streptomycin (Sigma)).  This was allowed to incubate for 
30 minutes at room temperature.  Then, 50μl of VERO cells at a concentration of 8x105cells/ml 
were added to each well and incubated at 37
o
C under 5% CO2 for 96 hours.  Cellular metabolic 
activity was measured using the MTT Reduction Assay as described below.  The percentage of 
cellular metabolic activity was calculated using the following formula: 
 
[OD (sample) – OD (positive control)] / [OD (negative control) – OD (positive control)] x 100. 
 
The 50% cytotoxic dose (CD50) value was determined using dose-response curves as the toxin 
concentration causing a 50% reduction in cellular metabolic activity [69] (Figure 2). 
 
4.2.2 Flow Cytometry of bovine PBMC and IL populations  
 Flow cytometry was done on freshly isolated bovine PBMC and IL (from the ileal 
Peyer’s patches and the jejuna lamina propria) to confirm the presence of the Stx receptor on the 
cell surface.  Since the IL population is heterogeneous, cells were first incubated with a 
monoclonal antibody to CD45 (a leukocyte antigen) to distinguish the leukocytes from other cell 
types.  This step was not done with the PBMC population.  Twenty microliters of rat anti-CD77 
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monoclonal antibody (2mg/ml, Clone 3813, Immunotech) was incubated with 1x10
6
 cells which 
were incubated on ice for 15 minutes and washed three times in FACola.  Then, 100μl of FITC 
anti-rat IgM (100μg, eBioscience #11-0990-82) was added to each well.  The preparation was 
allowed to sit on ice for 15 minutes and subsequently washed in FACola three times.  The 
amount of specific antibody binding was calculated by subtracting the population of cells that 
bound the isotype-matched irrelevant monoclonal antibody. 
 
4.2.3 Bovine PBMC and IPPL Viability in the presence of purified Shiga toxin 2 
4.2.3.1 MTT Viability 
 The cellular metabolic activity was assayed by measuring the reduction of tetrazolium 
salts (3-[4,5-dimethyl-2-thiazolyl]-2,5-diphenyl tetrazolium bromide).  After cell isolation 
(protocols described in sections 3.2.1 and 3.2.2) bovine PBMCs and IPPL were resuspended in 
DMEM (Sigma #D6429) supplemented with 10% FBS (Seracare), 1% non-essential amino acids 
(Gibco #11140), 1% sodium pyruvate, 1% HEPES (Sigma #IMH0887), 0.1% gentamycin (Gibco 
#15750-060) and 0.1% mercaptoethanol. In stimulation assays, the media was additionally 
supplemented with concavalin A (ConA) (Sigma #C5275) at 5μg/ml or lipopolysaccharide from 
E. coli O111:B4 (LPS) (Sigma #L2630) at 25μg/ml. 
  Briefly, 10μl of MTT stock solution (5mg/ml in PBS) was added to each well of a 96-
well plate.  The reaction was incubated at 37
o
C for four hours and then stopped by the addition 
of 100μl of detergent reagent.  The dye crystals were dissolved by the addition of 100μl of 10% 
SDS in distilled water.  The plates were left at room temperature overnight and absorbance read 
using a Titerteck Multiscan ELISA plate reader with a test wavelength of 540nm and a reference 
wavelength of 680nm.  The percentage of cellular metabolic activity was calculated using the 
following formula: 
[OD (sample) – OD (positive control)] / [OD (negative control) – OD (positive control)] x 100. 
 
4.2.3.2 Propidium Iodide staining 
 The incorporation of propidium iodide was determined in the presence and absence of 
purified Stx2.  PBMCs were incubated with varying concentrations of Stx2 and IPPL (Intestinal 
Peyer’s patch Lymphocytes isolated from the ileum) populations were incubated with a fixed 
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concentration (2000CD50) of Stx2.  The freshly isolated cell populations (3x10
5
cells/well) were 
incubated either 96 hours (PBMC) or 12 hours (IPPL) with Stx2 at 37
o
C under 5% CO2.  
Following the incubation, 2.5μg/ml propidium iodide (PI) (Sigma) was added to each well and 
the plate was allowed to sit on ice for 20 minutes.  The cells were collected and subjected to flow 
cytometric analyses. 
 
4.2.3.3 Proliferation assay 
 Lymphocyte proliferation was determined in the presence and absence of purified Stx2.  
First, freshly isolated cell populations (3x10
5
 cells/well) were incubated for either 12 (IPPLs) or 
96 (PBMCs) hours at 37
o
C under 5% CO2 with a fixed concentration of purified Stx2 
(2000CD50).  Twenty microliters of 0.4μCi of 
3
H-thymidine (Amersham Pharmacia, Piscataway, 
NJ) was added to each well.  The plate was allowed to incubate for 6 hours at 37
o
C under 5% 
CO2.  The plates were immediately frozen until the incorporation of 
3
H-thymidine could be 
assessed in a beta counter (Topcount, PerkinElmer Inc., CA, USA).  Cell proliferation was 
calculated as the mean counts per minute (c.p.m.) of triplicate cultures and expressed as a 
stimulation index (c.p.m. in the presence of stimulus / c.p.m. in the absence of stimulus). 
  
4.2.4 Cytokine Analysis 
 A detailed ELISA protocol is described in section 3.6.4. After cell isolation (protocols 
outlined in sections 3.2.1 and 3.2.2), bovine PBMCs and IPPLs were incubated with purified 
Stx2 at 2000CD50 for 96 and 12 hours respectively.  After the appropriate incubation time, each 
cell type was centrifuged for 5 minutes at 14000 rpm and media was decanted from each well 
without disturbing the cell pellet.  One hundred microliters of media was immediately applied to 
IFNγ, TNFα, IL12 or IL10 specific pre-coated ELISA plates and diluted in a two-fold serial 
dilution series for cytokine concentration evaluation.   
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Figure 2.  Cytotoxicity assay using VERO cells to determine the CD50 value for the Stx2 
preparation.  Ten-fold dilutions of the purified Stx2 preparation were added to a 96 round 
bottom plate and 50μl of VERO cell suspension (8x105 cells/ml) was added to each well.  The 
toxin-cell mixture was allowed to incubate at 37
o
C under 5% CO2 for 96 hours.  Cell viability 
was assessed using MTT reduction.   
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4.3 Results 
4.3.1 Flow Cytometric Analysis on bovine PBMC and IPPL populations to confirm 
expression of Shiga toxin Receptor 
 To confirm surface expression of the Shiga toxin receptor on bovine PBMCs and IPPLs, 
flow cytometric analysis using an anti-CD77/Gb3 monoclonal antibody, was completed as 
described [67].  Flow cytometric analysis indicated that a percentage of both bovine PBMC and 
IPPL populations bound the monoclonal antibody and therefore expressed the Stx receptor on 
their cell surface.  Approximately 7% of the IPPL isolated from the jejunum were CD77
+
 and 
approximately 10% of the IPPL isolated from the ileum were CD77
+
 (Figures 3 and 4).  Results 
of PBMC staining with the anti-CD77 monoclonal antibody revealed that 13% of the population 
was CD77
+
.  PBMC populations were also stimulated with LPS and results revealed that 22% of 
the stimulated bovine PBMC population was CD77
+
 (Figure 5). Therefore we can conclude that 
bovine lymphocyte populations isolated from the ileum, jejunum and blood express the Stx 
receptor on their cell surface. 
 
4.3.2 Cellular metabolic activity of bovine PBMC and IPPL populations in the presence of 
purified Stx2 in vitro.    
 To determine the effect of Stx2 on cellular metabolic activity, freshly isolated bovine 
PBMC and IPPL populations were incubated with varying concentrations of purified Stx2 and 
cellular metabolic activity measured as described [68].   The results (Figure 7) indicated that 
Stx2 did not affect the cellular metabolic activity as assessed by MTT reduction of the bovine 
PBMC population in vitro after 4 days of incubation with the toxin.  The cellular metabolic 
activity of bovine PBMCs incubated with either ConA or LPS after four days was approximately 
100%.  The cellular metabolic activity of bovine PBMCs incubated with either mitogen and 
purified Stx2 was also approximately 100%.  Identical results were also obtained for the bovine 
IPPL populations which indicated that Stx2 (within the concentration range of 2ng/ml to 
0.02pg/ml) did not affect their cellular metabolic activity in vitro as assessed by the MTT 
reduction assay after 12 hours of incubation with the toxin. The cellular metabolic activity of 
bovine IPPLs incubated with ConA or ConA + Stx2 after 12 hours was approximately 60% 
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(Figure 6a) and 55% (Figure 6b).  Neither supplementation with ConA or LPS was required to 
see the effects of Stx2 on either bovine PBMC or IPPL metabolic activity. 
 
4.3.3 Propidium Iodide staining of bovine PBMC and ileal IPPL populations after exposure 
to Shiga toxin 2. 
 The incorporation of propidium was determined in the presence and absence of purified 
Stx2.  Propidium iodide intercalates into DNA nonspecifically and apoptotic cells expel their 
cellular contents into the environement including free DNA.  Therefore to determine if Stx2 
induces lymphocyte death, we stained bovine PBMCs and ileal IPPLs with propidium iodide 
after exposing them to purified Stx2 for either 96 or 12 hours (Tables 4 and 5).  Approximately 
60% of PI-positive IPPL cells were found in the presence of Stx2 and this was identical to the 
results obtained when IPPLs were incubated alone without Stx2.  This was also observed in 
ConA-stimulated cultures.  Similar results were obtained when bovine PBMCs were stained with 
PI.  Cells were incubated either alone or stimulated with LPS and in the presence of varying 
concentrations of Stx2.  The results indicated that similar amounts of PI was incorporated at the 
three toxin dilutions used when comparing stimulated cultures with or without Stx2 and 
nonstimulated cultures with or without Stx2.  Overall, more PI was incorporated in the 
stimulated cultures compared to nonstimulated cultures but this is not surprising as the mitogen 
will induce proliferation.  We therefore concluded that Stx2 does not affect lymphocyte viability 
within the bovine PBMC or IPPL populations in vitro. 
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Figure 3.  Flow cytometry analysis of the cells isolated from the jejunum of a six month old 
calf.  CD45 positive cells were first identified within the population of cells that resulted from 
the digestion.  From the resulting CD45 positive leukocytes, CD77 positive cells were identified.  
All samples were performed in duplicate (b) and (c).  The appropriate controls (isotype and 
secondary antibody) (a) were included on each 96 well plate and used to exclude any non-
specific antibody binding that may occur during the analysis (Table 3). 
a. 
b. 
c. 
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Figure 4.  Flow cytometry analysis of the cells isolated from the ilem of a six month old calf.  
CD45 positive cells were first identified within the population of cells that resulted from the 
digestion.  From the resulting CD45 positive leukocytes, CD77 positive cells were identified.  
All samples were performed in duplicate.  Sample 1 (a) and sample 2 (b) each represent a 5cm
2
 
piece of the ileum taken from the same six month of calf.  Ten thousand events were acquired for 
each sample.  The appropriate controls (isotype and secondary antibody) (c) were included on 
each 96 well plate and used to exclude any non-specific antibody binding that may occur during 
the analysis (Table 3). 
 
c. 
b. 
a. 
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Figure 5.  Flow cytometry analysis of bovine PBMC population using the anti-CD77 
monoclonal antibody.  Freshly isolated bovine PBMCs were subjected to flow cytometry to 
confirm that the cell population expresses the Stx receptor on their surface.  The appropriate 
controls (isotype and secondary antibody) were included on each 96 well plate and used to 
exclude any non-specific antibody binding that may occur during the analysis (Table 3). 
Quadrant Statistics 
File Data 007                                  Sample ID: PBMC + CD77 
Gated Events: 2501                       Gate G3                                                                            
    Quad location: 13,0 
 
Quad             Event      % Gated         X Mean            Y Mean 
UL                 2367          94.64               5.00                 124.59 
UR                 134              5.36               20.54               192.67 
 
 
Quadrant Statistics 
File Data 008                                      Sample ID: PBMC +CD77 +ConA                       
Gated Events: 2527                          Gate G3                                 
                    Quad location: 13,0 
             
 
Quad             Event      % Gated           X Mean         Y Mean 
UL                   1840          72.81            6.56                129.33 
UR                   687            37.19            51.57              169.84 
 
Quadrant Statistics 
File Data 009                        Sample ID: PBMC +ConA SecCtrl IgM FITC                  
Gated Events: 983                               Gate G3 
                                                                Quad location: 13,0 
 
Quad             Event      % Gated            X Mean           Y Mean 
UL                  797             81.08              6.37                116.19 
UR                 186              18.92              19.84             179.20 
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Figure 6.  Effect of Stx2 on the cellular metabolic activity of bovine ileal IPPL populations 
in vitro as assessed by MTT reduction assay.  Cells were incubated in a 96 well plate at 37
o
C 
under 5% CO2 for 12 hours in the presence of a ten-fold dilution series of Stx2 [68].  The culture 
media was either free of mitogen or supplemented with 5μg/ml ConA.  Cells incubated in media 
were used as a negative control and cells treated with 1% SDS were used as a positive control.  
Values represent the averages from triplicate determinations of one animal and ileal IPPL 
poplations isolated from cow 1 (a) and cow 2 (b). 
a. 
b. 
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Figure 7.  Effect of Stx2 on the cellular metabolic activity of bovine PBMC population in 
vitro as assessed by MTT reduction assay [183].  Cells were incubated in a 96 well plate at 
37
o
C under 5% CO2 for 96 hours in the presence of a ten-fold dilution series of Stx2.  The culture 
media was either free of mitogen or supplemented with 5μg/ml ConA or 25μg/ml LPS.  Cells 
incubated alone were used as a negative control and cells treated with 1% SDS were used as a 
positive control.  Values represent the averages from triplicate determinations of one animal and 
PBMC poplations isolated from cow 1 (a) and cow 2 (b). 
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4.3.4 Proliferation of bovine PBMC and IPPL populations exposed to Shiga toxin 2. 
 To determine if Stx2 inhibits proliferation in bovine lymphocytes, we assessed the 
incorporation of tritiated thymidine in the presence and absence of purified Stx2.  A preliminary 
experiment was done in order to assess if results would differ if either mitogen (ConA) or toxin 
was added to the assay first (data not shown).  The results indicated that the assay was not 
sensitive to either experimental condition and both mitogen and toxin were added to the assay 
together at time zero.  The mitogen-induced proliferation of the bovine PBMC populations was 
not inhibited in vitro in the presence of Stx2 at a toxin concentration of 2000pg/ml (2000CD50) 
[68] after 96 hours of incubation.  The results indicated that the stimulation index (SI) was 
approximately 50 when stimulated PBMC cultures were incubated with Stx2 which was the 
same for stimulated PBMC cultures in the absence of Stx2 (Figure 8a).  Statistical analysis using 
the Mann Whitney test showed proliferation of PBMC populations in the presence of Stx2 were 
signicantly lower (P<0.01) than either PBMC population stimulated with ConA (in the presence 
or absence of Stx2) (Figure 8a). 
 Proliferative responses of the bovine ileal IPPL populations were measured using cells 
from four different calves.  The calves were approximately three months of age and ConA was 
chosen as the positive control.  The results in Figure 8b indicate that Stx2 inhibited the mitogen-
induced proliferation of the ileal IPPL population in vitro.  When stimulated IPPL cultures were 
incubated with Stx2, the SI was approximately 3.5.  The results of stimulated IPPL cultures in 
the absence of Stx2 showed a SI of 13.  Statistical analysis using the Mann Whitney showed that 
they were significantly different (P<0.05), indicating that Stx2 was able to downregulate bovine 
immune responses by inhibiting the mitogen-inducted proliferation of the ileal IPPL populations 
in vitro.  The mitogen, Con A was also able to stimulate proliferation in the ileal IPPL 
populations that differed significantly (P<0.01) from the unstimulated cultures.  The SI values 
determined for the IPPL populations were very low suggesting a percentage of the population 
after 12 hours is no longer alive (Figure 8b). 
 
4.3.5 Cytokine concentration determination in the presence of Shiga toxin 2. 
 To determine if Stx2 modulates bovine immune responses through cytokine production, 
bovine PBMC and ileal IPPL lymphocyte populations were incubated with purified Stx2 at a 
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concentration of 200CD50 for varying time intervals.  After incubation with Stx2, culture media 
was tested for the presence of different cytokines.  Unstimulated cells incubated without Stx2 
were compared to unstimulated cells incubated with the toxin and cells stimulated with the 
mitogen ConA were compared to cells stimulated with ConA and purified Stx2 (Figures 9 and 
10).  Statisical analysis using the Mann-Whitney test showed that ConA-stimulated PBMC and 
IPPL populations produced significantly higher (P<0.05) IL4, TNFα, IFNγ and IL10 
concentrations than unstimulated cultures (for example PBMC/IPPL + ConA versus 
PBMC/IPPL and PBMC/IPPL + ConA +Stx2 versus PBMC/IPPL + Stx2).  The results indicate 
that Stx2 did not significantly alter either IL12 (PBMC), IL4 (IPPL), TNFα or IL10 levels in 
ConA-stimulated bovine PBMC and IPPL preparations (PBMC/IPPL + ConA versus 
PBMC/IPPL + ConA+ Stx2).  IFNγ concentrations produced by PBMCs stimulated with ConA 
were significantly higher (P<0.05) than IFNγ concentrations produced by ConA-stimulated 
PBMCs in the presence of Stx2.  This result was not observed with the IPPL population.  IL12 
concentrations produced by unstimulated PBMCs were significantly lower (P<0.05) than IL12 
concentrations produced by ConA-stimulated PBMCs as well significantly lower (P<0.05) IL12 
concentrations were observed upon comparing unstimulated PBMCs and unstimulated PBMCs 
incubated with Stx2.  
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Table 4.  Survival of Stimulated and Unstimulated Bovine PBMCs after Exposure to 
Purified Stx2.  Propidium iodide staining of bovine PBMCs after incubation with a) PBMCs 
only b) PBMCs + 2000CD50 purified Stx2 c) PBMCs + 200CD50 d) PBMCs + 0.25 μg/ml LPS + 
2000CD50 e) PBMCs + 0.25 μg/ml LPS + 200CD50 
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Table 5.  Survival of Stimulated and Unstimulated Bovine ileal IPPLs after Exposure to 
Purified Stx2.  Propidium iodide staining of bovine lymphocytes isolated from the ileal Peyer’s 
Patches incubated with a) IPPL alone b) IPPL alone (PI control) c) IPPL + 2000CD50 purified 
Stx2 (cow 1) d) IPPL + 2000CD50 purified Stx2 (cow 2) e) IPPL + 5μg/ml ConA (cow1) f) IPPL 
+ 5μg/ml ConA + 2000CD50 purified Stx2 (cow 1) f) IPPL + 5μg/ml ConA (cow1) g) IPPL + 
5μg/ml ConA + 2000CD50 purified Stx2 (cow 2). 
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Figure 8.  Proliferation of bovine PBMC and IPPL preparations in the presence and 
absence of purified Stx2.  Freshly isolated a) PBMCs (2.5 x10
5
) and b) IPPLs (2.5 x10
5
) + 
ConA (5μg/ml) + Stx2 (2000CD50) were incubated at 37
o
C at 5% CO2.  After 96 hours of 
incubation (12 hours for IPPLs), the incorporation of 
3
H-thymidine was assessed using a beta 
counter as described above. *P<0.05;  ** P<0.01. 
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IL10 Cytokine Production by bovine PBMCs
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Figure 9.  Cytokine production (IL10, IL12, TNFα and IFNγ) by bovine PBMCs in the 
presence of Stx2.  Freshly isolated bovine PBMC preparations were either stimulated with 
ConA (5μg/ml) and incubated with 2000CD50 Stx2 (■, ▲) or remained unstimulated and 
incubated with 2000CD50 Stx2 (●, ▼).  Cytokine production including a) IL10, b) IL12, c) TNFα  
and d) IFNγ was determined using cytokine-specific capture ELISAs.  Statistical analysis was 
done using the Mann Whitney test.  *P<0.05. 
* 
* 
* 
a. 
d. c. 
b. 
* 
* 
* * 
* 
* 
* 
* 
* 
* 
* 
* 
72 
 
IL10 Cytokine Production by bovine IPPLs
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IL4 Cytokine Production by bovine IPPLs
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Figure 10.  Cytokine production (IL10, IFNγ, IL4, and TNFα) by bovine IPPLs in the 
presence of Stx2.  Freshly isolated bovine ileal IPPL preparations were either stimulated with 
ConA (5μg/ml) and incubated with 2000CD50 Stx2 (▲,▼) or remained unstimulated and 
incubated with 2000CD50 Stx2 (●, ■).  Cytokine production including a) IL10, b) IFNγ, c) IL4 
and d) TNFα was determined using cytokine-specific capture ELISAs.  Statistical analysis was 
done using the Mann Whitney test.  *P<0.05. 
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Figure 11.  Cytokine standard graphs. Standard graphs were produced using a) rHuIL12, b) 
rBoIFNγ, c) rBoIL10, d) rBoTNFα and e) rBoIL4 in order to determine the cytokine 
concentrations resulting from the in vitro incubation of bovine PBMCs and IPPLs in the presence 
of Stx2 (Table 2).  Two-fold dilutions of each cytokine standard were applied to a 96 round 
bottom plate and the optical densities were recorded and graphed. 
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4.4 Discussion 
 To date, no clinical disease or histopathology has been reported in cattle following 
infection with STEC.  Experimentally infected calves less than three weeks of age develop 
diarrhea but these symptoms have been attributed primarily to Stx1 secreting STEC strains [184].  
The purpose of this study was to investigate the effect of Stx2 on bovine immune cells.  
Previously, Dean-Nystrom et al [70] showed that the ileum and colon of experimentally infected 
calves suffering from STEC-induced diarrhea were colonized with viable bacteria thus 
confirming the presence of STEC within the bovine gut.  In 2002, Stamm et al [178] showed that 
lymphocytes isolated from the bovine gut as well as from blood express a functional Stx receptor 
on their surface confirming that the shiga toxins can interact with cells of the immune system 
within the bovine host.  This led us to hypothesize that Shiga toxin 2 could modulate the bovine 
mucosal immune response thereby contributing to STEC pathogenesis.  This hypothesis is 
supported by two previous observations, including one by Menge et al [167] who reported a 
reduced number of intraepithelial lymphocytes after exposure to Stx1 and as well by Smith et al 
[171] who also reported a depletion of lymphocyte numbers in the submucosal lymphoid 
follicles in two five week old calves infected with an STEC strain. 
 In the present study we showed that Shiga toxin 2 inhibited the mitogen-induced 
proliferation of lymphocytes in vitro originating from the Peyer’s patches of the ileum.  This 
inhibition was seen after 12 hours of incubation with purified Stx2 at a concentration of 
2000CD50 (approximately 2000pg/ml).  This effect was seen using four individual ileal IPPL 
preparations originating from four 3-month old Holstein calves (Figure 8b).  Mangeney et al 
[185] have previously demonstrated a correlation between Gb3 expression and cellular 
activation/differentiation.  We have shown in this study that unstimulated IPPL express the Gb3 
receptor on their surface although at low levels.   Therefore a mitogen-induced increase in Gb3 
expression may account for the activation-dependent effect of Stx2.  Cellular metabolic activity 
of the same ileal IPPL populations remained unaltered in the presence of 2000CD50 Stx2.  This 
result agreed with the PI staining of the same population of cells (Table 3).  Although it has been 
shown that Stx1 induces apoptosis in VERO cells after 8 hours of incubation as well as the 
bovine lymphoma cell line BL-3 and the human B lymphoma cell line Daudi [68, 186, 187], we 
did not observe a decrease in lymphocyte viability due to Stx2 after 12 hours of incubation at 
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2000CD50.  The perturbation of cytokines by Stx2 was also examined to fully understand the 
immunomodulating effects of Stx2.  Menge et al [69] showed that incubation with Stx1 
increased the percentage of bovine PBMCs expressing IL-2 receptor and a reduction in CD71-
expressing lymphocytes suggesting Stx1 may inhibit cell activation by inhibiting IL2 release.  In 
the present study, we examined cytokine profiles of IL10, IL4, TNFα and IFNγ after incubation 
with Stx2 after 12 hours.  Results indicated no significant differences in cytokine concentrations 
when stimulated ileal PPLs were either in the presence or absence of Stx2.   
 To fully examine the modulatory role by Stx2 on bovine immune cells, we determined 
the effect of Stx2 on bovine PBMCs in vitro as well.  Flow cytometric analysis using a 
monoclonal antibody to the receptor Gb3 indicated that bovine PBMCs do express the shiga toxin 
receptor on their surface (Figure 4 and 5).  Confirmation of the binding specificity of the 
monoclonal antibody to CD77 was done by Menge et al in 2001 [67].  Flow cytometry result 
indicated that circulating lymphocytes within the bovine host could interact with Stx2 which is in 
agreement with results obtained by Menge et al 2001 [67].  Cellular metabolic activity was 
determined after 96 hours of incubation with 2000CD50 Stx2 and results indicated that Stx2 does 
not alter cellular metabolic activity in vitro (Figure 7).  This was in agreement with the PI 
staining done on the same population of cells.  The results indicated no increase in PI-positive 
PBMCs after exposure to purified Stx2 for 4 days (Table 3).  This was in agreement with results 
observed by Menge et al [68] in 1999 when they concluded that Stx1 does not affect bovine 
PBMC viability after 96 hours of incubation.  The perturbation of cytokines in the presence of 
Stx2 was also examined.  The results of our cytokine specific ELISAs indicated that Stx2 does 
not modulate IL10, TNFα or IL12 cytokine concentrations when comparing ConA-stimulated 
cultures either in the presence or absence of purified Stx2.  This result agrees with Menge et al 
[69] when they concluded that Stx1 affects bovine lymphocytes independent of various cytokines 
including TNFα.  IFNγ concentrations in ConA-stimualted PBMC cultures though did differ 
significantly.  ConA-stimulated PBMCs in the presence of Stx2 produced more IFNγ 
(approximately 4000pg/ml) than ConA-stimulated PBMCs which produced approximately 
3000pg/ml. 
 Dean-Nystrom et al [70] showed that calves experimentally inoculated with E. coli 
O157:H7 strain 933 showed bacterial colonization in their rectum, cecum, colon and ileum and 
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Nart et al [17] concluded from their studies that E. coli O157:H7 colonizes the terminal rectum 
demonstrating tissue tropism for E. coli O157:H7 within the bovine host.  In 1995 Cray et al 
[188] concluded from their study using preweaned calves and adult cattle that E. coli O157:H7 
does not spread from the alimentary tract to other organs such as the kidneys, liver or spleen.  
Therefore, we felt it was logical to study the effect of Stx2 on the population of lymphocytes 
exposed to E. coli O157:H7.  In young ruminants, the ileum is composed primarily of Peyer’s 
patch tissue consisting of contiguous aggregations of lymphoid follicles [137]. In the present 
study, we isolated lymphocyte populations from the Peyer’s patches and results indicate that 
Stx2 downregulates lymphocyte proliferation in these specialized immune structures.  Magnuson 
et al [189] showed that intestinal epithelial cell proliferation was lower in cattle that remained 
culture positive for E. coli O157:H7 than intestinal epithelial cell proliferation in cattle that 
cleared the bacteria.  In 2006, Hoffman et al [190] reported that cattle inoculated with an Stx 
negative O157 strain developed significant PBMC proliferation to an Stx2
+
 heat-killed strain 
after being challenged with an Stx2
+
 O157 strain compared to the group of cattle initially 
inoculated with an Stx2
+
 strain.  These results, along with the current results all suggest that 
Shiga toxins play a role in STEC pathogenesis in cattle.  Current studies failed to show a 
relationship between the induction of attaching and effacing proteins such as intimin and 
persistent infection of E. coli O157:H7 suggesting that an alternative virulence factor may be 
responsible [191, 192].  Cattle shed E. coli O157:H7 intermittedly throughout their lifetime with 
studies revealing up to 75% of dairy cattle and 63% of feedlots having culture-positive animals 
[193].  An individual animal can remain culture positive for over one year but usually averages 
30 days with no seasonal preference [194, 195].  Recent reviews by Meyer-Broseta et al [196, 
197]  concluded that E. coli O157:H7 is “ubiquitously distributed within cattle” which remain 
clinically normal.  Therefore it is no surprise that the relationship between cattle and E. coli 
O157:H7 needs to be understood in order to reduce colonization in cattle and subsequently lower 
exposure to the human population.  This study provides one piece of evidence that supports the 
immunomodulating capabilities of Shiga toxins particularly Stx2 within the bovine host.  We 
speculate that the percentage of receptor-bound Stx2 that is not internalized perturbs normal 
lymphocyte functions, including proliferation, thereby drastically reducing the magnitude of the 
bovine immunological response. 
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5.0 Effect of Shiga Toxin 2 on Cytokine Secretion by Bovine Intestinal Epithelial Cells  
 
5.1 Introduction 
 Upon infection with STEC, humans may develop a series of clinical symptoms that range 
in severity; watery diarrhea develops into HC involving bloody diarrhea, abdominal pain and 
fever (70% of cases) [38].  If infection persists, HUS may develop within six days of infection 
and include symptoms such as abdominal pain, vomiting, bleeding from the nose and decreased 
urine output which ultimately may lead to acute kidney failure.  The mortality rate for HUS is 5-
10% [9, 81].  Thus, following major human outbreaks, STEC have been considered an emerging 
zoonotic pathogen of significant public health concern. 
 Shiga toxin 1 (Stx1) and Shiga toxin 2 (Stx2) produced by STEC are one group of 
principle virulence factors attributed to the progression of disease in humans.  Shiga toxin 2 is an 
A-B protein comprised of one A subunit to every five B subunits.  The B subunits are 
responsible for recognizing and binding to the receptor, Gb3.  Traditionally the activity of the 
Shiga toxins is cytotoxic.  The A subunit of the toxin is internalized via clatharin-coated pits 
where it is responsible for inhibiting protein synthesis [52].   
 Studies on Shiga toxins and cytokine induction/inhibition have proven difficult with 
variable results due to species-specific and cell type-specific differences.    In humans, data has 
suggested that Shiga toxins and cytokines work cooperatively to create the pathological changes 
observed during HUS [52].  Pro-inflammatory cytokines such as TNF, IL6 and IL8 have been 
shown to be elevated in the urine but not in the serum of HUS patients suggesting a renal source 
of production [198].  In cattle, however, Stxs do not appear to behave as proinflammatory factors 
as they do in humans.  Moussay et al [199] showed using bovine intraepithelial lymphocytes that 
Stx1 did not alter IL2, TNFα or IFNγ mRNA transcript levels.  As well Menge et al [69] 
concluded that Stx1 did not modulate bovine immune responses through a cytokine-mediated 
effect.  Finally, using a bovine ligated loop model, Stevens et al [200] revealed that Stx1 does not 
induce intestinal inflammation in vivo therefore suggesting that Stxs are involved in STEC 
colonization and pathogenesis.  
 To date, the interaction between human or bovine intestinal epithelial cells and the Shiga 
toxins remains obscure.  Because STEC is a non-invasive pathogen, it has been hypothesized that 
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the Stxs cross the human intestinal epithelium, to reach the bloodstream and travel to susceptible 
organs.  Therefore, the intestinal epithelium is one of the first lines of defence and how it 
responds to these invading toxins has different implications for human and cattle hosts.  The 
production of chemokines by intestinal epithelial cells directs other immune cells in the adjacent 
and underlying mucosa ultimately affecting the generation of an immune response.  Recently, 
Thorpe et al showed that Stx1 significantly induces C-X-C chemokines such as IL8, GRO-α and 
GRO-β at the mRNA level in a human intestinal epithelial cell line HCT-8 suggesting that in 
humans they have an important role in providing chemoattractant signals in response to infection 
[201, 202].  The generation of chemokines is important for neutrophil recruitment which is part 
of the acute inflammation during haemorrhagic colitis in humans.  Experiments using bovine 
intestinal epithelial cell lines though showed Stx1 was unable to stimulate the release of 
granulocyte chemoattractants in vitro or induce intestinal inflammation in vivo [199, 200].   
 In the present study, we hypothesize that Stx2 modulates the local bovine immune 
response within the gastrointestinal tract by downregulating cytokine gene expression from 
intestinal epithelial cells.  We therefore tested the effect of purified Stx2 and a secreted protein 
preparation isolated from a wild type Stx2
+
 E. coli strain on the expression of selected cytokine 
genes in vitro by real-time PCR using a bovine intestinal epithelial cell line.  Recent publications 
in support of our hypothesis have shown that Stx1 inhibits the activation and proliferation of 
bovine lymphocytes in vitro [68].  Published data (Chapter 4) from our laboratory suggests that 
purified Stx2 inhibits the mitogen-induced proliferation of lymphocytes in vitro isolated from the 
ileal Peyer’s patches of cattle.  In 2004, Menge et al [203] showed that Stx1 depletes the ileal 
mucosa of CD8+ T cells in a ligated loop model.  As well published data (Chapter 6) from our 
laboratory suggests Stx2 depletes the ileal Peyer’s patches of CD4+ T cells during a ligated loop 
model of STEC infection.  Finally, Moussay et al  [199] recently showed that Stx1 failed to alter 
cytokine-specific gene expression of multiple cytokines from intraepithelial lymphocytes 
isolated from the ileum of cattle.  Consequently the purpose of this study was to examine if Stx2 
alters transcription of selected cytokines genes.  Therefore, these results will supplement our 
knowledge as to how STEC controls intestinal inflammation and the mucosal immune defence in 
cattle consequently permitting colonization and persistence. 
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5.2 Materials and Methods 
5.2.1 Culturing of bovine intestinal epithelial cell line 
 The bovine intestinal epithelial cell line used in the present study has been previously 
characterized and described by Kauschik et al [204] and has been confirmed to be suitable for 
studying host cell responses to pathogens.  The bovine intestinal epithelial cell line was cultured 
in a 1:2 mixture of Dulbecco’s Modified Eagle’s medium (DMEM) supplemented with 10% 
Fetal Bovine Serum (FBS) (Seracare), 1M HEPES (Sigma H0887), gentamycin (Gibco 15750-
060), apo-transferrin (Sigma T1428), epidermal growth factor (Sigma E9644), hydrocortisone 
(Sigma H0135) and insulin (Sigma I0516).  Cells were seeded onto a 75x75 tissue culture flask 
(Corning CellBind #3290) and grown to confluence at 37
o
C under 5% CO2. 
 
5.2.2 Confirmation of Stx Receptor using Flow Cytometry 
 A more detailed protocol for receptor identification is outlined in Section 3.7.  Briefly, 
after cell harvesting, cells were thoroughly resuspended in FACola and transferred to round 
bottom microtiter plates.  Fifty microliters of the anti-CD77 monoclonal antibody was added to 
each well.  FACola was added to each well and the plates were centrifuged.  This was repeated 
two more times for a total of three washes.  One hundred microliters of the goat anti-rat IgM 
fluorochrome conjugated secondary antibody (100μg, eBioscience #11-0990-82) was added to 
each well.  A total of three washes were done again and at the end 2% formaldehyde in PBS was 
added to each well. Negative controls included cells with media only.  The amount of specific 
antibody binding was calculated by subtracting the population of cells that bound an isotype-
matched relevant monoclonal antibody (Table 3).   
  
5.2.3 RNA purification  
 A total of 1.0x10
7
 bovine intestinal epithelial cells were incubated in the presence or 
absence of Stx2 (2000CD50, approximately 2000pg/ml) for 6 hours at 37
o
C under 5% CO2.  Cells 
were then harvested and washed twice with cold PBSA and resuspended in 1ml of Trizol 
(Sigma).  Samples were stored at -20
o
C until RNA isolation.  Upon thawing of samples, 200μl of 
chloroform was added and the samples were incubated at room temperature for 3 minutes, 
centrifuged for 10 minutes at 12000xg and the aqueous phase collected.  Isopropanol was added 
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to each sample and incubated for 5 minutes at room temperature before applying to a Qiagen 
mini-column.  RNA was isolated using the Qiagen RNeasy kit isolation protocol.  Briefly, cells 
were centrifuged for 15 seconds at 9000 x g.  DNase digestion was performed on column using a 
Qiagen DNase kit (Qiagen).  To each sample, a total of 30U of DNase suspended in RNase- and 
DNase-free water was added to the column and incubated at room temperature for 15 minutes. 
The column was washed twice to remove the DNase using 350μl washing buffer (RW1).  
Another two washes to remove any remaining DNA were done using 500μl of buffer RPE.  To 
elute RNA, 100μl RNase free water was added to the column and centrifuged at 9000 x g for one 
minute.  The samples were stored immediately at -20 °C.  The RNA concentration and integrity 
was determined by capillary electrophoresis on a Bioanalyzer (Agilent Technologies, 
Mississauga, ON).    
 
5.2.4 cDNA Synthesis 
 The protocol for first-strand cDNA synthesis was followed according to the Manufacturer 
(Invitrogen).  Briefly, 1μg of RNA was added to 10μl of 2X RT reaction mix and 2μl of RT 
enzyme mix.  All incubations were done in a thermal cycler.  The mixture was incubated at 25
o
C 
for 10 minutes followed by incubation at 50
o
C for 30 minutes.  The reaction was then terminated 
at 85
o
C for 5 minutes.  Nucleic acid content was estimated spectrophotometrically using the 
A260/A280 ratio. 
 
5.2.5 Quantitative RT-PCR (qRT-PCR) 
 Quantitative RT-PCR and data analyses were performed as described [205]. All qRT-
PCR reactions contained 1μl target cDNA, 0.2μM each of forward and reverse primers (Table 6), 
and 9μl of qRT-PCR SuperMix (Invitrogen). Deionized, diethylpyrocarbonate-treated double 
distilled water was added to a final volume to 15μl.  Reactions were run in duplicate in 96-well 
RT-plates covered with optical quality tape 170 (Bio-Rad) using the iCycler iQ Real-Time PCR 
detection system (Bio-Rad).  Amplification was performed using the following protocol: 
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Cytokine Gene Primer Sequence   (5’         3’) 
IFNγ FWD-TCAAATTCCGGTGGATGATCTGC 
REV-GACCATTACGTTGATGCTCTCCG 
IL6 FWD-ATCAGAACACTGATCCAGATCC 
REV-CAAGGTTTCTCAGGATGAGG 
IL12 FWD-ATGAGAGTTGCCTGGCTTCCAGAG 
REV-GCGTGAAGAAGGATGCAGAGCTTG 
IL8 FWD-AGTGTGGCCCACTCTCAATAAC 
REV-CAAGAGCCAGAAGAAACCTGAC 
TNFα FWD-CTCTTCTGCCTGCTGCACTTC 
REV-CCATGAGGGCATTGGCATACG 
Β-actin FWD-AGGCATCCTGACCCTCAAGTA 
REV-GCTCGTTGTAGAAGGTGTGGT 
 
Table 6.  DNA primer sequences used for amplification of cytokine genes.  The forward 
primer contained a ribosome binding site sequence and the starting sequence of each gene.  The 
reverse primer contained the necessary sequence for amplification at low annealing temperatures.  
FWD: forward, REV: reverse 
 
 
 
 
 
 
 
 
 
 
 
83 
 
initial denaturation at 95 °C for 3 minutes (cycle one), followed by cycle two (95 °C, 15 seconds; 
60 °C for 30 seconds; 76 °C for 30 seconds) which was repeated 45 times. Cycle 3 ran at 95 °C 
for 1 minute.  Cycle 4 was preset at 45 °C ramping to 95 °C with 1 °C increase each 30seconds. 
The final hold temperature was 22 °C.  Each plate had a negative template control that contained 
all the reagents except cDNA.  The amplification of the product was determined by measuring 
the amount of SYBR Green I dye incorporated in the PCR product and plotted as fluorescence 
versus cycle number. The SYBR Green I dye is a double stranded DNA binding dye that emits 
fluorescence as the double stranded DNA is generated. The fluorescence intensity increases 
proportionally to the double stranded DNA concentration [206].  
 The relative difference in gene expression was calculated and represented as fold change  
2
-ΔΔct 
[206], where the Ct was defined as the cycle number at which the first detectable 
fluorescence increase above the threshold was observed.   ΔCt = Ct value of target gene minus Ct 
value of internal control (Ct value of β-actin rRNA). The ΔΔCt = ΔCt of test minus ΔCt of 
control.  The qRT-PCR reactions were carried out in duplicate and the data showed fold change 
in mRNA which is 2 
–ΔΔct
 [206].  
 
5.2.6 Secreted Protein Preparation 
 A detailed protocol for isolating secreted proteins is described in section 3.4.  Briefly, 
secreted proteins were isolated from a Stx2
+
 wild type E. coli O157:H7 (1961) and Stx2
-
 mutant 
E. coli O157:H7 strains (92192).  Twenty millilitres of wild type Stx2
+
 E. coli O157:H7 and 
mutant Stx2
-
 E. coli O157:H7 were grown up to stationary phase overnight in LB (or LB + 
15μg/ml gentamicin for mutant strain).  Both the Stx2+ wild type E. coli O157:H7 strain and the 
Stx2
-
 mutant E. coli O157:H7 overnight cultures were subcultured the next morning and allowed 
to grow to log phase using constant aeration (OD600 of approximately 0.7).  The supernatants 
were concentrated as described [174].   
 
5.2.7. Cytokine Analysis 
 A detailed ELISA protocol for determining cytokine production is described in section 
3.6.  Bovine intestinal epithelial cells were incubated with purified Stx2 (concentration of 
2000CD50) for 6 hours.  After the incubation, the supernatant was removed from the tissue 
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culture flask.  One hundred microliters of media was immediately applied to an IFNγ-specific 
pre-coated ELISA plate and diluted in a two-fold dilution series for cytokine concentration 
evaluation.  
 
5.3 Results 
5.3.1 Flow Cytometry of bovine intestinal epithelial cell line to confirm expression of Shiga 
toxin Receptor 
 To establish if the bovine intestinal epithelial cell line expresses Shiga toxin receptor 
(Gb3), we used flow cytometry to measure the amount of anti-CD77/Gb3 binding.  Once the 
presence of surface Gb3 was confirmed, we used the cell line to determine the effects of Stx2 on 
cytokine gene expression.  The flow cytometry results are shown in Figure 12 and indicate that 
the bovine intestinal epithelial cells express the Stx receptor on their cell surface.  We concluded 
that this is an appropriate cell line to use to investigate the effects of Stx2 on cytokine gene 
expression. 
 
5.3.2 Cytokine profile of the bovine intestinal epithelial cell in the presence of purified Stx2. 
 To determine if Stx2 downregulates cytokine gene expression from intestinal epithelial 
cells, we tested the effect of purified Stx2 on the expression of selected cytokine genes by real- 
time PCR using a bovine intestinal epithelial cell line.  The results of the qPCR analysis 
suggested lower cytokine gene expression of IFNγ, IL8, IL6 and IL12 in the presence of Stx2 
(Figure 13).   
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Figure 12.  Flow cytometry analysis of the bovine intestinal epithelial cell line.  An Anti-
CD77 monoclonal antibody was used to identify c) CD77 receptor bearing epithelial cells. The 
appropriate controls (a) isotype and b) secondary antibody) were included on each 96 well plate 
and used to exclude any non-specific antibody binding that may occur during the analysis (Table 
3). 
 
a. 
b. 
c. 
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Statistical analysis of cytokine gene expression in the presence of Stx2 showed it was not 
significantly different than cytokine gene expression in the absence of Stx2 for IFNγ, IL8, IL6, 
TNFα and IL12.  The qPCR results are shown in Figure 13 and indicated that IFNγ cytokine 
gene expression was approximately 0.3 fold less than IFNγ gene expression of the bovine 
intestinal epithelial cell line incubated without toxin.  IL6, IL12 and IL8 cytokine gene 
expression were approximately 0.8 0.7 and 0.5 fold less respectively when compared to gene 
expression in the absence of Stx2 (Figure 13).  TNFα cytokine gene expression remained 
unaltered in the presence of purified Stx2.  The β-actin gene was selected as an internal standard 
(loading control) as it is expressed in bovine cells.  No significant difference (P < 0.05) in β-actin 
gene expression was found when cells were either in the absence or presence of Stx2.  These 
observations suggest lower cytokine gene expression of IFNγ, IL6, IL12 and IL8 in the presence 
of Stx2.   
 
5.3.3 Cytokine profile of bovine intestinal epithelial cells in the presence of Secreted protein 
preparations with and without Stx2. 
 STEC uses type III secreted proteins to colonize its hosts and Stx2 is a component of the 
secreted protein “cocktail”.  Therefore, we wanted to determine if Stx2, in the presence of type 
III secreted proteins, modulates bovine immune responses through cytokine gene expression.  To 
do this, secreted protein preparations were isolated from a wild type Stx2
+
 E. coli O157:H7 strain 
(1961) and a mutant Stx2
- 
E. coli O157:H7 strain (92192) and cytokine gene expression was 
analyzed by real-time PCR using a bovine intestinal epithelial cell line.  The results of the qPCR 
analysis (Figure 14) indicated that cytokine gene expression of IFNγ, IL8, IL6 and IL12 was 
reduced in the presence of the secreted protein preparation isolated from the wild type Stx2
+
 E. 
coli O157:H7 strain when compared to cytokine gene expression of the bovine intestinal 
epithelial cell line incubated with the secreted protein preparation isolated from the mutant Stx2
- 
E. coli O157:H7 strain.  Statistical analysis of the cytokine gene expression in the presence of the 
wild type Stx2
+
 E. coli O157:H7 strain was not significantly different than cytokine gene 
expression in the presence of the mutant Stx2
-
 E. coli strain for IFNγ, IL8, IL6, TNFα and IL12.  
The β-actin gene was selected as an internal standard (loading control) as it is expressed in 
bovine cells. No significant difference (P< 0.05) in β-actin gene expression was found when cells 
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were either in the absence or presence of Stx2.  The data in Figure 14 suggested a trend to 
support the hypothesis that cytokine gene expression is downregulated in the presence of Stx2.   
 
5.3.4 IFNγ production by bovine intestinal epithelial cells in the presence of purified Stx2. 
 To substantiate the results of the cytokine gene expression analysis, IFNγ-specific 
ELISAs were done to evaluate IFNγ protein concentrations resulting from incubation of the 
bovine intestinal epithelial cell line with purified Stx2.  The results indicated that there was less 
IFNγ produced by the cells exposed to Stx2 compared to cells not exposed to Stx2 although 
statisical analysis using the Mann-Whitney test indicated that the levels of IFNγ were not 
significantly different (Figure 15).  Approximately 800ng/ml of IFNγ was produced by the 
bovine intestinal epithelial cells not exposed to Stx2 and approximately 500ng/ml of IFNγ was 
produced by the cells exposed to Stx2.  Why the cell line in the absence of any stimuli/mitogen 
produced the amounts of IFNγ observed has yet to be determined (Figure 15). 
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Figure 13.  Cytokine gene expression levels in the presence of purified Shiga toxin 2.   
Bovine intestinal epithelial cells were incubated for 6 hours with purified Shiga toxin 2 
(2000CD50 as determined on VERO cells).  After the 6 hour incubation, cells were collected, 
RNA extracted and cDNA was prepared.  Each cytokine was normalized against β-actin gene 
expression in the presence and absence of Stx2.  Data represents duplicate qPCR analysis of each 
cytokine gene from two independent experiments.   
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Figure 14. Cytokine gene expression in the presence of the secreted protein cocktails 
isolated from the wild type Stx2
+
 E. coli O157:H7 strain and the mutant Stx2
-
 E. coli 
O157:H7 strain.  After 6 hours of incubation, bovine intestinal epithelial cells were collected, 
RNA extracted and cDNA was made.  Each cytokine was normalized against β-actin gene 
expression in the presence and absence of Stx2.  Data represents duplicate qPCR analysis of each 
cytokine gene from three independent experiments.   
 
 
 
 
 
 
 
 
 
 
 
 
90 
 
 
C
el
ls
 a
lo
ne
C
el
ls
 +
 S
hi
ga
 to
xi
n2
 
0
200
400
600
800
1000
Bovine Inestinal Epithelial Cells + Treatment
n
g
/m
l 
IF
N

 
Figure 15.  IFNγ production by bovine intestinal epithelial cells in the presence of Stx2.  
The bovine intestinal epithelial cell line was split at a 1:2 ratio using the culture media described 
above and allowed to grow in a 75x75 tissue culture flask until confluent (96 hours at 37
o
C under 
5% CO2).  On the fourth day, the purified Stx2 preparation was added to the tissue culture flask 
and allowed to incubate with the cells for 96 hours at 37
o
C under 5% CO2.   
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5.4 Discussion 
 Mucosal surfaces are principal sites of entry for bacterial pathogens.  The epithelial cells 
lining these mucosal surfaces are often the host’s first line of defence providing a physical 
barrier between the pathogen and the host’s internal environment [207].  In the gastrointestinal 
tract, the epithelial cells play an active role in producing signals that either induce or suppress the 
neighbouring immune and inflammatory cells in the mucosa [207].  Since STEC is a non-
invasive pathogen, adherence to the intestinal epithelium is of particular importance for long 
term colonization within the bovine host.  Published data regarding the expression of the Stx 
receptor on intestinal epithelial cells has been variable due to methodological constraints and 
exact lineage of cell lines.  A number of reports have demonstrated the binding of Stx1 or the 
anti-CD77 antibody to the crypt regions of both bovine and human intestinal cell lines [85, 208, 
209].  Hoey et al [208] observed Stx receptors on the surface of a bovine intestinal epithelial cell 
line  and Stamm et al [178] described a bovine colonic cell line that is Stx receptor positive and 
bound rStxB1 molecules.  In the present study, we also show Stx receptor expression on the 
surface of the bovine intestinal epithelial cell line using a monoclonal antibody to the CD77 
antigen.  The cell line used in the present study has been characterized and described by 
Kauschik et al [204] and has been confirmed suitable for studying host cell responses to 
pathogens. 
 Dean-Nystrom et al [210] showed that STEC strains are able to colonize the epithelium 
of the small intestine, the gall bladder, colon and the rectum of calves within 96 hours after oral 
inoculation.  Therefore it has been hypothesized that STEC adherence to the intestinal epithelium 
is important for STEC colonization in cattle.  E. coli O157:H7 has the ability to intimately attach 
to cells by rearranging the actin cytoskeleton using a type III secretion system found on the 
pathogenicity island called LEE.  There is substantial amount of published data to support the 
hypothesis that E. coli O157:H7 uses LEE-encoded proteins to destroy tight junctions and 
intimately attach to intestinal cells [211].  But there is a growing amount of data revealing other 
factors independent of LEE that are required for colonization of the intestinal epithelium [212-
214]. 
 To date, there are numerous studies demonstrating that STEC modulates host immune 
responses in epithelial cells using a variety of mechanisms.  STEC flagellin has been shown to be 
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a potent proinflammatory molecule in vitro but its expression in vivo has not yet been 
demonstrated.  Yamasaki et al [215] showed Stx-dependent cytokine induction in a human colon 
epithelial cell line independent of bacterial LPS or any other bacterial component.  As well, 
Thorpe et al [201, 202] have shown an induction of IL8 in the presence of Stx1 from a human 
colonic epithelial cell line.  On the other hand, Hauf et al [216] have shown that EspB suppresses 
cytokine-induced NF-κB activation.  Similar experiments using HCT-8 cells did not demonstrate 
IL8 induction after 3 hours of incubation with purified Stx2 [202].  In the present study, we show 
a trend suggesting Stx2 suppresses cytokine induction at the transcriptional level in a bovine 
intestinal epithelial cell line. 
 The data suggests that induction of cytokines in humans may be of significance in the 
pathogenesis of HUS.  Since cattle do not develop HUS or any clinical disease upon infection 
with STEC, it was our hypothesis that the role of Stxs in STEC-epithelial cell interaction results 
in the downregulation of bovine immune responses which is contrary to what is seen in humans.  
Therefore, the present study is an in vitro analysis of the effect of Stx2 on cytokine gene 
expression at the transcriptional level in bovine intestinal epithelial cells. The results in the 
present study indicate that induction of the cytokines IL12, IL6, IL8 and IFNγ from a bovine 
intestinal epithelial cell line was suppressed in the presence of Stx2.  To date, there is limited 
published data to supplement our findings.  Recently, Bellmeyer et al [217] demonstrated that a 
Stx
+
 EHEC strain suppressed inflammatory responses to cytokines and Stx itself compared to an 
Stx
-
 isogenic mutant strain.  Also, Berin et al [218] failed to show an induction of IL8 in the 
presence of purified Stx2 from Caco-2 cells.  Menge et al [219] showed that Stx1 perturbs the 
cytokine profile of bovine intraepithelial lymphocytes, immune cells situated within the 
gastrointestinal epithelium.  Experiments using a bovine intestinal epithelial cell line showed 
Stx1 was unable to stimulate the release of granulocyte chemoattractants in vitro or induce 
intestinal inflammation in vivo [199, 200].  Phillips et al [167] have reported on STEC O157:H7 
strains whose adhesion is restricted to the follicle-associated epithelium of ileal Peyer’s patches.  
The implications of this finding could suggest that factors (such as the Stxs) expressed by STEC 
are conveniently situated near induction sites within the GALT in order to exert their 
immunomodulating effects [220].  Consequently these findings as well as the data presented here 
points to the possibility of an immunomodulatory role for Stxs within the bovine host to promote 
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STEC colonization and persistence.  Despite the fact that there is very little published data 
regarding STEC-epithelial cell interactions, further understanding is crucial in order to develop 
effective strategies to reduce STEC shedding from the bovine host and thereby reduce human 
exposure and disease. 
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6.0 In Vivo Analysis of the Immunomodulatory Effects of Shiga toxin 2 using a Gut-loop 
Model 
 
6.1 Introduction 
 Shiga-toxin producing E. coli (STEC) is a significant zoonotic pathogen causing a range 
of clinical symptoms that may lead to hemolytic uremic syndrome (HUS) if infection persists.  
The mortality rate for HUS is 5-10% [9, 81].  Hemolytic uremic syndrome is a consequence of 
the Shiga toxins (1 and 2) produced by STEC, which were inititally described in Shigella 
dysenteriae [38]. 
 The Shiga toxins are A-B proteins comprised of one A subunit to every five B subunits.  
The B subunits are responsible for recognizing and binding to the receptor, Gb3, a 
glycosphyngolipid having many different cellular roles.  Apart from being a bacterial toxin 
receptor, Gb3 is also a tumour and blood group antigen and a regulator of cell proliferation [58].  
Traditionally the role of the Shiga toxins was thought to only be cytotoxic.  The A subunit of the 
toxin is internalized via clatharin-coated pits where it is responsible for inhibiting protein 
synthesis.  Recently, the role of the Shiga toxins has expanded and experiments suggest that they 
may also have an immunomodulatory role during STEC pathogenesis.  In 2001, Menge et al [67, 
68] showed that bovine lymphocytes isolated from the gastrointestinal tract and blood express 
functional Stx receptors on their surface.  Lowered lymphocyte proliferative responses are seen 
in vitro in the presence of Stx1 with both human and bovine immune cells [68, 179].  However, 
the effect of Stx1 is believed to be restricted to B cells in humans but extends to both B and T 
cells in bovines [178, 179, 199].   
 To date, many in vitro studies have been done that indicate that bacterial products are 
involved in inhibiting the activity of host cells [221].  EspB, part of the type III secretion system 
of E. coli O157:H7, has been shown to suppress host NF-κβ activation and Menge et al have 
showed that Shiga toxins downregulate lymphocyte proliferation [68, 216].  Based on these 
results, it has been suggested that Shiga toxins are important virulence factors contributing to 
STEC persistence in cattle.  Therefore, an in vivo investigation is crucial to our understanding of 
STEC immune suppression.  We hypothesize that Shiga toxin 2 modulates the bovine mucosal 
immune system in vivo.  To test this hypothesis, an in vivo model described by Gerdts et al [222] 
95 
 
using multiple intestinal loops surgically made in the jejunum.   In young ruminants, the ileum is 
comprised almost exclusively of Peyer’s patch tissue extending up to two meters in length [137].  
Each loop included a portion of Peyer’s patch tissue and served as an independent site to analyze 
the mucosal immune response to a wild strain of E. coli O157:H7 producing Stx2 and an 
insertionally inactivated Stx2
-
 E. coli O157:H7 mutant strain.  In 2004 Menge et al [203] used 
intestinal loops to study the effects of Stx1 on ruminant intraepithelial lymphocyte populations 
and concluded that the ileal loop model is a useful tool to study mucosal responses to STEC in 
the bovine host.  Results of the present investigation indicated that loops exposed to the wild 
type E. coli O157:H7 strain had a significant reduction in their CD4+ T cell population when 
compared to loops exposed to the Stx2
-
 E. coli O157:H7  mutant strain.  Analysis of cytokine 
concentrations from the different loops failed to show a significant effect of the different E. coli 
O157:H7 strains.  These results indicate that Stx2 may be an important immune modulator 
within the bovine host contributing to STEC pathogenesis. 
 
6.2 Materials and Methods 
6.2.1 Bacterial strains and growth conditions 
 The STEC strains used in this study were a wild type Stx2
+
 strain (1961) and an isogenic 
Stx2
- 
strain (92192) (obtained from Dr Carlton Gyles, University of Guelph, Guelph, Ontario, 
Canada).  Previous characterization of the Stx2
-
 mutant strain 92192 revealed an insertion 
mutation in the stx2 gene rendering the strain gentamicin resistant.  The night before the surgery 
a single colony forming unit of the wild type E. coli O157:H7 strain was taken from an LB plate 
and inoculated into 20mls of Luria Broth (LB) (Gibco).  Also, a single colony forming unit of the 
mutant E. coli O157:H7 grown up on an LB + 15μg/ml gentamycin plates was inoculated in 
20mls LB + 15μg/ml gentamycin (Gibco #15750-060).  The cultures were allowed to grow 
overnight to stationary phase at 37
o
C with constant aeration.  The next morning, 3mls of each 
overnight culture was inoculated into 30mls of fresh LB +/- 15μg/ml gentamycin and the cultures 
were allowed to grow to log phase which is approximately an OD600 of 0.7.  At this time, 15mls 
of each log phase culture were removed and placed on ice for transport to the surgery room.  
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6.2.2 Animal Experiments 
 The animal experiment performed was in accordance with the University of 
Saskatchewan Committee on Animal Care which are consistent with the guidelines provided by 
the Canada Council for Animal Care.  A 6 week old Holstein bull calf was fed twice daily with 
free access to water.  The calf was observed daily prior to surgery and remained free of any 
clinical symptoms such as diarrhea.  The calf was fasted for 12 hours prior to surgery. 
 
6.2.3 Ligated Ileal Loop model 
 The bovine ligated jejunal loop model was described previously by Gerdts et al [222] and 
a bovine ligated ileal loop model was previously employed by Menge et al [203].  This 
procedure was followed with minor modifications.  Briefly, the calf was anaesthetized for the 
duration of the experiment (approximately 6 hours) by intravenous administration of 
pentobarbitone sodium.  The calf was positioned in dorsal recumbence and a midline abdominal 
incision was made.  Throughout the surgery, the ileum was constantly moistened with warm 
phosphate-buffered saline without calcium and magnesium (PBSA; pH7.2).  A segment of the 
ileum was surgically prepared by removing ingesta and flushing twice with warm PBSA 
containing 250mg metronidazole.  The antibiotic solution was removed with a PBSA flush.  The 
ileal segment was further subdivided into loops which were approximately 6cm long.  Each loop 
included Peyer’s patch tissue which was grossly visible.  Three loops were designated wild type 
loops and were inoculated with 5mls of 1x10
7
/ml wild type E. coli O157:H7 that produces Shiga 
toxin 2.  Three loops were inoculated with 5mls of 1x10
7
/ml mutant E. coli O157:H7 that does 
not produce Stx2 and were designated mutant loops.  Two loops were inoculated with saline and 
were designated control loops (total volume 5mls/per loop).  The continuity of the ileum was re-
established with an end-to-end anastomosis.  The calf was euthanized with an overdose of 
anaesthetic 24 hours post surgery.  The loops were collected and placed into individual glass 
beakers containing ice-cold CMF-HBSS/5% FBS/antibiotic/antimycotic solution.  The interspace 
intestinal regions were removed from the intestinal loops and were not used in cell isolation. 
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6.2.4. Intestinal Peyer’s Patch Lymphocyte Isolation 
 A detailed protocol for lymphocyte isolation is outlined in section 3.2.2.  Briefly, 
immediately upon loop retrieval, intestinal Peyer’s patch lymphocytes (IPPL) were isolated from 
all eight loops.  The tissue was cut into pieces and washed for 15 minutes in CMF-HBSS/5% 
FBS/antibiotic/antimycotic/10mM DTT at 37
o
C.  The tissue pieces were placed into a new flask 
containing CMF-HBSS/5% FBS /antibiotic/antimycotic/10mM EDTA for 60 minutes at 37
o
C.  
After 60 minutes, tissue pieces were washed for 180 minutes in CMF-HBSS /5% FBS/ 200U/ml 
collagenase 4/ 30μg/ml DNase I.  The supernatant was centrifuged and the pellet was 
resuspended in PBSA.  This was layered onto Ficoll-Hypaque and centrifuged.  The buffy coat 
was collected and washed three times in PBSA + 5% FBS.   
 
6.2.5 Flow Cytometry Analysis of Intestinal Peyer’s Patches lymphocytes  
 After cell isolation, IPPL populations from each loop were resuspended in cold FACola.  
One hundred microlitres of each cell preparation were transferred to round bottom microtiter 
plates at a final concentration of 1x10
6
 cells/well.  Fifty microliters of the monoclonal antibody 
specific for CD4 (VMRD CACT183A), CD8 (VMRD CACT80C), MHC class II (VMRD 
H34A), CDC11 (VMRD BAQ153A) and CD21 (AbD Serotec CC211/MCA1424G) was added 
to each well (Table 2).  This was allowed to incubate on ice for 15 minutes.  One hundred 
microliters of FaCola was added to each well and the plates were centrifuged for 2 minutes at 
350xg.  This was repeated two more times for a total of three washes.  One hundred microliters 
of the fluorochrome conjugated secondary antibody (Becton Dickinson FITC-Goat anti-mouse 
IgG diluted to 1/50) was added to each well and incubated on ice for 15 minutes.  A total of three 
washes were done again and at the end 200μl of 2% formaldehyde was added to each well to fix 
the samples.  The plate was stored at 4
o
C until ready to be analyzed (no longer than 2 weeks).  
Ten thousand events were acquired for each sample.  Negative controls included cells with 
media only.  The amount of specific antibody binding was calculated by subtracting the 
population of cells that bound the isotype-matched relevant monoclonal antibody (Table 2). 
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6.2.6 Cytokine profile Analysis  
 A detailed protocol for cytokine quantitation is described in Section 3.6.  The monoclonal 
antibodies to IFNγ, TNFα, IFNα and L12 were resuspended in coating buffer and applied to 96 
round bottom plates.  The appropriate biotinylated antibody was applied to each well.  The 
reactions were stopped when the OD405 of the first dilution of the standard curve reached an 
OD405 of approximately 2.000.   
 
6.2.7 PCR Analysis of Stx2
+
 Wild type E. coli O157:H7 strain and the Stx2
-
 Mutant E. coli 
O157:H7 strain 
 The extraction of genomic DNA from E. coli wild type Stx2
+
 strain (1961) and the 
isogenic Stx2
- 
strain (92192) were carried out as described [223].  The stx2A gene was amplified 
using primers based upon the E. coli O157H7 EDL933 sequence.  The sequence of the forward 
primer (Stx2AF) and reverse primer (Stx2AR) were (5’-GTTGTTAGCTCAGCCGGACA-3’) and 
(5’-TTTGCAGTAACGGTTGCAGA-3’), respectively.  The stx2A gene was amplified by 
polymerase chain reaction (PCR).  The PCR reaction was carried out as follows: denaturation at 
96
o
C for 1 minute, then 25 cycles of denaturation for 30 seconds at 95
o
C, annealing for for 30 
seconds at 60
o
C, extension for 1.5 minutes at 68
o
C and a final extension step for 5 minutes at 
68
o
C. 
 
6.3 Results 
6.3.1 Confirmation of an insertional mutation within the stx2A gene in the Mutant E. coli 
O157:H7 strain. 
 Previous characterization of the Stx2
-
 mutant E. coli O157:H7 strain (92192) revealed an 
insertion mutation in the stx2A gene conferring gentamicin resistance.  The Stx2
+
 wild type strain 
(1961) does not possess the transposon and is therefore gentamicin sensitive.  The presence of 
the transposon in the Stx2
-
 strain was confirmed using PCR analysis.  The stx2A gene is 
approximately 1000bps in size.  The PCR primers were designed with 200bps of flanking DNA 
on each side of the gene (Figure 16).  The stx2A gene from the mutant strain contains a 
gentamicin transposon that is approximately 540bps in size.  Therefore the total PCR product is 
approximately 2000bps (Figure 16).   
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6.3.2 Immunophenotype of IPPL exposed to a Stx2
+
 Wild type E. coli O157:H7 strain and 
an Stx2
-
 Mutant E. coli O157:H7 strain 
 Eight ligated “loops” were created in one 6 week old Holstein bull spanning the entire 
length of the ileum.  Each loop was inoculated with either the Stx2
+
 wild type E. coli O157:H7 
strain, the Stx2
-
 mutant E. coli O157:H7 strain or sterile saline.  Viable ileal IPPLs were isolated 
after 24 hours from each intestinal loop inoculated with the different E. coli O157:H7 strains.  
The immunophenotyping results indicated that the IPPL populations were similar in percentages 
when comparing the loops inoculated with either STEC strain or saline with the exception of one 
population of T cells. Statistical analysis, using the Dunn’s Multiple Comparison Test following 
one-way repeated ANOVA, indicated that the Stx2
+
 wild type E. coli O157:H7 strain 
significantly reduced the total number of CD4+ T cells (P<0.05) compared to the loops 
inoculated with the Stx2
-
 mutant E. coli O157:H7 strain.  Other lymphocyte populations were 
also assessed including CD8+ T cells, CD21+ B cells and dendritic cells (double stain for MHC 
II and CDC11).  No statistical differences could be detected in any of these lymphocyte 
populations when compared to loops exposed to the different STEC strains or saline (Figure 17). 
 
6.3.3 Cytokine Production by IPPL populations exposed to an Stx2
+
 Wild type E. coli 
O157:H7 strain or an Stx2
-
 Mutant E. coli O157:H7 Strain 
 Cytokine concentrations in the ligated loops exposed to either the wild type or the mutant 
E. coli O157:H7 strains were assessed using capture ELISAs in order to determine if Stx2 
modulates bovine immune responses through cytokine production.  The results indicated no 
significant difference in production of TNFα, IFNα and IL12 when comparing loops inoculated 
with either the Stx2
+
 or Stx2
-
 STEC strains.  We did observe elevated IFNγ, TNFα, IFNα and 
L12 cytokine levels in the loops inoculated with either STEC strain compared to the loops 
exposed to sterile saline (Figure 19).  Approximately 1800ng/ml of IL12 was detected in Stx2
+
 
loops and approximately 1500ng/ml of IL12 was detected in Stx2
-
 loops.  Both of these loops 
had an increase in IL12 levels compared to the loops exposed to sterile saline (approximately 
600ng/ml) (Figure 19a).  IFNα concentrations in the loops inoculated with either the Stx2+ or 
Stx2
-
 strains were 13pg/ml and 20pg/ml respectively (Figure 19b).  Almost identical cytokine 
concentrations were observed for TNFα production when loops were exposed to either STEC 
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strain.  The results indicate that TNFα and IFNα cytokine levels were elevated in the loops that 
were exposed to both types of E. coli O157:H7 strains compared to the loops that received only 
sterile saline (which were 1000pg/ml and 2pg/ml respectively).  When analyzing the IFNγ 
cytokine concentrations, the results indicated that approximately double the amount of IFNγ was 
produced in loops exposed to the wild type Stx2
+
 E. coli O157:H7 strain when compared to 
loops exposed to the mutant Stx2
-
 E. coli O157:H7 strain (Figure 19d).  Statistical analysis 
revealed that these values were not significantly different.  The levels of IFNγ were much lower 
in loops exposed to saline compared to the loops inoculated with the Stx2
+
 and Stx2
-
 E. coli 
O157:H7 strains (Figure 19d). 
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Figure 16.  Polymerase Chain Reaction analysis of the A subunit of the stx2 gene.  Genomic 
DNA from the Stx2
+
 wild type STEC strain and the Stx2
- 
mutant STEC strain was isolated and 
analyzed in order to confirm the presence of a gentamicin transposon in the stx2A gene of the 
mutant STEC strain.  Arrows indicate lane 3 is the PCR product of the stx2 gene isolated from 
the Stx2
-
 mutant STEC and lane 2 is the PCR product of the stx2 gene isolated from the Stx2
+
 
wild type STEC.   
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Figure 17.  Immunophenotyping of the ileal IPPL populations isolated from the ligated 
loops.  Freshly isolated IPPL populations from loops inoculated with a wild type Stx2
+
 STEC 
strain (●), the mutant Stx2- STEC strain (■), or saline (▲) were analyzed using flow cytometry.  
Statistical analysis using the Dunn’s Multiple Comparison Test following one-way repeated 
ANOVA indicated that the number of CD4 T cells isolated from the loops exposed to the wild 
type Stx
+
 STEC strain were significantly lower (P<0.05) when compared to the number of T 
cells isolated from the loops exposed to the mutant Stx2
- 
STEC strain.  *P<0.05. 
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Figure 18.  CD4+ T cell analysis of the ileal IPPL populations isolated from ligated loops. 
Freshly isolated IPPL populations isolated from loops inoculated with a wild type Stx2
+
 STEC 
strain (■), the mutant Stx2- STEC strain (▲), or saline (●) were analyzed using flow cytometry.  
Ten thousand events were acquired for each sample.  Statistical analysis using the Mann-
Whitney test indicated that the number of CD4 T cells isolated from the loops exposed to the 
wild type Stx
+
 STEC strain were significantly lower (P<0.05) when compared to the number of T 
cells isolated from the loops exposed to the mutant Stx2
- 
STEC strain. 
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Figure 19.  Cytokine production in ligated loops after exposure to Stx2.  Cytokine production 
was measured after incubation with either wild type Stx2
+
 E. coli O157:H7 strain (■), the mutant 
Stx2
-
 E. coli O157:H7 (▲) or saline control (●).  Supernatant collected from individual loops 
immediately after the calf was euthanized and applied to a) IL12, b) IL10, c) TNFα and d) IFNγ 
b. a. 
d. 
c. 
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specific ELISAs.  The data points represent cytokine production from individual loops.  
Statistical analysis using the Mann-Whitney test to analyze loops inoculated with wildtype Stx2
+
 
STEC and mutant Stx2
-
 STEC was done.  
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6.4 Discussion 
 It has been reported that calves inoculated with Stx2
+
 E. coli O157:H7 have significantly 
higher and longer fecal shedding of E. coli O157:H7 compared to calves inoculated with Stx2
-
 E. 
coli O157:H7 or a non-pathogenic E. coli [190].  Also, Stx2 can be detected in faecal samples of 
cattle and consequently probably achieves biologically active concentrations [224].  These 
results suggest that Stx2 may have a role in STEC pathogenesis within the bovine host.  What 
remains to be explained is how Stx2 increases STEC pathogenesis thereby acting as a virulence 
factor during STEC colonization.  The mechanism by which Stx2 facilitates STEC colonization 
is explained through the modulation of the bovine mucosal immune response.   The depletion of 
bovine CD4+ T cells within the ileum implies that these lymphocytes are either direct or indirect 
targets of Stx2.  In the present study, the CD4+ T lymphocytes were significantly reduced in the 
intestinal segments exposed to Stx2
+
 E. coli O157:H7 when compared to intestinal segments 
exposed to Stx2
-
 E. coli O157:H7.  There was also fewer CD4+ T cells in the intestinal segments 
exposed to saline upon comparing the CD4+ T cell population exposed to Stx2+ E. coli O157:H7 
which was not observed upon comparing with Stx2
-
 E. coli O157:H7 indicating an altered 
lymphocyte population in the presence of Stx2.  This is in agreement with the role of Stx1 during 
STEC colonization.  Menge et al [203] showed that Stx1 specifically targets bovine CD8+ 
intraepithelial lymphocytes within the ileum of calves.  The results indicated a significant 
reduction in the percentage of CD8+ intraepithelial lymphocytes after 12 hours of incubation 
with a Stx1
+
 E. coli strain.  In vitro studies have shown that Stx1 is also able to inhibit bovine 
peripheral lymphocyte proliferation suggesting a general immune suppression [68] although 
studies done by Johnson et al [102] have confirmed antibody responses to STEC antigens in 
cattle during experimental infections [102].  Therefore, a generalized immunosuppression in 
cattle by Shiga toxins has not been demonstrated.  The present study provides direct evidence 
that Stx2 produced during STEC infection can modulate the specific lymphocyte population of 
the local mucosal immune system within cattle. 
 The gut-associated lymphoid tissue (GALT) is anatomically and functionally unique from 
the peripheral parts of the immune system.  The GALT is constantly exposed to antigens in 
various different forms and has evolved the ability to distinguish between dangerous and useful 
antigens.  Therefore it is of no surprise that the lymphocytes from the GALT also differ 
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phenotypically and functionally from peripheral lymphocytes.  Lymphocytes activated in the 
GALT will recirculate back to mucosal tissue [136] and this is due to the fact that GALT-
activated lymphocytes have a decreased expression of L-selectin and an increased expression of 
α4β7 [136].  L-selectin is required for cell interaction with peripheral lymph nodes and α4β7 
interacts with MAdCAM-1 which is expressed on mucosal tissues [136].  STEC colonizes the 
gastro-intestinal mucosa while its products interact with the GALT.  Dean-Nystrom et al [70] 
showed that calves inoculated with E. coli O157:H7 had A/E lesions in their rectum, colon and 
ileum suggesting STEC colonization in these three principle sites.  To date, this is the first report 
on the effect of Stx2 on this unique population of lymphocytes in vivo within the bovine host.   
 Studies on Shiga toxins and cytokine induction/inhibition have proven difficult with 
results being variable due to species-specific and cell type-specific differences.    In humans, data 
has suggested that Shiga toxins and cytokines work cooperatively to create the pathological 
changes observed during HUS [52].  Pro-inflammatory cytokines such as TNF, IL6 and IL8 have 
been shown to be elevated in the urine but not in the serum of HUS patients suggesting a renal 
source of production [198].  Louise and Keusch both showed that TNFα treatment of a human 
umbilical vein endothelial cell line and a human saphenous vein endothelial cell line increased 
sensitivity to Stxs possibly by increasing the number of Stx receptor in vitro [225, 226].  Van 
Setten et al [227] also showed that Stx1 increased synthesis of TNFα, IL6 and IL8 in 
nonstimulated freshly isolated human monocytes in vitro.   Hughes et al [228, 229] showed an 
increase in proximal tubule TNFα production after exposure to Stx1 and also revealed that IL-1 
increased Stx1 binding, but did not alter total cell amounts of Gb3 or synthesis of Gb3.  In 1999 
Yamasaki et al [215] showed a Stx-dependent cytokine induction in a human colon epithelial cell 
line independent of bacterial LPS or any other bacterial component.  Therefore to date, the data 
suggests that induction of cytokines in humans may be of significance in the pathogenesis of 
HUS. 
 Cattle however do not develop HUS upon infection with E. coli O157:H7 but remain 
clinically normal [188].  Dean-Nystrom et al [70] showed in 1997 that E. coli O157:H7 strains 
were only pathogenic in neonatal calves approximately 12-36 hours of age and concluded that 
EHEC O157:H7 strains were not pathogenic in calves 3 weeks of age and older.    Consequently, 
it remains to be determined if inflammatory processes play a significant role in cattle upon E. 
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coli O157:H7 infection.  Menge et al [69] showed in 2003 that Stx1 does not alter IL2, TNFα or 
IFNα concentrations but rather modulates bovine immune responses by directly reducing 
lymphocyte populations.  Moussay et al [199] also confirmed that Stx1 does not alter the amount 
of mRNA specific for IL2, IL10 and IFNγ in intraepithelial lymphocytes but did reveal a higher 
amount of IL4 specific mRNA.  This effect was only specific for intraepithelial lymphocytes as 
the same experiment with PBMCs did not produce the same result [199].  In the present study, 
cytokine production was determined in the gut after 24 hours of exposure to wild type Stx2
+
 E. 
coli O157:H7 and mutant Stx2
-
 E. coli O157:H7.  The results indicated that TNFα and IFNα 
cytokine levels were elevated in the loops that were exposed to both types of E. coli O157:H7 
strains compared to the loops that received only sterile saline.  The TNFα and IFNα cytokine 
concentrations though did not differ significantly when comparing the loops inoculated with 
either Stx2
+
 or Stx2
-
 strains.  A similar trend was also observed with IL12 concentrations.  When 
comparing the ligated loops inoculated with either the Stx2
+
 or the Stx2
-
 E. coli strain, there was 
no significant difference between the amounts of IL12 produced but both of these loops had an 
increase in IL12 levels compared to the loops exposed to sterile saline.  There was a significant 
increase in IFNγ levels in the loops inoculated with the wild type Stx2+ E. coli O157:H7 strain 
when compared to the loops inoculated with the mutant Stx2
-
 E. coli O157:H7 strain.  When 
comparing the loops exposed to sterile saline, the levels of IFNγ were lower compared to the 
loops inoculated with the Stx2
+
 and Stx2
-
 E. coli O157:H7 strains.  Therefore these results 
indicate that the presence of STEC does trigger the bovine immune response to produce 
cytokines as all of the loops inoculated with either E. coli strain did produce elevated cytokines 
compared to loops exposed to sterile saline.  Since none of the cytokine concentrations differed 
significantly between the loops inoculated with either E. coli strains though, we cannot attribute 
the increase in cytokine concentrations to Stx2 but rather to the bacteria itself and/or bacterial 
products such as LPS.  Consequently, the results indicate that Stx2 does not modulate the bovine 
immunological response through a cytokine-mediated effect but rather on a specific lymphocyte 
population situated in the gastro intestinal tract.  The present study confirms the growing amount 
of published data that demonstrates bovine immune cells are a predominant target for Stx2. 
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7.0  Immunomodulatory Effects of Shiga toxin 2 during Active Immunization 
 
7.1 Introduction 
 Shiga toxin-producing E. coli (STEC) is an important food- and water-borne pathogen of 
humans, causing a variety of symptoms of which Haemolytic Uremic Syndrome (HUS) is the 
worst.  The mortality rate for HUS is 5-10% [9, 81].  The link between HUS and STEC infection 
is well understood.  In order to reduce the incidence of human exposure and thus disease, it is 
imperative to reduce the amount of STEC that is shed from principle animal reservoirs.  Cattle 
are the primary non-human reservoir for STEC and are able to shed STEC for long periods of 
time without showing any clinical disease. 
 A number of prevention and treatment strategies are being studied in order to reduce the 
amount of STEC in cattle thereby reducing exposure and risk to humans.  Antibiotic treatment in 
cattle is controversial due to the problem with bacterial resistance.  Therefore much effort has 
been put into reducing the survival and transmission of STEC by focusing on farm management, 
disinfectant practices, probiotics and bacteriophage use within cattle [162].   On-farm 
interventions have been exploited including chlorination of water, general disinfection of living 
quarters, switching grain-fed cattle to an all hay diet prior to slaughter and quarantining animals 
until they test negative [157].  General disinfection and chlorination of water produced less than 
desirable results and quarantining animals proved impractical due to the transient nature of faecal 
shedding [155].  Finally, vaccination of cattle to reduce STEC shedding is being investigated by 
numerous scientific laboratories. 
 Since cattle are associated with human STEC infections, they serve as a logical vaccine 
target as a means to reduce human infections [162].  Several vaccine trials have been attempted 
with very promising results.  In 2004 Potter et al [162] successfully reduced colonization of 
STEC by vaccinating with type III secreted proteins.  Vaccination results showed a significant 
reduction in the number of bacteria shed in feces, the numbers of animals that shed, and the 
duration of shedding in an experimental challenge model.  In 2005, Peterson et al [230] 
performed a single commercial feedlot trial also to evaluate the effects of vaccinating cattle with 
type III secreted proteins.  Results of the trial showed that vaccination reduced the proportion of 
cattle shedding E. coli O157:H7 in their feces.  One of the most recent vaccine trials published in 
110 
 
2009 by Smith et al [169] used 3683 cattle and a type III secreted protein vaccine.  In order to 
detect shedding E. coli O157:H7, the terminal rectal mucosa was swabbed 3-5cm proximal to the 
rectoanal juncture.  The results showed only 11 of 382 vaccinated animals were positive for E. 
coli O157:H7 revealing that vaccinated cattle were significantly less likely to be colonized with 
E. coli O157:H7 compared to nonvaccinated cattle [169].  Even though published data exists 
supporting vaccination in cattle as a means to reduce STEC, commercially available vaccines are 
not being used by farms and STEC continues to persistently colonize cattle and remain a 
significant zoonotic pathogen of humans causing disease and death. 
 The secreted proteins used in the above vaccine trials have all been isolated from Stx2
+
 E. 
coli O157:H7 strains [162].  Stx2 is an A-B protein comprised of one A subunit for every five B 
subunits.  The B subunits are responsible for recognizing and binding to the receptor, Gb3.  Gb3 
is a glycosphyngolipid ubiquitously found on eukaryotic membranes.  Traditionally the role of 
the Shiga toxins was thought to only be cytotoxic.  The A subunit of the toxin is internalized via 
clatharin-coated pits where it is responsible for inhibiting protein synthesis.  Epidemiological and 
experimental data have revealed that Stx2 is more relevant than Stx1 [231].  For example, Stx2 is 
about 1,000 times more toxic for human renal microvascular endothelial cells than Stx1 [49].   
The Stx2 family consists of Stx2, Stx2c, Stx2c2, Stx2d, Stx2e, and Stx2f [50].  Immunization 
trials using rabbits and pigs have shown that the Stx2 toxoid is protective upon further Stx2 
holotoxin challenge [232, 233].  Studies using the B subunit of Stx2 as a vaccine candidate have 
been ongoing [56] but problems with large-scale production have arisen due to the instability of 
the B subunits without the A subunit.  Although one study by Marcato et al [56] showed that 
rabbits immunized with the B subunit survived a subsequent challenge with the Stx2 holotoxin.  
 Reduced numbers of intraepithelial lymphocytes after exposure to Stx1 in vivo have been 
reported by Menge et al [203].  Similarily, Smith et al [234] have reported a depletion of 
lymphocyte numbers in the submucosal lymphoid follicles in five week old calves infected with 
an STEC strain.  In vitro experiments have also demonstrated reduced lymphocyte proliferation 
in the presence of purified Stx1 [68].  These results have led to the hypothesis that the Shiga 
toxins may have immunomodulating effects in cattle and as a consequence, immunity to STEC 
as well as other co-administered vaccines may not be optional.  Therefore we wanted to 
determine if Stx2 modulates bovine immune responses during active immunization in cattle.  We 
111 
 
hypothesize that bovine immune response to a heterologous antigen such as hen egg lysozyme 
(HEL), will be downregulated during active immunization in the presence of Stx2.  Two trials 
will be presented with the first trial using a purified Stx2 preparation.  Bovine humoral and 
cellular immune responses to the academic antigen, HEL were evaluated.  The second trial used 
secreted protein preparations isolated from a wild type Stx2
+
 E. coli strain and a secreted protein 
preparation isolated from a mutant Stx2
-
 E. coli strain.   Again bovine humoral and cellular 
immune responses to the commercial antigen, HEL were evaluated.  The results from both trials 
indicate that Stx2 downregulates peripheral bovine immune responses during active 
immunization. 
 
7.2 Materials and Methods                                                  
7.2.1 Trial Design 
 To determine the effect of Stx2 on induction of bovine immune responses to heterologous 
antigens, immune responses to hen egg lysozyme (HEL) (Sigma #L6876) were determined using 
adult Holstein cows immunized with 500μg HEL with or without Stx2.  HEL was formulated 
with 30% VSA3 as the adjuvant and a total of 2mls was administered subcutaneously in the neck 
of each animal.  In each trial, vaccinations occurred on days 0 and 21.  Serum samples were 
collected on days 0, 6, 10, 14, 21, 28 (35 if relevant).  Bovine proliferative responses were 
analyzed on days 14, 21, 28 (and 35 if relevant) using freshly isolated PBMCs. 
 
7.2.1.1 Trial 1:  Antigenic Dosing of HEL 
 To establish the effect of Stx2 on induction of bovine immune responses to HEL, an 
appropriate antigenic dose of HEL was determined first in the absence of Stx2 using a 35 day 
trial consisting of four adult Holstein cows divided into two groups.  Group 1 received 250μg 
HEL + 30% VSA [235] and group 2 received 500μg HEL + 30% VSA [235].  Samples were 
taken from each cow on the days noted above. 
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7.2.1.2 Trial 2: Immune responses to HEL immunization in the presence and absence of 
Stx2 
 Immune responses to hen egg lysozyme (HEL) were compared in the presence and 
absence of Stx2 to establish the effect of Stx2 on bovine immune responses.  This was 
determined by immunization with either HEL alone or HEL coadministered with Shiga toxin 2.  
Therefore group 1 received 500μg HEL, 30% VSA [235] and 2μg Shiga toxin 2 per dose and 
group 2 received 500μg HEL and 30% VSA per dose [235].  The trial consisted of two groups of 
8 adult Holstein cows and the duration of the trial was 30 days.  The blood samples were taken 
from each cow on the days noted above. 
 
7.2.1.3 Trial 3: Secreted protein trial 
 Immune responses to HEL and secreted proteins were determined in the presence and 
absence of Stx2 to determine the effect of Stx2 on the induction of bovine immune responses.  
hree groups of five cows were chosen and the vaccine formulations (per cow per dose) included 
group 1 (wild type group) which received 500μg HEL + 50μg secreted protein cocktail from wild 
type Stx2
+
 E. coli O157:H7 + 30% VSA [235], group 2 (mutant group) which received 500μg 
HEL + 50μg secreted protein cocktail from mutant Stx2-deficient E. coli strain + 30% VSA [235] 
and group 3 (mutant + Stx2 group) which received 500μg HEL + 50μg secreted protein cocktail 
from mutant Stx2
-
deficient E. coli + 30% VSA  [235] + 2μg purified Stx2 (Section 3.1).  The 
trial consisted of three groups of 5 adult Holstein cows and the duration of the trial was 35 days.  
The blood samples were taken from each cow on the days noted above. 
 
7.2.2 Secreted Protein Preparations 
 A detailed protocol for isolating secreted proteins is described in section 3.4.  Briefly, 
secreted proteins were isolated from the Stx2
+
 wild type E. coli O157:H7 strain (1961) and the 
Stx2
-
 mutant E. coli O157:H7 strain (92192).  Twenty millilitres of wild type Stx2
+
 E. coli 
O157:H7 and mutant Stx2
-
 E. coli O157:H7 strains were grown up to stationary phase overnight 
in LB (or LB + 15μg/ml gentamicin for mutant strain).  Both the Stx2+ wild type E. coli 
O157:H7 strain (1961) and the Stx2
-
 mutant E. coli O157:H7 (92192) overnight cultures were 
subcultured the next morning by inoculating 5mls into 500mls of minimal medium (M9 solution 
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(Sigma-Aldrich, St. Louis, MO, USA) [175] supplemented with 0.5M MgSO4 + 5% casamino 
acids + 0.5% glucose + 1% NaHCO2) and allowed to grow to log phase using constant aeration 
(OD600 of approximately 0.7).  Cultures were centrifuged twice removing the supernatant each 
time.  The supernatants (containing the secreted proteins) were concentrated using a 10K 
Amicon filter (Fischer) and nitrogen gas at 4
o
C as described [174]. 
 
7.2.3 Western Blot Analysis of Stx2 
 The secreted proteins were isolated from the Stx2
+
 wild type E. coli O157:H7 strain 
(1961) and the Stx2
-
 mutant E. coli O157:H7 strain (92192).  The proteins were separated by 
PAGE and transferred to a nitrocellulose membrane by electroblotting as recommended by the 
manufacturer (BioRad Laboratories) with a few modifications.  The resolving gel and stacking 
gel were made as usual however SDS was omitted from the mixture.  The 2X buffer also did not 
contain SDS or DTT.  The secreted proteins were not boiled prior to electrophoresis as 
recommended by the Stx Western Blot SOP.  Western blot analysis was then carried out using 
mouse monoclonal anti-Stx2 (OEM Concepts MAV67-212, 1mg/ml diluted to 1μg/ml for 
Western analysis). After incubation (for approximately 3 hours) with primary antibody, the 
membrane was washed three times with PBS-T and incubated with a secondary antibody 
conjugated to alkaline phosphatase for approximately 1 hour (Goat anti-mouse IgG (H+L) (KPL, 
Gaithersburg, MA, USA). 
 
7.2.4 Enzyme-linked Immuno-Sorbent Assay (ELISA) 
 Hen egg lysozyme was prepared in coating buffer at 100μg/ml and 100μl of this solution 
was used to coat each well of a 96-well plate. The plates were covered with a lid, wrapped with 
saran wrap and placed inside a plastic bag to avoid drying, and incubated overnight for 16 hours 
at 4 
o
C.  After incubation, the coating solution was removed and plates were washed 5 times with 
phosphate-buffered saline (PBS, 0.85% NaCl (w/v), pH7.0) containing 0.5% (v/v) of Tween 20 
(PBST).  The wells were blocked with 200μl/well of PBS-0.5% Tween 20 containing 0.03% 
gelatine (v/v) (PBST-g) for 2 hours at room temperature.  Both serum and positive controls were 
serially diluted in four-fold increments in PBST-g and incubated for 1 hour.  After five washes, 
alkaline phosphatase-conjugated polyclonal goat anti-bovine IgG and monoclonal sheep anti-
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bovine IgG1 and IgG2 (Kirkegaard and Perry laboratories, Gaithersburg, MD, USA) were 
diluted to 1:5000 in PBST-g and 100μl of diluted antibody was added to each well and incubated 
for 1 hour.  After five washes, 100μl of freshly prepared para-nitrophenyl phosphate (PNPP, 
1mg/ml, Sigma #N3254) substrate solution in DE buffer (10.5ml of 1 M Diethanolamine, 1ml of 
0.5 M MgCl
2
6H
2
O and 990ml of distilled water) was added per well and incubated for 45 
minutes at room temperature.  Finally using a microtitre plate reader, the absorbance was read at 
405nm with reference set at 490nm using the SOFTmax Pro program. 
 
7.2.5 IFNγ ELISPOT assay 
 The IFNγ ELISPOT protocol was carried out over three days.  On day one, the anti- IFNγ 
antibody was diluted 1/3000 in sterile coating buffer and millipore HA plates were coated with 
100μl per well.  The millipore HA plates were wrapped in Saran wrap and refrigerated overnight 
at 4
o
C.   
 The morning of the second day, the millipore HA plates were washed in sterile PBSA 
four times.  The millipore HA plates were blocked using 100μl of 1% albumin/PBSA and were 
incubated for 1 hour at 37
o
C.  The blocking media was removed after 1 hour and 100μl of 
antigen (HEL, concentration 100μg/ml) was added to each well resulting in a final HEL 
concentration of 10μg/ml per well.  At the same time, 100μl of freshly isolated bovine PBMCs 
were added to each well at a concentration of 10
7
/ml and the plates were incubated overnight at 
37
o
C.  Negative (media) controls and positive Concavallin A (ConA) controls were used on each 
Millipore HA plate.   
 On the third day, the millipore HA plates were submerged in double distilled H2O 
(ddH2O) for 5 minutes to lyse all cells and then washed three times in PBST and twice in double 
distilled H2O.  Rabbit anti-bovine IFNγ was diluted 1/1500 in 1% albumin/PBSA and 100μl 
added to each well and allowed to incubate at room temperature for 2 hours.  The millipore HA 
plates were washed five times in PBST and twice in double distilled H2O.  After washing was 
completed, 100ul of substrate nitroblue tetrazolium (NBT) salt and 5-bromo-4-chloro-3-indolyl 
phosphate (BCIP) was added to each well.  The millipore HA plates were allowed to develop for 
a maximum 30 minutes then were washed in ddH2O and allowed to air dry for 24 hours.  The 
spots were counted manually using a dissecting microscope. 
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7.2.6. Proliferation assay 
 Lymphocyte proliferation was determined by adding 3x10
5
 cells/well of freshly isolated 
bovine PBMCs (Section 3.2.1) into a round bottom 96 well plate and incubating for 96 hours at 
37
o
C under 5% CO2 with 10μg/ml HEL.  On the fourth day, 20μl of 0.4μCi of [
3
H]-thymidine 
was added to each well.  The plate was allowed to incubate for 6 hours at 37
o
C under 5% CO2.  
Following this, the plates were immediately frozen until the incorporation of [
3
H]-thymidine 
could be assessed using a scintillation counter.  
 
7.2.7 Cytokine ELISAs 
 A detailed protocol for cytokine quantitation is described in Section 3.6.  Briefly, a 
monoclonal anti-IL4 antibody (Table 2) was resuspended in coating buffer and 100μl applied to 
a 96 round bottom plates and allowed to incubate at 4
o
C overnight, then the plates were washed 
four times with TBST and 100μl of each sample was applied to the plates and diluted two-fold.  
The plates were washed four times with TBST and the appropriate biotinylated antibody (Table 
2) was applied to each well.  The plates were allowed to incubate for one hour at room 
temperature followed by four washes with TBST.  One hundred micoliters of streptavidin 
alkaline phosphatase (diluted 1/5000) was added to each well for one hour.  The plates were 
washed again in TBST and 100μl of PNPP substrate was added to each well.  The reaction was 
stopped with 0.3M EDTA when the OD450 of the first dilution of the standard curve reached an 
OD450 of approximately 2.000.   
 
7.2.8 Western Blot Analysis of Secreted Protein Preparations 
 A detailed protocol for western blotting is described in Section 3.4.  SDS polyacrylamide 
gel electrophoresis of secreted proteins was carried out to confirm the presence and absence of 
Stx2 in the secreted protein preparations isolated from the wild type Stx2
+
 E. coli O157:H7 strain 
and the mutant Stx2
-
 mutant E. coli O157:H7 strains.   Briefly, total protein was loaded onto an 
SDS-PAGE gel.  The proteins were separated at 120 volts in a gel apparatus (Bio-Rad) for 
approximately 1 hour.  For immunobloting, proteins were transferred from the gel to a 
nitrocellulose membrane (Bio-Rad) using a power supply (PowerPac200, Bio-Rad). After the 
proteins were transferred to the nitrocellulose, the membrane was removed from the apparatus 
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and blocked with 1% milk overnight at 4 
o
C.  After overnight incubation, the membrane was 
washed three times with PBS-T and incubated with a cocktail of primary antibodies raised 
against secreted proteins in a rabbit (produced at VIDO by D. Asper).  After incubation with the 
primary antibodies, the membrane was washed three times with PBS-T and incubated with a 
secondary antibody conjugated to alkaline phosphatase (Goat anti-rabbit IgG (H+L) (KPL, 
Gaithersburg, MA, USA).  After incubation with the secondary antibody, the membrane was 
washed once with PBS-T and additional once with alkaline phosphatase (AP) buffer.  Finally, the 
membrane was incubated with the substrate, NBT/BCIP until color developed.   
 
7.2.9 Cytotoxicity Assay 
 The cytotoxic activity of the secreted protein preparations were determined as described 
by Gentry et al [182].  Briefly, 50μl of a10-fold dilution series of the secreted protein 
preparations were applied to a 96 well plate containing 0.15M NaCl.  Fifty microliters of cell 
culture media containing 10% FBS, 2mM glutamine, 100U penicillin and 100mg/ml 
streptomycin was added to each well and the plates were incubated for 30 minutes at room 
temperature.  Following this, 50μl of VERO cells were added to each well at a concentration of 
8x10
5
cells/ml and incubated at 37
o
C under 5% CO2 for 96 hours.  Cellular metabolic activity was 
measured using the MTT Reduction Assay as described [183].   
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7.3. Results 
7.3.1. Humoral and Cellular Immune responses to Hen Egg Lysozyme (HEL) 
 To measure bovine immune responses to the commercial antigen, HEL, an appropriate 
antigen dose was required to induce an immunological response large enough to be measured but 
not too strong to mask any potential effect of Stx2.  Therefore, a pilot trial was done using four 
Holstein cows which were divided into two groups (outlined in section 7.2.1.1).  The cows were 
given either 250μg HEL or 500μg HEL 21 days apart and serum and PBMCs were sampled to 
determine antibody and proliferative responses.  The results of the trial indicated that the cows 
receiving 500μg of HEL produced antibody responses (total IgG, IgG1 and IgG2) that were 
numerically higher than the cows that received 250μg of HEL.  Very little HEL-specific antibody 
could be detected on day 7 of the trial in the cows that received 250μg HEL but the cows that 
received 500μg of HEL had a 10-fold higher response for all three antibody isotypes tested.  On 
days 14 and 21, total IgG, IgG1 and IgG2 antibody titers of both groups were almost identical.  
On the last day of the trial, the cows that received 250μg HEL had a median IgG antibody titer 
slightly above 100 and the cows that received 500μg HEL had a median antibody titer of slightly 
over 1000 (Figure 20a).  Therefore these results suggested that 500μg HEL was a more 
appropriate antigenic dose for HEL because the total IgG response was greater in this group but 
not overwhelming so that it might mask any effect of Stx2 in the later trials. 
 To measure bovine proliferative responses to HEL, two concentrations of HEL (1μg/ml 
and 10μg/ml) were used to determine the appropriate in vitro restimulation concentration (Figure 
21).  The results indicated that cells restimulated with 10μg/ml compared to cells restimulated 
with 1μg/ml showed proliferative responses that could easily be measured using the 
incorporation of [
3
H]-thymidine suggesting that this was an effective HEL concentration.  The 
results also indicated that cells from cows receiving 500μg HEL produced a proliferative 
response that were similar to the cows which received 250μg HEL when 10μg/ml HEL was used 
as the restimulation concentration.  The results indicated that cells from cows which received 
250μg HEL and 500μg HEL gave variable results when restimulated with 1μg/ml.  We 
concluded based on both the humoral and cellular responses, that future trials determining the 
effects of Stx2 during active immunization would use 500μg HEL as the antigenic dose and 
10μg/ml HEL for restimulation assay. 
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Figure 20.  Serological responses following vaccination with HEL.  The a) total IgG antibody 
activity to HEL, b) IgG1 antibody activity to HEL and c) IgG2 antibody activity to HEL during 
the course of a 28 day trial in which cows received either 250μg HEL (●) or 500μg HEL (■)  
were measured using ELISA as described above.  The trial consisted of four animals, two 
animals per group and each data point represents a duplicate antibody titre. 
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Figure 21.  Proliferation of bovine PBMCs to HEL.  Proliferation of freshly isolated bovine 
PBMC preparations stimulated with either a) 1μg/ml HEL or b) 10μg/ml HEL were measured by 
the incorporation of [3H]-thymidine during the course of a 28 day trial in which cows received 
either 250μg HEL (●) or 500μg HEL (■).   
 
 
 
b. 
a. 
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7.3.2 Humoral Immune responses in the presence of purified Shiga toxin 2 
 To determine the effects of Stx2 on bovine immune responses to HEL during active 
immunization, a trial was designed involving 16 Holstein cows divided into two groups.  The 
control group was immunized twice with HEL alone and the treatment group was immunized 
with HEL and purified Stx2.  The results (Figure 22) indicated that Stx2 downregulated total IgG 
antibody activity to HEL.  Throughout the duration of the trial, the antibody titre to HEL of the 
control group increased until approximately day 21.  On day 21, both groups were boosted and 
the antibody activity increased again in the control group.  The antibody activity of the treated 
group (receiving 500μg HEL and 2μg Stx2) did not follow the same pattern as the control group 
(receiving 500μg HEL only) remaining significantly lower throughout the 30 days of the trial 
(Figure 22).  To account for the repeated measures design of this experiment and the non-normal 
distribution of the data, differences between the experimental groups, over time, were examined 
by first summing the data for each animal over time, ranking the data to transform it to an 
approximate normal distribution and then performing an ANOVA on the ranks of the summed 
data.  When the ANOVA’s were significant (P<0.05) differences between treatments at each 
time point were tested using the Wilcoxon Rank Sum Test.  Therefore based on these statistical 
parameters, data collected on days 10, 14, 21, 23, 28 and 30 were significantly different between 
the control and treated groups (Table 7). 
 The levels of two antibody subtypes, IgG1 and IgG2, to HEL were also measured 
throughout the trial (Figures 23 and 24).  The results showed a very similar pattern to the total 
IgG antibody activity discussed above.  Based on the statistical parameters outlined above, IgG1 
and IgG2 antibody activity on days 14, 21, 23, 28 and 30 were significantly different between the 
control and treated groups (Table 7).  Therefore the data presented suggests a significant 
downregulation of bovine humoral immune responses in the presence of purified Stx2 during 
active immunization. 
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Figure 22.  Kinetics of the total HEL-specific IgG antibody production during the course of 
a 30 day trial.  Serological responses to HEL (         ) and HEL + Stx2 (       ) were measured 
using ELISAs as described above. Cows were vaccinated with 500μg of HEL followed by one 
boost, on day 21 of the trial.  The arrow represents vaccinations given at day 21. 
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Figure 23.  Kinetics of the HEL-specific IgG1 antibody production.  Serological responses to 
HEL (         ) and HEL + Stx2 (       ) were measured using ELISAs as described above.  Cows 
were vaccinated with 500μg of HEL followed by one boost, on day 21 of the trial.  The arrow 
represents vaccination given at day 21. 
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Figure 24.  Kinetics of the HEL-specific IgG2 antibody production.  Serological responses to 
HEL (         ) and HEL + Stx2 (       ) were measured using ELISAs as described above.  Cows 
were vaccinated with 500μg of HEL followed by one boost, on day 21 of the trial.  The arrow 
represents vaccination given at day 21. 
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Table 7.  Statistical analysis of the serological responses (total IgG, IgG1 and IgG2) and 
proliferative responses to HEL.  To account for the repeated measures design of this 
experiment and the non-normal distribution of the data, differences between the experimental 
groups, over time were examined by first summing the data for each animal over time, ranking 
the data to transform it to an approximate normal distribution and then performing an ANOVA 
on the ranks of the summed data.  When the ANOVA’s were significant (P<0.05) differences 
between treatments at each time point were tested using the Wilcoxon Rank Sum Test.  Based on 
these statistical parameters, data collected on days 10, 14, 21, 23, 28 and 30 were significantly 
different (in bold) between the control and treated groups. 
 
 
 
 
 
 
 
 Day 
Dadddd
dyDaD
a3  
Day 6  Day 
10  
Day 
14  
Day 21  Day 23  Day 
28  
Day 
30  
Total IgG  0.2424  0.3170  0.0054  0.010  0.0009  0.0009  0.0009  0.0009  
IgG1  0.1394  0.1275  0.0180  0.0054  0.0011  0.0009  0.0009  0.0009  
IgG2  0.2691  0.4945  0.0831  0.0239  0.0180  0.0927  0.010  0.0136  
Proliferation  -  -  -  0.0078  0.0023  -  0.0114  -  
Day 3 Day 6 Day 10 Day 14 Day 21 
 21 
Day 23 Day 28 Day 30 
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7.3.3 Cellular Immune responses in the presence of purified Shiga toxin 2 
 To determine the effects of Stx2 on bovine cellular immune responses during active 
immunization, a trial was designed involving 16 Holstein cows divided into two groups.  The 
control group was immunized twice with HEL alone and the treatment group was immunized 
with HEL and purified Stx2.  PBMCs were isolated from blood samples and bovine proliferative 
responses to HEL were determined using the incorporation of [
3
H]-thymidine.  The results 
(Figure 25) showed that bovine proliferative responses were downregulated in the presence of 
Stx2.  On day 14, a stimulation index (SI) value for the treated group was approximately 1.0 and 
the SI value for the control group was approximately 3.5.  On day 21, an SI value for the treated 
group was approximately 0.7 and the SI value for the control group was approximately 2.0.  On 
day 28, an SI value for the treated group was approximately 1.0 and the SI value for the control 
group was approximately 3.9 (Figure 25).  Statistical analysis using the Mann-Whitney test 
indicated that cows immunized in the presence of Stx2 (treated group receiving 500μg HEL and 
2μg Stx2) had significantly lower proliferative responses on days 14, 21 and 28 upon 
restimulation with 10μg/ml HEL than cows immunized in the absence of Stx2 (control group 
receiving 500μg HEL) (Table 7).   
 
7.3.4 Effect of Shiga toxin 2 on Cytokine Production 
 To determine the effects of Stx2 on bovine cytokine production during active 
immunization, IFNγ and IL4 concentrations were determined using the same group of cows 
described above.  The number of IFNγ producing PBMCs was determined numerically upon 
restimulation with 10μg/ml HEL on days 14, 21 and 28 of the trial.  Upon comparing the data 
collected from the treated group with the control group, it was established that there was no 
measurable difference between the two groups on any of the days tested (Figure 26).  IL4 
cytokine concentrations were also evaluated on days 14, 21 and 28 of the trial.  The results 
showed that IL4 concentrations did not differ significantly between the two groups on any of the 
days tested (Figure 27).  These results suggest that Stx2 does not modulate antibody or 
proliferative responses by perturbing IFNγ or IL4 concentrations and the downregulation in 
antibody and proliferative responses observed were the result of a different mechanism. 
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Figure 25.  Bovine proliferative responses to HEL in the presence of Stx2.  Freshly isolated 
bovine PBMC preparations isolated from cows vaccinated with either HEL (●) or HEL + Stx2 
(■) were restimulated with 10μg/ml HEL and proliferative responses measured using 3H-
thymidine as described above.  Statistical analysis using the Mann-Whitney test indicated that 
proliferation was significantly higher (P<0.05) on days 14, 21 and 28 in the control group 
compared to proliferation of bovine PBMCs in the treated group. 
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Figure 26.  IFNγ production by bovine PBMCs in the presence of Stx2 compared to IFNγ 
production in the absence of Stx2.  Freshly isolated bovine PBMCs from cows vaccinated with 
either HEL (●) or HEL + Stx2 (■) were restimulated with 10μg/ml HEL for 96 hours at 37oC 
under 5% CO2 and the resulting number of IFNγ secreting cells numerically counted as described 
above.  Statistical analysis using the Mann-Whitney test indicated that IFNγ production did not 
differ significantly (P<0.05) on days 14, 21 and 28 upon comparison of the control group and the 
treated groups. 
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Figure 27.  IL4 production by bovine PBMCs in the presence of Stx2 compared to IL4 
production in the absence of Stx2.  IL4 concentrations determined from cows vaccinated with 
either HEL (●) or HEL + Stx2 (■) during the course of a 30 day trial. Statistical analysis the 
Mann-Whitney test indicated that IL4 production did not differ significantly (P<0.05) on days 
14, 21 and 28 upon comparison of the control group and the treated groups. 
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7.3.5 Characterization of Secreted protein preparations to Determine the Effect of Stx2 on 
Bovine Immune Responses 
 Vaccination with the current secreted protein vaccine reduces the number of E. coli 
O157:H7 shed in feces, the numbers of animals that shed E. coli O157:H7, and the duration of 
shedding in an experimental challenge model [162].  The secreted proteins used for 
immunization in the trial were isolated from an Stx2
+
 E. coli O157:H7 strain.  The objective of 
the current study was to determine if Stx2 downregulates bovine immune responses during active 
immunization, therefore immunization of cattle with secreted protein preparations  isolated from 
a wild type Stx2
+
 E. coli O157:H7 strain and an isogenic mutant Stx2
-
 E. coli O157:H7 strain 
was carried out.  The secreted proteins were isolated from both E. coli strains and western 
analysis was performed on both protein preparations to confirm the presence of secreted proteins 
(Figure 28).  A polycolonal antibody preparation to E. coli O157:H7 secreted proteins was 
produced in our lab by D. Asper and used in the present study.  Figure 28 confirmed the presence 
of secreted proteins in both protein preparations.  The concentrations of both protein preparations 
were also determined and we showed that both secreted protein preparations contained 1μg/μl of 
secreted proteins (Table 8). 
 Western blot analysis was done after PAGE separation to confirm the presence of Stx2 in 
the secreted protein preparation isolated from the wildtype Stx2
+
 E. coli strain and the absence of 
Stx2 in the secreted protein preparation isolated from the mutant Stx2
-
 E. coli strain.  A 
monoclonal antibody to Stx2 confirmed Stx2 expression and production from the wild type E. 
coli O157:H7 strain and also confirmed the absence of Stx2 production from the mutant E. coli 
O157:H7 strain.  By comparison with the low molecular weight protein ladder used during the 
western blot analysis we showed a single band migrating in the 60kDa protein range (Figure 29).  
The molecular weight of Stx2 is approximately 65 kDa.  The cytotoxic activity of the secreted 
protein preparations was determined as described above (Section 7.2.9) using VERO cells as the 
target.  The results of the assays (Figure 30) showed that the secreted proteins isolated from the 
wild type Stx2
+
 E. coli O157:H7 strain had a CD50 value of 100pg/ml and the preparation 
isolated from the mutant Stx2
-
 E. coli strain had an approximate CD50 value of >100ng/ml, 
indicating that the total secreted protein preparation isolated from the mutant Stx2
-
 strain lacked 
cytotoxic activity. 
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Figure 28.  Western blot analysis of the secreted proteins.  Proteins were separated by SDS-
PAGE, transferred to nitrocellulose and probed with a polyclonal antibody to secreted proteins 
produced at VIDO by D. Asper.  Lane 2 = secreted proteins isolated from the wild type Stx2
+
 E. 
coli O157:H7 strain and lane 3 = secreted proteins isolated from the mutant Stx2
-
 E. coli strain.   
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Table 8.  The concentrations of the secreted protein preparations determined using a 
standard BSA graph.  The OD750 of three different amounts of protein (10μl, 20μl and 40μl) 
were measured as described above.  The OD readings were used to extrapolate the protein 
concentrations from the BSA standard curve.  It was calculated that both protein preparations 
were 1μg/μl.   
 
 
 
 
 
 
 
 
 
 
 
 
Volume OD750  
wild type 
preparation 
OD750 mutant 
preparation 
10ul 0.019 0.018 
20ul 0.030 0.024 
40ul 0.045 0.041 
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Figure 29.  Western blot analysis of secreted proteins.   Lane 2 = the mutant Stx2
-
 E. coli 
O157:H7 strain (92192) secreted protein preparation and lane 3 = the wild type Stx2
+
 E. coli 
O157:H7 strain (1961) secreted protein preparation.  These results demonstrate that the protein 
recognized by the Stx2 monoclonal antibody is present in the secreted protein preparation 
isolated from the wild type Stx2
+
 E. coli strain.   
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Figure 30.  Cytotoxicity of STEC secreted proteins as determined by MTT reduction.  The 
secreted protein preparations were isolated from the a) mutant Stx2
-
 E. coli O157:H7 strain 
(92192) and the b) wild type Stx2
+
 E. coli O157:H7 strain (1961).  Both secreted protein 
preparations were diluted in a 10-fold dilution series and incubated with VERO cells (1x10
6
) for 
96 hours at 37
o
C.   
 
 
 
 
 
a. 
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7.3.6 Humoral Immune responses in the presence of secreted proteins 
 To determine the effects of Stx2 on bovine immune responses during active 
immunization, a trial was designed involving 15 Holstein cows divided into three groups 
(containing 5 cows per group).  Group 1 was immunized with secreted proteins isolated from a 
wild type Stx2
+
 E. coli O157:H7 strain (1961) and HEL.  Group 2 was immunized with a protein 
preparation isolated from a mutant Stx2
-
 E. coli strain (92192) and HEL and group 3 was 
immunized with a protein preparation isolated from a mutant Stx2
-
 E. coli strain (92192), 
purified Stx2 and HEL.  Serum samples were collected and immune responses against HEL and 
secreted proteins were determined (Figures 31-33).  The results indicated that Stx2 
downregulated total IgG, IgG1 and IgG2 antibody activity to HEL.  Very little antibody could be 
detected until day 6 of the trial.  From day 6 to day 21, the total IgG titer of group 2 (without 
Stx2) increased.  On day 21, all three groups were boosted and the antibody activity continued to 
increase in group 2.  The antibody activity of groups 1 and 3 did not follow the same pattern as 
group 2 (without Stx2) but remained significantly lower throughout the 30 days of the trial.  
Statistical analysis revealed that data collected on days 14, 21, 28 and 35 were significantly 
different between group 2 (without Stx2) and groups 1 and 3 (Tables 9 and 10).  No statistical 
difference was detected between groups 1 and 3 throughout the entire trial.  The results also 
showed that total IgG antibody activity to secreted proteins was downregulated in the presence of 
Stx2 (Figure 33) and that the antibody activity followed the same trend noted above to HEL.   
  
7.3.7 Cellular Immune responses in the presence of secreted proteins 
 To determine the effects of Stx2 on bovine immune responses during active 
immunization, cellular immune responses to HEL were also measured on days 21 and 28 of the 
trial.  Freshly isolated bovine PBMCs were restimulated with 10μg/ml of HEL for 96 hours and 
proliferation was measured by the incorporation of [
3
H]-thymidine.  The results indicated that on 
both days, proliferation was slightly higher in cells from the animals immunized with the mutant 
Stx2
-
 secreted protein preparation (Group 2) relative to the cells from the animals immunized 
with the Stx2-containing formulations (Groups 1 and 3).  Statistical analysis using the Dunn’s 
Multiple Comparison Test following one-way repeated ANOVA indicated no significant 
difference between the three groups on either day tested.  These results differed from the 
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proliferation results in Trial 2 (Figure 25), when animals were immunized with purified Stx2 
alone and proliferation was found to be statistically different between the control and treated 
groups.  In the current trial, proliferation could have been suppressed by other 
proteins/components of the secreted protein preparations thus creating an overall suppression in 
all three groups.  A general trend suggesting slightly higher proliferation in group 2 was 
observed (Figure 34) but this not statistically different compared to groups 1 and 3. 
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Figure 31.  Kinetics of the total HEL-specific IgG antibody during the course of a 35 day 
trial.  Animals were immunized with STEC secreted proteins and HEL in the presence (      ,  
            ) and absence of Stx2 (       ).  Serological responses to HEL were measured using ELISA 
as described above.  Arrows represent vaccinations given at day 0 and day 21.  The Dunn’s 
Multiple comparison analysis was done at each time point between all three groups and the 
results of the statistical analysis are shown in Tables 9 and 10.  
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Figure 32.  Kinetics of the total HEL-specific IgG1 antibody during the course of a 35 day 
trial.  Animals were immunized with STEC secreted proteins and HEL in the presence (         
and          ) and absence of Stx2 (      ).  The serological responses to HEL were measured using 
ELISA as described above.  Arrows represent vaccinations given at day 0 and day 21.  The 
results of the statistical analysis are in Tables 9 and 10. 
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Figure 33.  Kinetics of the total secreted protein-specific IgG antibody during the course of 
a 35 day trial.  Animals were immunized with STEC secreted proteins and HEL in the presence 
(         and        ) and absence of Stx2 (
…….
).  The serological responses to secreted proteins were 
measured using ELISA as described above.  Arrows represent vaccinations given at day 0 and 
day 21.  The results of the statistical analysis are in Tables 9 and 10. 
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 P Values 
 Day 0 Day3 Day6 Day14 Day21 Day28 Day35 
Total HEL-
specific IgG  
 
0.2222 
 
 
0.8340 
 
 
1.000 
 
 
0.0080 
 
0.0317 0.0079 
 
0.0159 
 HEL-specific 
IgG1 
 
* * 0.9063 
 
0.1188 
 
0.0200 
 
0.0179 
 
0.0342 
 
Total secreted 
protein-
specific IgG  
 
0.6752 
 
0.6905 
 
 
0.4020 
 
 
0.0079 
 
 
0.0080 
 
 
0.0079 
 
 
0.0079 
 
 
 
* p Value could not be determined due to lack of detectable titer. 
 
Table 9.  P values determined upon comparing serological responses to HEL throught the 
trial.  Serological responses from cattle that received the secreted protein preparation isolated 
from the wild type STEC strain were compared to serological reponses determined from cattle 
that received the secreted protein preparation isolated from the Stx2
-
 mutant STEC supplemented 
with purified Stx2.  Statistical significance has been defined as P < 0.05 and is shown in bold.  
The results indicated that total IgG antibody activity to HEL were significantly different of days 
14, 21, 28 and 35 of the trial and IgG1 antibody activity was significantly different on days 21, 
28 and 35 of the trial. 
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 P value 
 Day 0 Day3 Day6 Day14 Day21 Day28 Day35 
Total HEL-
specific IgG  
 
0.5476 
 
 
0.8413 
 
 
0.9166 
 
 
0.0079 
 
 
0.0159 
 
 
0.0079 
 
 
0.0952 
HEL-specific 
IgG1 
* * 0.6072 
 
 
0.1612 
 
 
0.0079 
 
 
0.0079 
 
 
0.0079 
 
 
Total secreted 
proteins-
specific IgG 
0.4206 
 
 
0.5476 
 
 
0.5476 
 
 
0.0079 
 
 
0.0119 
 
 
0.0079 
 
 
0.0079 
 
 
 
* p Value could not be determined due to lack of detectable titer. 
 
Table 10.  P values determined upon comparing serological responses in cattle throughout 
the trial.  Cows that received the protein preparation isolated from the Stx2
-
 strain were 
compared to the serological responses from the cows that received the secreted protein 
preparation isolated from the Stx2
-
 strain supplemented with purified Stx2.  Statistical 
significance has been defined as P < 0.05 and is shown in bold.  The results indicate that total 
IgG antibody activity to HEL were significantly different of days 14, 21, 28 and 35 of the trial 
and IgG1 antibody activity was significantly different on days 21, 28 and 35 of the trial. 
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Figure 34.  Proliferation of bovine PBMCs in the presence of Stx2.  Bovine PBMCs were 
isolated from cows immunized with either secreted proteins isolated from the wild type STEC 
strain (●), secreted proteins isolated from the Stx2- mutant strain (■) or secreted proteins from 
the Stx2
-
 mutant strain supplemented with purified stx2 (▲) and proliferation was measured on 
a) day 21 and b) day 28 using 
3
H-thymidine as described above.   
 
 
 
 
 
 
 
 
 
 
b. a. 
Modulation of Bovine Proliferative Responses by Stx2 
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7.4 Discussion 
 Several vaccine trials using secreted proteins have been attempted in order to reduce the 
prevelance of STEC in cattle and therefore reduce the incidence of human exposure to STEC.  In 
2004 Potter et al [162] successfully reduced colonization of STEC by vaccinating with several 
type III secretion proteins.  The results showed that vaccination resulted in a significant 
reduction in the numbers of bacteria shed in feces, the numbers of animals that shed, and the 
duration of shedding in an experimental challenge model [162].  One year later, Peterson et al 
[230] conducted a feedlot trial using secreted proteins (isolated using the same protocol as Potter 
et al [162]) from a wild type E. coli O157:H7 strain and showed that vaccination reduced the 
number of cattle shedding E. coli O157:H7.  Finally in 2009, Smith et al [169] showed that 2.9% 
of the terminal rectal muscosa of cattle vaccinated with the secreted protein preparation isolated 
from wild type E. coli O157:H7 were colonized and 17% of the terminal rectal mucosa were 
colonized in non-vaccinated animals.  Therefore published data exists to support the hypothesis 
that vaccination with secreted proteins does reduce E. coli O157:H7 carriage in cattle.  Even 
though published data exists supporting vaccination in cattle as a means to reduce STEC, 
commercially available vaccines are not being used by farms and STEC remain a significant 
zoonotic pathogen of humans causing disease and death.  In the present study, we hypothesized 
that immunity to STEC may not optional due to Stx2 and thus determined the effect of Stx2 on 
the bovine immune response during active immunization.   
 The Stxs are a major STEC virulence factor and  have been implicated in E. coli 
O157:H7 disease pathogenesis in humans [3] and immunmodulation in cattle [190].  There is a 
growing amount of data to suggest that the Stxs in cattle leads to immune suppression and 
persistent STEC colonization.  Downregulation of bovine immune responses by Stx2 (acquired 
from STEC infection or from vaccination) may therefore make immunity to STEC and other co-
administered vaccines not possible.  Menge et al showed that Stx1 specifically targets bovine 
CD8+ lymphocytes within the ileum of calves [203].  They demonstrated a significant reduction 
in the percentage of CD8+ intraepithelial lymphocytes after 12 hours of incubation with a Stx1
+
 
E. coli strain.  In vitro studies have shown that Stx1 is also able to inhibit bovine peripheral 
lymphocyte proliferation suggesting a general immune suppression [68].  Also it has been 
reported that calves inoculated with Stx2
+
 E. coli O157:H7 have significantly higher and longer 
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fecal shedding of E. coli O157:H7 compared to calves inoculated with Stx2
-
 E. coli O157:H7 or 
a non-pathogenic E. coli [190].  We have data suggesting that Stx2 inhibits bovine lymphocyte 
proliferation in vitro as well as reduces the number of CD4+ T cells in vivo during a bovine 
ligated loop model of STEC infection.  To extend this, two trials were performed in which cattle 
were immunized either in the presence or absence of Stx2 and the magnitude of bovine 
immunological responses (humoral and cellular) was measured.  The data indicates that Stx2 
alone as well as part of the secreted proteins isolated from a wild type Stx2
+
 E. coli O157:H7 
strain reduced bovine immune responses to an academic antigen HEL as well as the secreted 
proteins themselves.  These results suggest that vaccination with a secreted protein preparation 
that does not contain Stx2 (secreted protein preparation isolated from a mutant Stx2
-
 E. coli 
strain) could result in significantly better immunological responses in cattle compared to 
vaccination with a secreted protein preparation that does contain Stx2.   
 The data in the present study suggests that Stx2 downregulates bovine immune responses 
during active immunization.  Stx2 is likely required for long-term colonization of the bovine host 
and this is supported by the observation that Stx2
+
 E. coli O157:H7 were able to colonize cattle 
for longer periods of time compared to Stx2
-
 E. coli O157:H7 [190].  This would imply that 
Stx2
+
 E. coli O157:H7 remain in the gastrointestinal tract for longer periods of time enabling 
them to produce sufficient biologically active amounts of Stx2 within the gut lumen.  This free 
Stx2 would be available to interact with receptor-bearing cells.  Menge et al [203] showed that 
bovine lymphocytes isolated from the gastrointestinal tract as well as the blood express surface 
receptors for Stx2.  We have data confirming the presence of surface Gb3 on bovine lymphocytes 
isolated from the Peyer’s patches of the ileum and jejunum.  It was demonstrated by Stamm et al 
[178] that a certain percentage of Gb3-positive lymphocytes bound Stx2 but did not internalize 
the toxin suggesting that Stx2 may perturb normal cell functions through this interaction.  
Therefore, we propose the potential mechanism by which Stx2 might downregulate bovine 
immune responses is by remaining bound to Gb3
+
 lymphocytes within the gastrointestinal tract 
thereby inhibiting lymphocyte proliferation and thus the generation of an immunological 
response.  We have data demonstrating an inhibition of lymphocyte proliferation in the presence 
of purified Stx2 in vitro.  We have also shown a reduced number of bovine CD4+ T cell in the 
presence of Stx2 in vivo suggesting Stx2 might inhibit proliferation of this subgroup of 
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lymphocyte.  Menge et al [203] showed that Stx1 specifically targets bovine CD8+ lymphocytes 
within the ileum of calves.  The results indicated a significant reduction in the percentage of 
CD8+ intraepithelial lymphocytes after 12 hours of incubation with a Stx1
+
 E. coli strain.  Other 
toxins have also been shown to have immunomodulatory roles in animal models including the 
two anthrax toxins called Lethal toxin and Edema toxin [236].  Comer et al [236] showed that 
injection of mice with sublethal doses of either toxin inhibited the proliferation of T cells.  The 
data in the present study demonstrated reduced cellular immune responses in the presence of 
Stx2 implying an immunomodulatory role for Stx2 in bovines.  Hoffman et al [190] showed 
calves with prior exposure to an E. coli O157:H7 (Stx
+
) strain lacked significant lymphocyte 
proliferative responses to a heat-killed E. coli O157:H7 Stx2
+
 strain suggesting infections with 
STEC can suppress immune responses in cattle.  In addition, Christopher-Hennings et al [237] 
showed that gnotobiotic pigs persistently infected with a STEC strain had significantly reduced 
antibody titres to sheep erythrocytes as well as lowered proliferative reponses to subsequent 
exposure to mitogens such as ConA suggesting persistent infection is associated with a 
downregulation in immunological responses.  Therefore, based on these findings as well as the 
current study, a requirement for a Stx2
-
 E. coli mutant protein preparation when immunizing 
cattle with a secreted protein cocktail should be taken into consideration for future vaccination. 
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8.0 Discussion and Conclusions 
 STEC are a cause of severe illness and death in humans, and because cattle are an 
important reservoir for human exposure, it is important to reduce the amount of STEC in cattle to 
reduce human exposure and thus disease [238].  To date, very little is known about STEC 
pathogenesis in cattle in particular the virulence factors associated with long-term persistence.  It 
has been shown that cattle shed STEC for long periods of time throughout their lifespan without 
causing any clinical symptoms of disease [1, 169, 198].  Bacterial pathogens use a variety of 
mechanisms including toxins, to avoid immune responses and successfully colonize their hosts 
[46].  This has been reported for STEC but the mechanism has yet to be defined.  Therefore the 
primary objective of this project was to determine the effect of Shiga toxin 2 on bovine immune 
responses during STEC infection. We hypothesized that STEC uses Shiga toxin 2 to 
downregulate bovine immune responses thereby preventing the induction of the immune system 
and subsequent elimination from its host. 
 In this project, we hypothesized that Stx receptor-bearing lymphocytes are susceptible to 
Stx2 thereby altering normal lymphocyte functions.  Our results showed that leukocyte 
populations isolated from the jejunum and the ileum of cattle as well as an intestinal epithelial 
cell line express the Stx (Gb3) receptor on their surface.  Dean-Nystrom et al [70] showed that 
the ileum and colon of these experimentally infected calves were colonized with viable bacteria 
thus confirming the presence and tissue tropism of STEC within the bovine gastrointestinal tract.  
In accordance with this, Menge et al [203] showed that bovine lymphocytes isolated from the 
gastrointestinal tract as well as the blood express surface receptors for Stx2.  Stx receptor binding 
has been shown to be the principle determing factor in Stxs specificity and activity as 
demonstrated in pigs and rabbits [58].  Therefore, Stx receptor-bearing cells within the 
gastrointestinal tract would be potential targets during STEC colonization.  Results in the current 
study have shown that Stx2 inhibits the mitogen-induced proliferation of lymphocytes 
originating from the ileal Peyer’s patches.  This inhibition was seen after 12 hours of incubation 
with purified Stx2 (2000pg/ml) and 5μg/ml of Concavallin A.  In vitro experiments have also 
demonstrated reduced lymphocyte proliferation in the presence of purified Stx1 [68].  To further 
these results, an in vivo analysis using a ligated loop model with a wild type Stx2
+
 E. coli 
O157:H7 strain demonstrated the depletion of bovine CD4+ T cells within the ileum suggesting 
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part of the mechanism by which Stx2 facilitates STEC colonization is through the modulation of 
the bovine immune response.  Menge et al [203] showed that Stx1 specifically depletes bovine 
CD8+ lymphocytes within the ileum of calves and reduces the percentage of CD8+ 
intraepithelial lymphocytes after 12 hours of incubation with an Stx1
+
 E. coli strain.  The present 
study provides direct evidence that Stx2 produced during STEC infection can modulate 
lymphocyte populations in the mucosal immune system within cattle.   
 The epithelial cells lining the mucosal surface of the gastrointestinal tract are often the 
host’s first line of defence providing a physical barrier between STEC and the host’s internal 
environment [207].  In the gastrointestinal tract, the epithelial cells play an active role in 
producing signals that direct the neighbouring immune and inflammatory cells in the mucosa 
[207].  Therefore in this project, we hypothesized that Stx2 downregulates cytokine gene 
expression from the bovine intestinal epithelium thereby preventing the induction of important 
inflammatory cytokines.  In vitro analysis of the effect of Stx2 on cytokine gene expression at 
the transcriptional level in a bovine intestinal epithelial cell line showed that cytokine induction 
was mildly suppressed in the presence of Stx2.  Data resulting from a purified Stx2 preparation 
and a secreted protein preparation isolated from a wild type Stx2
+
 E. coli O157:H7 strain showed 
a slight downregulation of IL12, IL6, IL8 and IFNγ gene expression compared to cytokine gene 
expression in the absence of Stx2.  These results could suggest that Stx2 has a role in STEC 
colonization since there are no signs of intestinal inflammation in STEC-infected cattle [219].  In 
agreement with our results, Bellmeyer et al [217] recently showed that E. coli O157:H7 
attenuates the induction of IL8 as well as inflammatory responses by intestinal eptithelial cells.  
As well, Hauf et al [216] confirmed that EHEC suppresses NF-κβ activation thereby inhibiting 
inflammatory processes.  Therefore, our results in conjunction with published data, suggests Stx2 
impairs bovine inflammatory processes by downregulating cytokine gene expression and is thus 
part of the pathogenic mechanism of STEC colonization. 
  With the growing amount of published data confirming the immunomodulation of Stx2 
within the bovine host [68, 69, 219], it is imperative to determine the effect of Stx2 during active 
immunization.  Therefore in the present study, two trials were performed in which cattle were 
immunized either in the presence or absence of Stx2 and the magnitude of bovine immunological 
responses (humoral and cellular) were measured.  Our results indicates that Stx2 alone as well as 
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part of the secreted protein preparation isolated from a wild type Stx2
+
 E. coli O157:H7 strain 
reduced bovine immune responses to a co-administered antigen, HEL, and to the secreted 
proteins themselves.  These results suggest that vaccination with a secreted protein preparation 
that does not contain Stx2 (secreted protein preparation isolated from a mutant Stx2
-
 E. coli 
strain) will result in significantly better immunological responses in cattle compared to 
vaccination with a secreted protein preparation that does contain Stx2. 
 The data in the present study suggests that Stx2 downregulates bovine immune responses.  
We hypothesized that STEC uses Shiga toxin 2 to downregulate bovine immune responses 
thereby preventing the induction of the immune system and subsequent elimination from its host.  
Stx2 is likely required for long-term colonization of the bovine host and this is supported by the 
observation that Stx2
+
 E. coli O157:H7 were able to colonize cattle for longer periods of time 
compared to Stx2
-
 E. coli O157:H7.  This would imply that Stx2
+
 E. coli O157:H7 remain in the 
gastrointestinal tract for longer periods of time than Stx2
-
 E. coli O157:H7 enabling them to 
produce sufficient amounts of Stx2 within the gut lumen.  It is been suggested that a proportion 
of free Stx2 traverses the intestinal epithelial cell layer [58] and reaches the bloodstream where it 
travels to distal organs.  This has never been substantiated by the finding of free Stx2 within the 
bloodstream of either cattle or humans.  As well, in 1995 Cray et al [188] concluded from their 
study using preweaned calves and adult cattle that E. coli O157:H7 does not spread from the 
alimentary tract to other organs such as the kidneys, liver or spleen. 
 Therefore, it is assumed that the majority of free Stx2 is either taken up by specialized M 
cells situated in the intestinal epithelium and/or traverses the epithelium [58] but remains in the 
underlying gastrointestinal tract tissues.  Here Stx2 is exposed to the gut-associated lymphoid 
tissue (GALT).  Receptors for Stx2 have been identified on bovine lymphocytes located 
peripherally in the blood as well as in the lamina propria [178].  A study done by Stamm et al 
[178] showed that a percentage of receptor-bound Stx2 was not internalized but remained bound 
to surface Gb3 on lymphocytes.  Therefore it is likely that Stx2 interacts with lymphocytes within 
the GALT without exerting cytotoxic effects [178].  In the present study, we confirm the 
presence of surface Gb3 on leukocyte populations (CD45+) isolated from the Peyer’s patches of 
the ileum and jejunum of cattle.  We speculate that Gb3
+
 leukocyte populations including 
lymphocytes (B and T cells), antigen presenting cells and dendritic cells situated in the 
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gastrointestinal tract bind free Stx2 [178] and that a percentage of receptor-bound Stx2 is not 
internalized but rather remains bound to surface Gb3 [178].  Receptor-bound Stx2 possibly 
perturbs normal cell functions such as proliferation [68].  It has been confirmed that Stx1 hinders 
bovine lymphocyte proliferation by blocking lymphocyte activation [68].  In the present study 
we demonstrated an inhibition of mitogen-induced proliferation in lymphocytes isolated from the 
gastrointestinal tract in the presence of purified Stx2.  Therefore we assume that reduced 
lymphocyte proliferation will affect the magnitude of the immunological response generated 
during STEC colonization thereby aiding in STEC pathogenesis. 
 To determine if STEC suppression of bovine mucosal immune responses is important in 
vivo, a bovine ligated loop model was employed.  Our results showed a reduction in CD4+ T 
lymphocytes isolated from the Peyer’s patches in the presence of a wild type Stx2+ strain.  This 
result suggests that Stx2 may preferentially target CD4
+
/Gb3
+
 T cells within the gastrointestinal 
tract.  Menge et al [203] showed a reduction in CD8+ T cells in the presence of a Stx1-producing 
strain suggesting a possible role for Stx1 in STEC persistence in calves.  Therefore, our results 
support the conclusion that Stx2 suppresses bovine mucosal immune responses.  We speculate 
that the reduced number of lymphocytes within the gastrointestinal tract in the presence of Stx2 
is in part due to an inhibition of lymphocyte proliferation as observed in our in vitro studies. 
 In order to address the lack of intestinal inflammation in cattle upon STEC colonization 
[178], the effect of Stx2 on cytokine production from an intestinal epithelial cell line was defined 
in the present study.  First, confirmation of surface Gb3 on a bovine intestinal epithelial cell line 
established by Kaushik et al [204] was performed.  Our results showed a reduction in cytokine 
gene expression from the bovine intestinal epithelial cell line in the presence of Stx2 suggesting 
Stx2 dampens inflammatory responses during STEC infection.  Recently Bellmeyer et al [217] 
showed that E. coli O157:H7 attenuates the induction of IL8 as well as host inflammatory 
responses by intestinal eptithelial cells.  Therefore we assume that Stx2 facilitates STEC 
intestinal colonization by inhibiting inflammatory responses mediated by cytokine production. 
 Taking into consideration the data in the present study to support the immunomodulatory 
role of Stx2 during STEC colonization, the question of whether immunity in cattle to STEC and 
other co-administered antigens was addressed.   Our results of two immunization trials in the 
presence of purified Stx2 and secreted protein preparations containing Stx2 demonstrated 
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reduced humoral and cellular immune responses in cattle.  Johnson et al [102] have confirmed 
reduced antibody responses to STEC antigens in cattle during experimental infections and 
Hoffman et al [190] have reported lower lymphocyte proliferation after infection of calves with 
STEC strains.  We therefore do no doubt that an immune response is generated during STEC 
infection by bacterial components such as LPS and flagellin [70, 216, 218, 239], but we do 
propose that the magnitude of the immunological response is significantly decreased to STEC 
proteins as well as other co-administerd antigens by Stx2. 
Our hypothesis that “STEC uses Shiga toxin 2 to downregulate bovine immune responses 
thereby preventing the induction of the immune system which contributes to long-term 
persistence in cattle” was partially proven in the present body of data.  We have successfully 
shown using multiple experiments that bovine immune responses are downregulated in the 
presence of Stx2 but we have not addressed if this immunological suppression facilitates long-
term persistence in the bovine host.  In order to further confirm our hypothesis that Stx2 
facilitates long-term STEC persistence in cattle, future cattle trials that include STEC challenge 
after vaccination need to be pursued.  Based on the present data, we would predict that cattle 
vaccinated with a secreted protein cocktail produced from a Stx2
-
 STEC strain would result in 
reduced colonization compared to cattle vaccinated with a secreted protein cocktail produced 
from a wildtype Stx2
+
 STEC strain.  A decrease in the number of cattle shedding STEC after 
vaccination as well as a decreased amount of STEC shed in the feces of cattle would suggest a 
reduction in colonization.  Therefore, future experiments are required to confirm our hypothesis 
regarding the role of Stx2 and STEC persistence in cattle.   
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